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ABSTRACT 
Inherited retinal degenerations (IRDs), with an overall global prevalence of 1/2,000, 
represent a major cause of blindness worldwide. IRDs are mostly inherited as monogenic 
conditions that are caused by mutations in genes preferentially expressed in photoreceptors 
(PRs) and retinal pigment epithelium (RPE) cells. Gene therapy represents a promising 
therapeutic strategy for IRDs. Vectors derived from the adeno-associated virus (AAV) 
have been proven to be the most efficient and safe tools for gene delivery to the retina.  
Further, AAV vectors have been successfully used in pre-clinical models and clinical trials 
focused on the treatment of IRDs. The major limitation to the use of AAVs is their 
packaging capacity, which is considered to be restricted to the size of the parental genome 
(4.7 kb) and thus hinders the treatment of certain forms of IRDs caused by mutations in 
genes whose coding sequence exceeds 5 kb in length, including the gene mutated in 
Stargardt disease (STGD), ABCA4. Thus, different strategies to overcome AAV cargo 
limitation have been investigated. One strategy for large gene transfer is based on “forced” 
packaging of large genes into AAV capsids (oversize AAV); this strategy, however, results 
in the production of viruses with a heterogeneous genome and thus may not be easily 
translated to the clinical arena due to safety concerns. Alternatively, the inherent ability of 
AAV genomes to undergo intermolecular concatemerization can be exploited to transfer 
large genes by splitting the expression cassette into two halves (<5 kb in size), each 
independently packaged in one of two separate (dual) AAV vectors. Dual AAV vectors 
can reconstitute a large gene via either splicing (dual AAV trans-splicing), homologous 
recombination (dual AAV overlapping) or a combination of the two (dual AAV hybrid). 
Dual AAV strategies have been used to efficiently delivery large genes to a number of 
tissues, however, the efficacy of the dual AAV systems for gene delivery to the retina 
remains to be investigated. 
Therefore, the goals of my Ph.D. project were to: 
- develop dual AAV vector-based strategies for large gene delivery to the retina; 
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- compare the efficiency of oversize to that of dual AAV vector strategies for the  
delivery of large genes both in vitro and in vivo, in the retina; 
- characterize the effect of AAV-mediated large gene expression in an animal model 
of STGD. 
To this aim, I generated oversize and dual AAV vectors encoding for either the reporter 
EGFP or the therapeutic ABCA4 protein to compare the efficacy of AAV vector systems 
in vitro using HEK293 cells and in vivo in mouse and pig eyes. I found that dual AAV 
vectors are more efficient than oversize vectors, both in vitro and in the retina. While dual 
AAV OV vectors are effective in transducing the RPE, dual AAV trans-splicing and 
hybrid approaches transduce efficiently PRs, in addition to RPE. Thus, as the PRs are the 
cell target for the treatment of STGD, I selected dual AAV trans-splicing and hybrid 
vectors as the candidate strategies to be tested in the mouse model of STGD (Abca4-/-). I 
injected subretinally one-month-old mice with dual AAV trans-splicing and hybrid vectors 
encoding for ABCA4 and found a significant improvement of the main STGD mice retinal 
abnormalities, including: lipofuscin accumulation, RPE thickening and recovery from light 
desensitization. 
In conclusion, my data show that dual AAV trans-splicing and hybrid vectors are an 
attractive strategy for gene therapy of STGD as well as other retinal diseases that require 
the delivery of large genes. 
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INTRODUCTION 
1. The eye and the retina 
1.1 The eye 
The eye is the highly specialized organ responsible for vision, the sense through which 
originates most of our high order neuronal activities: behaviour, learning, memory and 
emotions. It is composed of many specialized structures, organized into three main 
layers: i) the external fibrous layer, ii) the intermediate vascular layer and iii) the 
internal nervous layer (Blanks, 2001). The fibrous layer includes the sclera and the 
cornea (Fig. 1). The sclera is a dense, white, opaque, fibrous tissue that serves mainly as 
a protective barrier. The cornea is a transparent near-spherical dome at the front of the 
eye that refracts light to focus it to the internal nervous layer. The vascular layer is 
divided into two parts: anterior (iris and ciliary body) and posterior (choroid) (Fig. 1). 
The iris is a thin, circular structure responsible for controlling the diameter of the pupil 
and subsequently the amount of light reaching the retina. The ciliary body is important 
for accommodation, the process by which the eye maintains focus of an object at 
varying distances. The choroid provides oxygen and nourishment to the outer layers of 
the retina. The internal layer represents the sensory part of the eye, the retina, which is 
an extension of the central nervous system and is connected to the brain by the optic 
nerve (Fig. 1). In addition, a monolayer composed of specialized epithelial cells, the 
retinal pigment epithelium (RPE), separates the retina from the underlying choroid. The 
structures of the eye delimit three chambers of fluid: the anterior chamber (between 
cornea and iris), posterior chamber (between iris, zonule fibers and lens) and the 
vitreous chamber (between the lens and the retina). The first two chambers are filled 
with aqueous humor whereas the vitreous chamber is filled with a more viscous fluid, 
the vitreous humor (Fig. 1).  
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Figure 1. Schematic representation of the human eyeball 
Modified from (Colella et al, 2009) 
 
 
1.2 The retina 
The retina represents the structural and functional basis of vision, as it is the light 
sensitive tissue of the eye. The retina is half a millimetre thick and is divided into three 
layers of cells: i) the outer nuclear layer (ONL), that contains photoreceptor (PRs) cell 
bodies; ii) the inner nuclear layer (INL) consisting of cell bodies of the bipolar, 
horizontal, amacrine and Müller cells (MCs) and iii) the ganglion cell layer (GCL, Fig. 
2) (Blanks, 2001). In addition to these neuronal-derived layers, a monolayer of 
specialized epithelial cells, the RPE, overlays PRs. Importantly, PR cell function is 
intimately associated to that of the underlying RPE as this layer sustains PR cell 
integrity and metabolism (see section 1.4). 
Neuronal interconnections (synapses) between the cells of the retina are placed in 
distinct histological layers. The region containing synapses between PRs and bipolar or 
horizontal cells is known as the outer plexiform layer (OPL), while the area where 
bipolar and amacrine cells connect to the ganglion cells is the inner plexiform layer  
12 
 
(IPL, Fig. 2) (Blanks, 2001). Fine processes of MCs, the major glial cells of the retina, 
envelop, at least partially, all the neurons within the retina. These processes extend as 
radial fibres spanning from the ONL to the GCL. In the ONL, adherent junctions 
between MCs and PRs form the outer limiting membrane (OLM), while in the GCL the 
expanded MCs vitreal processes (end-feet) and the basement membrane (a surface 
modification of the vitreous body) form the inner limiting membrane (ILM, Fig. 2). The 
OLM and the ILM form diffusion barriers between the neural retina and the subretinal 
space or vitreous humour, respectively. 
 
 
Figure 2. Organization of the retina 
(A) A diagram that shows the schematic organization of the retina. Taken from 
(Abramoff et al, 2010). (B) Light micrograph of a vertical section through a human 
retina. Taken from http://webvision.med.utah.edu. 
 
 
The process of vision begins at the level of PRs, the light sensitive cells of the retina. 
Light rays focused through the lens must pass through the entire retina before reaching 
the PRs, which convert photons into a chemical stimulus through the process of 
phototransduction (see section 1.4). This stimulus is then integrated and processed by 
interneurons (bipolar, horizontal and amacrine cells) and transmitted to GCs through 
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synapses in the IPL. Finally, GC axons, which project towards the optic nerve head, 
carry the signal to the visual centres of the brain (Blanks, 2001). 
 
1.3 The photoreceptors: rods and cones 
PRs are highly specialized sensory neurons able to capture light stimuli 
(electromagnetic radiation/photons) and to convert them into an electrochemical signal. 
There are two types of PRs in the retina: rods and cones, which differ in their sensitivity 
to light (Blanks, 2001). Rods mainly function under low-light conditions, being a 
hundred-fold more sensitive than cones, and are responsible for peripheral and night 
vision (Fu, 1995). Cones respond to bright light, provide visual acuity and mediate 
colour vision. In the retina of vertebrates, rods represent the majority of PRs, reaching a 
rod:cone ratio of 35:1 in mice, 18:1 in humans and 8:1 in pigs. The human retina 
contains approximately 6 million cones predominantly located in the macula, a small 
and highly sensitive region near the centre of the retina, responsible for central vision 
(Fig. 1) (Ahnelt, 1998). Specifically, the cones are most densely packed within the 
central portion of the macula, the fovea. In the central portion of the fovea the blood 
vessels, GCL, INL and IPL are displaced and this allows light to reach cones with 
minimal distortion to allow for acute and detailed vision. In addition to cones, there are 
approximately 125 million rods, which are spread throughout the peripheral retina. 
Structurally, both rods and cones can be divided into four functional segments: the outer 
segment (OS), the inner segment (IS), the nucleus and the synaptic body (Fig. 3) 
(Blanks, 2001). The OS is a modified cilium constituted by an elaborate system of 
stacked membranous discs (1,000/PR) that derive from invaginations of the plasma 
membrane during development. In rods most of these invaginations become separated 
from the plasma membrane, while discs remain connected to the outer membrane in 
cones. The membranous sacs disintegrate near the apical surface of the cell and their 
14 
 
cellular debris are removed through phagocytosis by the adjacent RPE (Young, 1976). 
Newly formed discs that originate near the base of the OS gradually replace the older 
discs (Hinton, 2001). The degradation and phagocytosis of the sloughed OS follows a 
diurnal rhythm. The IS contains the cytoplasm and the organelles of the cells and it is 
linked to the OS through the connecting cilium. The connecting cilium is responsible 
for the intracellular transport and turnover of proteins from and to the OS. The synaptic 
body connects PRs to subsequent neuronal cells, the horizontal and bipolar cells, which 
represent the next stages in the vision cascade. 
 
Figure 3. Structure of the PRs cell (left panel) and differences between the rod and 
cone OS structures (right panel) 
Taken from http://what-when-how.com/neuroscience (A) and http://www.cis.rit.edu (B) 
 
 
Visual pigments and other key players of the phototransduction pathway localize to the 
OS discs where the conversion of light energy into electrochemical signals occurs 
(Blanks, 2001). The visual pigments expressed in the OS, named opsins, determine the 
light-sensitivity of the PRs. Opsins are light-sensitive, membrane-bound G protein-
15 
 
coupled receptors of the retinylidene protein family that covalently bind to a vitamin A-
based retinaldehyde chromophore, which undergoes photoisomerisation following the 
absorption of a photon. Rods contain the photopigment rhodopsin (max absorbance 
500nm). Cones contain one of three colour pigments that are uniquely sensitive to a 
particular wavelength of light: blue (445nm), green (535nm) or red (570nm). 
 
1.4 Phototransduction and the visual cycle 
Phototransduction is the biochemical pathway that takes place in OS discs, which 
mediates the conversion of photons into an electrochemical signal (Flannery, 2001). 
Phototransduction has been extensively studied in rods. In the absence of light, 
rhodopsin is bound to the 11-cis-retinal chromophore forming inactive rhodopsin (R) 
and the basal activity of the guanynyl cyclase keeps cGMP levels in the cell high(Fig. 
4). Both Na+ and Ca2+ enter the membrane channels leading to high Ca2+ levels and to 
the activation of guanylate-cyclase-activating protein (GCAP). The Ca2+-bound 
calmodulin (CaM) confers high cGMP affinity to cGMP-gated channels in the OS 
plasma membrane keeping them open and thus the PRs depolarized. Photons reaching 
PRs induce the isomerization of the 11-cis-retinal to all-trans-retinal, activate rhodopsin 
(R*), that releases all-trans-retinal and activates the G protein transducin (αβγ subunits) 
by catalyzing a GDP to GTP exchange. The dissociated α-subunit of transducin 
subsequently activates cGMP-phosphodiesterase 6 (PDE6), which rapidly hydrolyzes 
the cytoplasmic cGMP. The decreased cGMP concentration causes the closure of the 
cGMP-gated cation channels on the plasma membrane thus reducing the Ca2+ influx 
(Fig. 4). As a result, rods are hyperpolarized and release fewer glutamate transmitters 
from the synaptic region of the PRs to the connected bipolar cells. This initial signal is 
transmitted via second-order retinal neurons to the optic nerve and ultimately to the 
brain. Additional proteins are required to shut off the cascade. In the recovery phase 
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photoactivated rhodopsin (R*) is desensitized by phosphorylation, which is mediated by 
the binding of the rhodopsin kinase protein (RHOK) and arrestin. Retinal guanylyl 
cyclase (GC) and guanylate cyclase activating protein (GCAP) replenish cGMP levels 
in a Ca2+-dependent manner while the Na/Ca-K exchanger that resides on the plasma 
membrane, regulates Ca2+ homeostasis. All the components of the phototransduction 
cascade are arranged in close proximity at the disc membrane and at the plasma 
membrane of PRs (Fig. 4) (Flannery, 2001).  
  
Figure 4. Phototransduction pathway in rod PRs 
R: rhodopsin; R*: photoactivated rhodopsin; PDE6: phosphodiesterase 6; GCAP: 
guanylate cyclase activating protein; GC: guanylyl cyclase. Taken from 
http://mutagenetix.utsouthwestern.edu/phenotypic/phenotypic_rec.cfm?pk=282 
 
 
The phototransduction cascade is closely associated with the visual cycle, an enzymatic 
pathway that starts in the rod OS yet is completed in RPE, where retinoids that are 
isomerized by light are “recycled” back to the PRs (Fig. 5) (Hinton, 2001).  
As previously described, photoisomerization in rods converts the 11-cis-retinal to all-
trans-retinal, which is then released from rhodopsin, conjugated with the membrane 
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lipid phosphatidylethanolamine (PE) and transported by the ATP-binding cassette, 
subfamily A, member 4 (ABCA4) from the lumen side of the disc to the OS cytoplasm. 
Here it is converted to all-trans retinol by a retinol dehydrogenase (RDH). The all-trans 
retinol is then released from the OS and taken up by the RPE, thanks to the transport 
mediated by retinoid-binding proteins, such as interphotoreceptor retinoid-binding 
protein (IRBP), that are involved in the transport of the hydrophobic retinoids in 
aqueous environments (Fig. 5). In the RPE the all-trans-retinol undergoes a series of 
enzymatic reactions to be converted back to 11-cis-retinal. All-trans-retinol is esterified 
to a fatty acyl group by lecithin retinol acyltransferase (LRAT) to form all-trans-retinyl 
ester, which in turn is subjected to trans-isomerization to 11-cis-retinal through the 
actions of two enzymes (RPE65 and 11-cis retinol dehydrogenase). Finally, 11-cis-
retinal returns back to the OS where it is re-combined with the rhodopsin to form a new 
molecule of light-sensitive rhodopsin, completing the visual cycle (Fig. 5). 
 
Figure 5. The visual cycle 
RDH: retinol dehydrogenase; ABCA4: ATP-binding cassette, subfamily A, member 4; 
IRBP: interphotoreceptor retinoid-binding protein; LRAT: lecithin retinol 
acyltransferase; PE: phosphatidylethanolamine. Modified from (Molday & Zhang, 
2010) 
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2. Inherited retinal degenerations and Stargardt disease 
2.1 Inherited retinal degenerations (IRDs) 
Maintenance of the complex PR-RPE connections requires the tight regulation of highly 
specialized intracellular protein interactions and the harmonic activity of several 
hundred gene products, of which most can lead to retinal dysfunction or cell death when 
mutated. Thus, it is not surprising that many genetic disorders manifest in the eye. IRDs 
have an overall global prevalence of 1/2,000 (Sohocki et al, 2001) and represent a 
significant cause of blindness worldwide. They are mostly inherited as Mendelian traits 
and are characterized by extensive genetic and clinical heterogeneity, however, they 
share a common pathological landmark: progressive degeneration ultimately resulting in 
PRs cell death. Genetic defects in more than 200 genes, including a myriad of functions, 
are known to underlie the etiology of IRDs (Fig. 6, http://www.sph.uth.tmc.edu/retnet/).  
 
 
Figure 6. IRDs causative genes grouped by function 
Pie chart depicting the functional classification of genes implicated in PR degeneration. 
The data are from the Retinal Information Network (RetNet). ECM: extracellular 
matrix; pre-mRNA: precursor mRNA; unknown: function undetermined; VRD: 
vitreoretinal degeneration; EM: extra-cellular matrix. Taken from (Wright et al, 2010). 
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These genes are mainly expressed in rods, cones and RPE, where they perform essential 
functions. Due to the close interdependence between PRs and RPE, dysfunctions in 
either of these two cell layers can cause secondary dysfunctions to the other (Ryan 
2001). 
For simplicity, retinal dystrophies are typically classified into two types by their 
phenotypic characteristics: those that initially and primarily affect the peripheral vision, 
such as retinitis pigmentosa (RP), and those that primarily affect the macula, the 
macular degenerations including Stargardt disease (Molday & Zhang, 2010). RP affects 
one in 3,500 people and is typically characterized by night blindness, progressive loss of 
peripheral vision and subsequent loss in central vision that often leads to total loss of 
sight. Macular degenerations involve the loss of central vision, with varying degrees of 
peripheral vision deterioration, which can affect people of all ages. 
 
2.2 Stargardt disease (STGD) 
Stargardt disease (STGD1; MIM #248200), first described by the German 
ophthalmologist Karl Stargardt in 1909 (Stargardt, 1909) is the most common 
autosomal recessive, early-onset macular dystrophy with a reported prevalence of 
1:8,000-1:10,000 individuals (Fujinami et al, 2013; Noble & Carr, 1979; Walia & 
Fishman, 2009; Weleber, 1994), although the frequency of carrier of mutations in the 
gene causative of the STGD is thought to be as high as 2 in 100 (Zernant et al, 2011). 
STGD patients experience significant bilateral loss of central vision, photophobia and 
color vision abnormalities, parafoveal scotoma and slow dark adaptation (Allikmets, 
2007; Fishman et al, 1991; Walia & Fishman, 2009; Westerfeld & Mukai, 2008). The 
age of onset of the vision decrease is highly variable, however, it mainly occurs between 
childhood and adolescence/early adulthood and rapidly progresses. Visual acuity at 
presentation may range from as good as 20/20 to as bad as <20/200, with prior visual 
20 
 
acuity frequently being normal, and very few patients have further deterioration of their 
vision to finger counting or hand motions level (Rotenstreich et al, 2003). The prognosis 
for visual outcome is highly dependent on the age of disease onset. Typically, the first 
diagnostic approach for STGD can simply be made by direct ophthalmoscopy. STGD 
affects the macula with variable centrifugal expansion but fundus examination is 
frequently normal early in the disease’s progression, even if visual loss has already 
begun (Noble & Carr, 1979). Characteristic fundus manifestations arise later in the 
course of the disease and include pigment mottling, frank macular atrophy, a bull’s-eye 
appearance and fundus flecks. Fundus flecks are pisciform, dot-like, yellow-white 
lesions typically found in STGD patients (Fig. 7) (Allikmets, 2007; Anderson et al, 
1995; Stargardt, 1909).  
 
Figure 7. Fundus of a patient diagnosed with STGD  
Fundus photograph of the eye from a STGD patient showing the characteristic 
yellowish flecks around the macula and a defined area of central macular degeneration. 
Taken from (Allikmets, 2007)  
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Fundus flecks are manifestations of lipofuscin accumulation in the RPE but may also 
represent areas of regional depigmentation and atrophy (Molday & Zhang, 2010). 
Lipofuscin deposits are composed of a heterogeneous mixture of oxidized lipids, di-
retinoids and other components derived from the incomplete degradation of 
phagocytized PR OS (Delori et al, 1995; Eldred & Lasky, 1993). Electroretinographic 
(ERG) measurements are variable and are not usually considered diagnostic for the 
disease (Genead et al, 2009; Lois et al, 2001). A relatively novel diagnostic approach 
has been developed to determine the viability of the RPE in a non-invasive procedure: 
fundus autofluorescence imaging. This takes advantage of the innate fluorescence of 
lipofuscin to quantify its distribution throughout the RPE (von Ruckmann et al, 1995). 
An increase in fundus autofluorescence represents lipofuscin accumulation in the RPE. 
Inversely, areas of decreased fundus autofluorescence correlate to low levels of RPE 
metabolic activity, which normally underlies local atrophy and secondary PRs loss. 
Therefore, fundus autofluorescence has been proven to be a useful protocol, both in 
clinical practice and research, to study and diagnose STGD and one of the more 
efficient tools to determine the stage of disease (Gomes et al, 2009; Testa et al, 2012).  
 
2.3. ABCA4 as STGD causative gene 
In 1997, the gene for autosomal recessive STGD was first identified by the group of 
Allikmets and was found to encode a novel member of the ATP-binding cassette 
transporter superfamily (Allikmets et al, 1997). Also in 1997, the gene for the Rim 
protein, first identified in the late 1970’s as a high molecular weight glycoprotein, 
highly expressed in PRs OS (Molday & Molday, 1979; Papermaster et al, 1978), was 
cloned and found to encode the same ABC transporter mutated in STGD (Azarian & 
Travis, 1997; Illing et al, 1997; Nasonkin et al, 1998). This ABC transporter, initially 
known as ABCR, is now more commonly called ABCA4, as it was the fourth identified 
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member of the ABCA subfamily of ABC transporters. The ABCA4 gene maps to the 
short arm of chromosome 1. It is a large gene including 50 coding exons with an open 
reading frame of 6819 bp (Allikmets et al, 1997; Azarian et al, 1998). An important 
characteristic of ABCA4 is its extraordinarily high allelic heterogeneity and, indeed, 
there are over 600 disease-associated mutations that have been identified thus far 
(Zernant et al, 2011), that include missense, nonsense, splicesite, frameshift, small 
deletion and insertion and, more frequently, missense mutations (Fishman et al, 1999; 
Fumagalli et al, 2001; Lewis et al, 1999; Maugeri et al, 1999; Rivera et al, 2000). Given 
its high allelic heterogeneity, the most frequent disease-associated ABCA4 alleles (i.e., 
G1961E, G863A/delG863, and A1038V) have each been described in only about 10% 
of patients with STGD. This makes very difficult to identify causative mutations in 
STGD patients. Mutations in ABCA4 are also known to cause two more severe, 
clinically distinct, retinal degenerative diseases known as cone-rod dystrophy and 
retinitis pigmentosa, as well as some forms of age-related macular degeneration. Indeed, 
it is now generally believed that mutations in ABCA4 result in a spectrum of related 
retinal dystrophies, the severity of which depends on: i) the type of mutation and, 
subsequently, its effect on protein function (Fig. 8); ii) age of diagnosis; iii) stage of the 
disease; iv) genotypic variation of the patient (Cideciyan et al, 2009b; Maugeri et al, 
1999; Shroyer et al, 1999; van Driel et al, 1998).  
Stargardt-like diseases are typically recessively inherited, though dominant forms have 
been reported, which involve mutations in structural genes found on chromosomes six 
and four (STGD3, OMIM entry #600110 and STGD4, OMIM entry #603786) 
(Kniazeva et al, 1999; Stone et al, 1994). 
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Figure 8. Spectrum of ABCA4-related phenotypes  
Decreasing function of ABCA4 is thought to be associated with age-related macular 
degeneration (AMD) in some heterozygote mutations. Stargardt (STGD) patients have 
at least one missense allele, however, in cone-rod dystrophy (CRD) and retinitis 
pigmentosa (RP) patients are homozygous for severe mutations. Modified from (Dean, 
2003) 
 
 
2.3.1 ABCA4 structure and localization 
ABC transporters include a superfamily of proteins that typically transport a wide 
variety of compounds across cell membranes using ATP hydrolysis as an energy source 
(Dean & Annilo, 2005). The ABC superfamily is organized in seven subfamilies, 
ranging from ABCA to ABCG (Dean & Allikmets, 2001). The ABCA subfamily of 
ABC transporters consists of 12 members (Kaminski et al, 2006). The human ABCA4 
gene encodes a 2273 amino acid protein having a molecular mass of 256 kDa with the 
mature protein organized in tandem halves. Each half contains a transmembrane 
domain, consisting of six membrane-spanning, and a nucleotide binding domain; a large 
glycosylated exocytoplasmic domain separates the first membrane-spanning segment 
from a cluster of five transmembrane segments (Fig. 9) (Molday & Zhang, 2010). The 
two transmembrane domain form the substrate binding site, while the nucleotide 
binding domains are the sites for the ATP binding and hydrolysis. 
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Figure 9. Structural features of the ABCA4 transporter 
Topological model showing the organization of ABCA4 in the membrane. Each 
exocytoplasmic domain contains multiple N-linked oligosaccharide chains (hexagons) 
exposed to the lumen side of the disc membrane. ECD: exocytoplasmic domain; NBD: 
nucleotide binding domain. Taken from (Molday & Zhang, 2010) 
 
 
ABCA4 is almost exclusively expressed in the retina and in particular in PRs (both rods 
and cones) OS (Allikmets et al, 1997; Illing et al, 1997; Molday et al, 2000; Sun & 
Nathans, 1997). Immunoelectron microscopic studies have localized ABCA4 to the rim 
and incisures of the disc membrane in amphibian PR cells (Fig. 10) (Papermaster et al, 
1982). The initial finding that ABCA4 is localized to OS disc membranes together with 
its link to STGD provided the first evidence that ABCA4 may play a central role in PRs 
OS function. Biochemical and animal model studies have since established a critical 
role of ABCA4 in the visual cycle rather than in PR morphogenesis or structure. 
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Figure 10. ABCA4 localization on discs 
Schematic representation of a cutout portion of the rod outer segment with the stack of 
discs surrounded by the plasma membrane and the location of ABCA4 in the rim and 
incisure regions of the disc membrane. Modified from (Molday & Zhang, 2010) 
 
 
 
 
2.3.2 The Abca4-/- mouse sheds light on the role of ABCA4 in the visual cycle and on 
STGD pathogenesis.  
The first identification of ABCA4 as a member of the ABC transporter superfamily 
suggested its involvement in the transport of an unknown substrate in the PR OS. All-
trans retinal, the isoform of rhodopsin chromophore, was identified as a potential 
substrate of ABCA4 as it has the ability to stimulate ATP hydrolysis in reconstituted 
ABCA4 protein in vitro, which suggested that this could also be the in vivo substrate for 
ABCA4 (Sun et al, 1999). Studies of Abca4 knockout mice supported this hypothesis. 
This data suggested that ABCA4 functions as a “flippase” of the complex of all-trans 
retinal and PE across the disc membrane. Abca4 knockout mice were generated in 1999 
by the Travis group, through targeted gene disruption of the Abca4 locus (Weng et al, 
1999). This mouse model, however, did not fully recapitulate the phenotypes of STGD. 
These animals exhibited healthy PRs that did not show PRs degeneration under normal 
lighting conditions. However, recent reports found that in mice bred onto an albino 
background, which are more susceptible to light because of the absence of 
pigmentation, degeneration became evident at advanced ages (8-9 month) (Wu et al, 
2010a). The initial study also suggested that delayed dark adaptation, a symptom of 
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STGD, was demonstrated in Abca4-/- mice and that it was initiated by delayed 
clearance of all-trans-retinal, known to re-associate with opsin and activate the 
phototransduction cascade. Biochemical analyses of retinoid compounds and lipids 
from ocular tissues revealed alterations consistent with the presumed role of ABCA4 as 
the transporter of all-trans-retinal and/or N-retinylidene-PE. Indeed, these animals 
exhibited elevated levels of all-trans-retinal in OS following light exposure, elevated PE 
and N-retinylidene-PE in the retina and accumulation of lipofuscin deposits in the RPE 
cells (Mata et al, 2000; Weng et al, 1999). Lipofuscin deposits in Abca4-/- mice showed 
elevated levels of several fluorescent diretinoid compounds, including A2E, the final 
product of condensation of all-trans-retinal and N-retinylidene-PE (Fig. 11), and similar 
potentially toxic photoreactive compounds (Ben-Shabat et al, 2002; Kim et al, 2007; 
Mata et al, 2001; Mata et al, 2000; Radu et al, 2004; Sparrow & Boulton, 2005; Wu et 
al, 2009). Accumulation of A2E in the macular region of RPE, as well as many of the 
other compounds previously mentioned, is the hallmark of STGD and age-related 
macular degeneration (Mata et al, 2000).  
 
Figure 11. Reactions involved in the formation of A2E 
All-trans-retinal reacts with phosphatidylethanolamine (PE) to form N-retinylidene-PE. 
This condenses with all-trans retinal to produce the di-retinoid pyridinium-PE 
compound (A2PE) in outer segments. Upon phagocytosis from the RPE, A2PE can be 
hydrolyzed by lysosomal enzymes to A2E and phosphatidic acid (PA). Modified from 
(Molday & Zhang, 2010) 
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The results of the characterization of Abca4-/- mice have definitively supported the 
concept that ABCA4 plays an essential role in the visual cycle and, specifically, the 
possible role of ABCA4 in the regeneration of the all-trans-retinal chromophore.  
All-trans-retinal has to be reduced to all-trans-retinol by the retinol dehydrogenase 
(RDH8), localized in the cytoplasmic side of the discs, before it can be recycled. 
However, it is know that a fraction of all-trans-retinal reversibly reacts with PE in the 
disc membrane to form N-retinylidene-PE (Fig. 12A) (Anderson & Maude, 1970; 
Poincelot et al, 1969). This adduct cannot cross the membrane by itself and thus is 
trapped on the lumen side of the disc where it is no longer accessible to RDH8. In this 
context, ABCA4, works as a lipid transporter and “flips” N-retinylidene-PE to the 
cytoplasmic side of the disc membrane, utilizing ATP hydrolysis as an energy source. 
Once in the cytoplasm, N-retinylidene-PE can dissociate and be converted to all-trans 
retinol, thus re-entering the visual cycle (Fig. 12A).  
In this model, ABCA4 functions to remove all-trans-retinal and related retinoid 
compounds from PR OS. Compatibly with this model, ABCA4 loss would result in the 
accumulation of A2E-containing lipofuscin granules in RPE, one of the characteristic 
features of STGD. Indeed, in the absence of ABCA4, N-retinylidene-PE and all-trans-
retinal accumulate inside the disk, as observed in Abca4-/- mice, and subsequently, the 
levels of A2PE, the product of their condensation, also greatly increase in PR OS 
(Eldred & Lasky, 1993; Mata et al, 2001; Mata et al, 2000) (Fig. 12A). OS phagocytosis 
by RPE cells results in an increase in A2E content via lysosomal enzyme-mediated 
A2PE hydrolysis (Sparrow et al, 2008). As A2E and related diretinoids cannot be 
readily metabolized, they progressively accumulate in RPE cells, forming the 
fluorescent lipofuscin deposits seen in STGD patients and Abca4-/- knockout mice (Fig. 
12B). The accumulation of A2E in RPE cells negatively affects RPE cell function and 
viability. Indeed, A2E has been reported to act as a detergent that disrupts intracellular 
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membranes, a photosensitizer resulting in free radical production that can adversely 
affect DNA and membrane lipids, an inhibitor of RPE phagocytosis and degradative 
functions, as well as an inhibitor of cholesterol efflux from RPE cells (Eldred & Lasky, 
1993; Finnemann et al, 2002; Holz et al, 1999; Lakkaraju et al, 2007; Molday & Zhang, 
2010; Sparrow et al, 2003; Sparrow et al, 2008; Sparrow et al, 2000; Vives-Bauza et al, 
2008). 
Due to the close interdependence between RPE and PR, the degeneration of RPE cells 
caused by the A2E related damages, will consequently result in PRs death (Fig.12B), 
ultimately causing the loss in the vision experienced by STGD patients. 
 
 
Figure 12. Proposed biological role of ABCA4 and mechanism responsible for 
STGD 
(A) Illustration of the proposed biological role of ABCA4. The left part of the diagram 
represents a rod OS disk with a functional ABCA4, whereas the right part represents a 
rod OS disk with an inactive ABCA4. Hexagons with carbon backbone represent all-
trans-retinal (black) and all-trans-retinol (red). RDH: all-trans-retinol dehydrogenase 8. 
RPE: retinal pigment epithelium. Modified from (Tsybovsky et al, 2010). (B) Diagram 
showing how the loss in the function of ABCA4 as N-retinylidene-PE transporter 
results in PR degeneration and vision loss. Modified from (Molday & Zhang, 2010). 
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3. Gene therapy strategies for IRDs 
 
3.1 The eye as target for gene therapy 
Effective treatments for IRDs are currently unavailable. However, during the past three 
decades, the identification of the genes causative of many IRDs has paved the way to 
the development of gene therapy-based strategies. 
Gene therapy aims to deliver corrective nucleic acids (DNA/RNA) to a cell, tissue or 
target organ, in order to treat and ultimately cure a disease. The eye is a suitable target 
for gene transfer thanks to several features. It is small and enclosed, thus allowing for 
the use of small vector/transgene doses to achieve a therapeutic effect. It is an immuno-
privileged site, as tight junctions between RPE cells and the presence of the blood-retina 
barrier limit the spreading of the vector in the circulation, thus, minimizing the 
activation of the immune system against either the vector components or transgene 
product (Bainbridge et al, 2006). The effects of gene delivery can be monitored closely, 
frequently and non-invasively; specifically, retinal morphology can be assessed by 
optical coherence tomography (OCT) while retinal function can be assessed by 
electroretinograms (ERGs), visual evoked potentials (VEPs) and measurement of 
afferent pupillary light responses (PLRs). Many ocular diseases are bilaterally 
symmetrical allowing a unique environment to compare the effects of vector/gene 
delivery to disease progression in the contralateral eye. Finally, surgical procedures 
have been adapted for the transfer of genetic material into specific ocular compartments, 
as to preferentially target a particular ocular cell type. The two most common methods 
of delivery are intravitreal and subretinal injection (Stieger et al, 2011). Intravitreal 
injection consists of the release of the therapeutic agent in the vitreous and results in the 
exposure of the anterior retina (GC and INL). Subretinal injection, alternatively, 
deposits the vector below the retina, in a virtual space between the RPE and the PRs, 
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inducing a regional and reversible detachment called a bleb. Subretinal vector delivery, 
though more invasive than the intravitreal, exposes the outer retina to the therapeutic 
agent and is currently the most efficient method for targeting PRs and RPE cells, which 
are the cell types mainly affected by many forms of IRDs.  
 
Figure 13. Routes of injection for ocular gene delivery  
Modified from (Stieger et al, 2011) 
 
 
Gene therapy-based strategies recently developed for the treatments for IRDs have 
shown promising results in several animal models of retinal degeneration and in recent 
clinical trials have confirmed their efficacy and safety in humans, thus suggesting that 
gene therapy is a valuable and viable therapeutic option for otherwise untreatable 
diseases that cause blindness (Allocca et al, 2006; Bainbridge et al, 2008; Cideciyan et 
al, 2009a; Colella et al, 2009; Maguire et al, 2009; Maguire et al, 2008; Simonelli et al, 
2010; Vandenberghe & Auricchio, 2012). 
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3.2 AAVs as tools for gene transfer to the eye 
Nucleic acids do not readily cross cell membranes, consequently it is necessary to 
envelope the genetic material in a delivery vehicle that can be either viral or non-viral 
(polymeric or lipidic complexes). Non-viral gene transfer efficiency has increased over 
the last several years, however, the resulting transfection rate remains low and the 
expression of the transgene is short lived. Consequently, many studies have 
demonstrated higher transduction efficiency in the retina using viral gene delivery rather 
than non-viral (Andrieu-Soler et al, 2006). Viral vectors commonly used for ocular gene 
transfer are derived from adenoviral, lentiviral or adeno-associated (AAV) viruses 
(Kumar-Singh, 2008; Lipinski et al, 2013). Among these, vectors derived from AAVs 
are currently the most used and promising vehicles for therapeutic gene delivery to the 
retina, given their favourable safety profile and the long-term gene expression that is 
observed after a single AAV administration (Stieger et al, 2011; Vandenberghe & 
Auricchio, 2012). 
AAV is a small (20-25 nm in diameter), non-enveloped, icosaedric virus, native to 
humans and non-human primates, that packages a single strand DNA genome of 4.7 kb 
(Berns & Giraud, 1996) (Fig. 14). It belongs to the Parvoviridae viral family and it is a 
dependovirus, because it can replicate in the nucleus of target cells only in the presence 
of helper viruses. In fact, it was originally isolated as a contaminant of adenoviral 
cultures and thus given the name adeno-associated virus. The AAV genome is flanked 
by two palyndromic inverted terminal repeats (ITRs) that are 145 nucleotides in length  
and includes two open reading frames, rep and cap (Daya & Berns, 2008). Rep encodes 
for proteins involved in the replication of the viral DNA, the packaging of newly 
synthesized single stranded AAV genomes and the genome integration in the AAVS1 
locus on human chromosome 19. Cap encodes for the VP1, 2 and 3 proteins that form 
the AAV capsid. In the AAV vector genome, the only viral sequences that are required 
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in cis are the ITRs, while the sequences encoding rep and cap can be exchanged with 
the exogenous DNA of choice (Daya & Berns, 2008). Rep and cap are instead required 
for the production of AAV vectors and, therefore, they are provided in trans to the 
packaging cells together with the adenoviral helper functions. Recombinant AAV 
vectors can be produced at high yields by transient triple transfection of mammalian 
cells or by infecting packaging eukaryotic or insect cells (Wright, 2008; Zolotukhin, 
2005).  
 
 
Figure 14. Schematic representation of the structure and genome of AAV vectors 
(A) 20 nm icosahedral capsid of the AAV virion containing a single-stranded DNA 
AAV genome; (B) Rep and cap genes flanked by ITRs. The different rep and cap 
transcripts are produced from their respective promoters (P5 and P19 for rep and P40 
for cap). The asterisk indicates the alternative ACG codon used to produce VP3; (C) 
Secondary structure of one ITR from AAV2 showing the rep binding elements (RBEs) 
and the terminal resolution site (TRS). These sequences are used by the viral regulatory 
protein Rep during AAV replication to process the double-stranded intermediates. 
Taken from (Lipinski et al, 2013) (A, C)  and (Daya & Berns, 2008) (B). 
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The triple trasfection method is the most commonly used method of AAV production 
and is based on co-transfection of three plasmids into permissive cells (usually human 
embyonic kidney 293 cells): one containing the gene of interest flanked by the ITRs, the 
second a packaging plasmid encoding for the rep and cap proteins, and the third plasmid 
encoding the adenoviral helper genes. Column chromatography or CsCl- gradient 
centrifugation is used to purify cellular and viral (empty capsid) contaminants.  
AAVs transduction occurs through a cascade of steps beginning with an interaction of 
the viral capsid with specific receptors on the cell surface; internalization of the virion is 
subsequently mediated by endocytosis and intracellular trafficking through the 
endocytic/proteasomal compartments. Finally, the virion reaches the nucleus, where it is 
uncoated allowing the single stranded genome to be transcribed creating double-
stranded DNA, ultimately resulting in transcription of the transgene (Wu et al, 2006). In 
the absence of Rep proteins, the recombinant AAV genomes remain episomal and 
random integration occurs at very low efficiency (Smith, 2008).  
Dozens of different AAV variants (serotypes) have been identified to date, either 
isolated as naturally occurring infectious agents or as molecular clones (Vandenberghe 
et al, 2009). The availability of many serotypes is one of the major strengths of the 
AAV vector platform, as the versatility of the AAV vectors production system allows 
the easy exchange of capsids among various AAV variants. This exchange creates 
hybrid vectors that contain a genome with the same AAV ITRs (i.e., those from AAV2) 
and the capsid from a different variant (Auricchio, 2003). AAVs obtained through this 
transcapsidation system are named AAV2/n, where the first number refers to the ITRs 
and the second to the capsid (Fig.15).  
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Figure 15. Scheme of the generation of AAV vectors from various AAV serotypes 
Transfection of packaging cells with plasmids containing the AAV genome (with the 
gene of interest flanked by the AAV2 ITRs) and the packaging sequences (the cap gene 
encoding for the capsid proteins and the rep gene from serotype 2 to allow the most 
efficient packaging of a viral genome with the AAV2 ITRs) results in the production of 
recombinant AAV vectors. The tropism of the hybrid virions containing the genome of 
one serotype (i.e. AAV2) and a different capsid (AAV2/1–9) mainly depends on the 
capsid. Taken from (Surace & Auricchio, 2008). 
 
 
Each AAV serotype has unique transduction characteristics (i.e target cells, kinetic of 
transgene expression) because different AAV capsids interact with different receptors 
on target cells and impact the post-entry transduction steps and this allows the user to 
choose the most appropriate AAV serotype for the disease/organ of interest 
(Vandenberghe et al, 2009; Wu et al, 2006). For example, the AAV2 capsid proteins 
interact with membrane-associated heparin sulphate proteoglycans, with avb5 integrin 
(Summerford et al, 1999), fibroblast growth factor-1 (Qing et al, 1999), hepatocyte 
growth factor (Kashiwakura et al, 2005) and laminin (Akache et al, 2006) as 
coreceptors. By contrast, AAV1 capsid interacts with alpha2,3 and alpha2,6 sialic acids 
that are present on N-linked glycoprotein receptors (Vandenberghe et al, 2009), AAV4 
and AAV5 bind preferentially to a 2,3 sialic acid or platelet-derived growth factor (Di 
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Pasquale et al, 2003) (Kaludov et al, 2002) and AAV3, AAV8 and AAV9 bind laminin 
(Akache et al, 2006). 
 
3.3 AAV serotypes for PR transduction 
The transduction efficiency of the different retinal cell types by numerous AAV 
serotypes has been extensively documented using several reporter proteins (Allocca et 
al, 2007; Auricchio et al, 2001b; Lebherz et al, 2008). AAV vectors often have a broad 
tropism (Table 1), however, when evaluating the transduction capability of a serotype, it 
is important to take into account that the viral capsid is only one of several factors that 
determine specificity and efficacy of retinal cell transduction; cell transduction and 
targeting is also influenced by the route of vector administration.  
 
Table 1. AAV serotype tropism in various species following subretinal injection 
RPE: retinal pigmented epithelium, PR: photoreceptors, MC: Muller cells, INL: inner 
nuclear layer, GC: ganglion cells, n.d.: not determined. Modified from (Stieger et al, 
2011). 
 
 
Following subretinal injection, most AAV serotypes efficiently transduce RPE cells, 
with AAV2/1, AAV2/4 and AAV2/6 being the most efficient in various animal models 
(Auricchio et al, 2001a; Dinculescu et al, 2005; Rabinowitz et al, 2002; Yang et al, 
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2002). This efficient transduction could result from an inherent permissiveness of the 
RPE to AAV infection (specifically, the presence of AAV receptors and co-receptors at 
the RPE cell membrane) or from the phagocytic properties of the RPE that could 
facilitate entry of AAV particles (Vandenberghe & Auricchio, 2012). Conversely, the 
levels of PRs transduction vary significantly among different serotypes. The first 
evidence that AAV can target PRs in addition to the RPE was provided using AAV2/2 
(Ali et al, 1996), however, transduction was relatively inefficient. Since the majority of 
mutations causing IRDs, including STGD, occur in genes expressed in PRs (Dryja, 
2001), this concern prompted the search for AAV serotypes able to overcome this 
limitation. AAV2/5, 2/7, 2/8 and 2/9 have all been demonstrated to efficiently transduce 
PRs, in addition to RPE (Allocca et al, 2007; Auricchio et al, 2001b; Lotery et al, 2003) 
with AAV2/8 being the most efficient serotype in mice (Allocca et al, 2007), pigs 
(Mussolino et al, 2011), dogs (Stieger et al, 2008) and non-human primates 
(Vandenberghe et al, 2011) (Fig. 16).  
 
Figure 16. AAV2/8 transduction in mouse, pig and non-human primates retinas 
Subretinal administration of AAV2/8 expressing EGFP in C57BL/6 mice (A), pig (B) and non-
human primates (C). RPE: retinal pigmented epithelium, PR: photoreceptors. White arrows: 
Müller cell nuclei, red arrows: Müller cell endfoot membranes. Modified from (Allocca et al, 
2007) (A), (Mussolino et al, 2011) (B), (Vandenberghe et al, 2011) (C). 
 
 
In contrast, AAV vectors of any serotype have lower transduction efficiency when 
delivered intravitreally and AAV2/2 and AAV2/6 are currently the only serotypes found 
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capable of transducing retinal cells from the vitreous, with a pattern mainly restricted to 
GC and MC (Fig. 17).  
 
Figure 17. Transduction efficiency of the rAAV serotypes following intravitreal 
injection 
Taken from (Hellstrom et al, 2009). 
 
 
One of the reasons for the limited efficiency of AAV vectors to transduce retinal cells 
after intravitreal injection is the presence of the ILM at the junction of neuroretina and 
vitreous, which forms a structural and biochemical barrier for AAVs, likely due to the 
presence of specific receptors that sequester the viruses (Stieger et al, 2011). 
Accordingly, it has been shown that when the ILM is disrupted, either by progression of 
a retinal degeneration or by digestion with nonspecific proteases, it becomes possible to 
achieve a broader pattern of expression after intravitreal injection. Indeed, Dalkara et al. 
have shown that following ILM digestion, the AAV serotypes 2/1, 2/2, 2/5, 2/8, and 2/9, 
were all capable of transducing retinal cells, although to a variable degree, with the 
AAV2/5 serotype being the most efficient (Dalkara et al, 2009). 
In recent years, the potential of AAV vectors for the treatment of IRDs has been greatly 
enhanced by the development of new AAV serotypes, either through in vitro evolved or 
rationally-modified AAV capsids. Among these new serotypes, multiple tyrosine 
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mutants have shown significantly enhanced transduction properties, both by subretinal 
and, more importantly, intravitreal delivery. These mutants were developed by the 
Srivastava group in an attempt to redirect the intracellular trafficking of AAVs to obtain 
higher levels of transduction by escaping the proteasomal-mediated degradation. Basic 
trafficking studies suggested that capsid tyrosine residues could be phosphorylation 
sites that predestine AAV capsids for ubiquitination and subsequent proteosomal 
degradation, and thus by mutating these residues could result in increased transgene 
expression. To test this hypothesis, different AAV serotypes containing one or more 
tyrosines to phenylalanine substitution(s) were generated and demonstrated increased 
gene transfer efficiency in various in vitro and in vivo settings (Petrs-Silva et al, 2009; 
Zhong et al, 2008). In particular, they found that the single (Y444F, Fig. 18A) and triple 
mutants of AAV2/2 (Y444, 500, 730F) and 2/8-Y733F (Fig. 18A) had both stronger and 
more widespread transduction compared to their wild type counterparts when delivered 
subretinally in mice (Petrs-Silva et al, 2009). Strikingly, quadruple and pentuple 
tyrosine-mutant AAV2/2 vectors (Fig. 18B) have demonstrated efficient transduction of 
PRs following intravitreal delivery (Petrs-Silva et al, 2011).  
 
Figure 18. Transduction profiles of the AAV2/2 and AAV2/8 tyrosine mutants 
(A) Representative sections depicting EGFP fluorescence throughout the retina after 
subretinal delivery of AAV2/2 Y444F or AAV2/8 Y733F. Modified from (Petrs-Silva 
et al, 2009). (B) Immunostaining for GFP protein expression in retinal sections after 
intravitreal delivery of AAV2/2 quadruple mutant (Y272, 444, 500, 730F). Modified 
from (Petrs-Silva et al, 2011). 
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This last finding is particularly attractive for the treatment of IRDs, as intravitreal 
delivery of AAV vectors would allow for a more widespread and homogeneous 
transgene expression and would reduce the risk of surgical morbidity. 
Similar widespread retinal transduction after intravitreal delivery has been recently 
obtained from Dalkara and co-workers with a new AAV variant (7m8) identified 
through in vivo–directed evolution (Dalkara et al, 2013). Importantly, this vector 
provided therapeutic amounts of transduction of PR cells and RPE in both normal 
murine retina and in murine models of human retinal diseases. In addition, Dalkara and 
co-workers showed that intravitreal delivery of 7m8 vector results in PRs transduction 
also in the nonhuman primate retina, in which the ILM is a significantly thicker physical 
barrier to the retina than in rodent. In contrast, the 7m8 mediated RPE transduction in 
non human primate seemed to be impaired from the thick ILM, as they could not detect 
transgene expression in the RPE. 
 
3.4 Clinical success of AAVs for ocular gene therapy  
AAVs have been successfully used in dozens of proof-of-concept studies, both in small 
and large animal models that have demonstrated efficacy of AAV-mediated gene 
therapy for the treatment of recessive and dominant IRDs (Stieger et al, 2011). 
Historically, however, AAV-mediated gene delivery has been more effective in the 
treatment of IRDs caused by mutations in genes expressed in the RPE (Dejneka et al, 
2004; Gargiulo et al, 2009; Smith et al, 2003; Surace et al, 2005), rather than those 
caused by mutations in genes expressed in PRs (Bennett et al, 1996) (Allocca et al, 
2011; Schlichtenbrede et al, 2003), probably because of the above described features of 
the RPE (i.e. transducibility), the need for finely regulated transgene expression in PRs 
and/or the different rate of retinal degeneration that is usually faster in PRs diseases 
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(Smith et al, 2009). In fact, among the proof-of-concept studies, the most successful and 
advanced have been those performed in the Briard dog model of Leber Congenital 
Amaurosis type 2 (LCA2), which is homozygous for a null mutation in the RPE65 gene 
that encodes the RPE-specific all-trans retinol isomerase responsible for regenerating 
visual pigment after light exposure (Acland et al, 2001). Different groups have, indeed, 
proved that AAV2-mediated subretinal delivery of the RPE65 gene restores vision in 
this dog model (Acland et al, 2005; Le Meur et al, 2007; Narfstrom et al, 2003). This 
extraordinary result has opened the doors to three independent clinical trials tasked to 
test the safety and efficacy of subretinal administrations of AAV2 in LCA2 patients 
(Bainbridge et al, 2008; Hauswirth et al, 2008; Maguire et al, 2008). Notably, despite 
some differences among the various clinical trials (i.e. differences in regulatory 
sequences included in the vector, in the process of vector production and purification, 
independent selection and follow up of the patients, and independent surgical delivery), 
all trials have shown similar positive results. Importantly, these trials suggest that retinal 
gene therapy with AAV is safe and well tolerated in humans, that vision can be 
improved in patients that have suffered from severe visual function impairment, in some 
cases for decades, and that re-administration of AAV to the subretinal space is feasible, 
effective and safe.   
 
3.5 Overcoming AAV’s limits 
Despite these important successes in pre-clinical and clinical studies, AAV is still 
excluded for gene therapy of many diseases. This is primarily due to its major 
limitation: the packaging capacity, which is considered to be restricted to the size of the 
parental genome (4.7 kb). This hinders the treatment of certain forms of IRDs caused by 
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mutations in genes whose cDNA exceeds 5 kb, such as ABCA4 (Table 2). Thus, various 
strategies are being investigated to overcome AAV cargo limitations.  
 
 
Table 2. Examples of large genes associated with IRDs 
USH1F: Usher syndrome type IF; CSNB2: congential stationary night blindness type 2; 
RP: retinitis pigmentosa; ad: autosomal-dominant; ar: autosomal recessive; USH1B: 
Usher syndrome type IB; STGD1: Stargardt disease; LCA10: Leber congenital 
amaurosis type 10; USH1D: Usher syndrome type ID; USH2A: Usher syndrome type 
IIA; USH2C: Usher syndrome type IIC. 
 
 
DISEASE CAUSATIVE GENE 
CELL 
AFFECTED 
cDNA 
SIZE 
(kb) 
USH1F 
Protocadherin-related 15 
(PCDH15) 
Neurosensory 
retina 
5.9 
CSNB2 
Calcium channel, voltage-dependent, L type, 
alpha 1F subunit 
(CACNA1) 
Photoreceptors 5.9 
ad RP 
Small nuclear ribonucleoprotein 200 kDa 
(SNRNP200) 
Photoreceptors 
and RPE 
6.4 
ad or ar RP 
Retinitis pigmentosa 1 
(RP1) 
Photoreceptors 6.5 
USH1B 
Myosin 7A 
(MYO7A) 
Photoreceptors 
and RPE 
6.7 
STGD1 
ATP-binding cassette, sub-family A, member 4 
(ABCA4) 
Photoreceptors 6.8 
ad RP 
Pre-mRNA processing factor 8 homologue 
(PRPF8) 
Photoreceptors 
and RPE 
7.0 
Occult 
macular 
dystrophy 
Retinitis pigmentosa 1-like 1 
(RP1L1) 
Photoreceptors 7.2 
LCA10 
Centrosomal protein 290 kDa 
(CEP290) 
Photoreceptors 7.5 
USH1D 
Cadherin 23 
(CDH23) 
Neurosensory 
retina 
10 
USH2A and 
RP 
Usherin 
(USH2A) 
Neurosensory 
retina 
15.6 
ad macular 
dystrophy 
Hemicentin 1 
(HMCN1) 
Photoreceptors 
and RPE 
17 
USH2C 
G-coupled receptor 98 
(GPR98) 
Neurosensory 
retina 
18.9 
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Several groups have attempted to "force" large genes into one of the many AAV capsids 
available by developing the so-called oversize AAV vectors (Fig. 19) (Allocca et al, 
2008; Grieger & Samulski, 2005; Hirsch et al, 2010). Notably, oversize AAVs have 
been successfully used to achieve therapeutically-relevant levels of transgene 
expression in rodent and canine models of human inherited diseases (Grose et al, 2012; 
Lopes et al, 2013; Monahan et al, 2010), including the retina of the Abca4-/- mice, 
resulting in significant and stable morphological and functional improvement of 
diseased cells (Allocca et al, 2008). However, the mechanism underlying oversize 
AAV-mediated PR transduction remains elusive. In contrast to what was originally 
proposed (Allocca et al, 2008; Grieger & Samulski, 2005; Wu et al, 2007), oversize 
AAV vectors do not contain a pure population of intact, large genomes but rather a 
heterogeneous population of mostly truncated genomes (≤5 kb in length) (Dong et al, 
2010a; Lai et al, 2010; Wang et al, 2012; Wu et al, 2010b). Following infection, re-
assembly of these truncated genomes in the target cell nucleus has been proposed as a 
mechanism for oversize AAV vector transduction (Dong et al, 2010a; Hirsch et al, 
2010; Hirsch et al, 2013a; Lai et al, 2010; Wu et al, 2010b). Independent of transduction 
mechanism and in vivo efficacy, the heterogeneity of oversize AAV genomes remains a 
major limitation for their application in human gene therapy. 
Alternatively, the inherent ability of AAV genomes to undergo intermolecular 
recombination at their ITRs to form concatemeres (Duan et al, 1998) has been exploited 
to transfer large genes in vivo by splitting a large gene expression cassette into halves 
(<5 kb in size), each contained in one of two independent (dual) AAV vector (Duan et 
al, 2001; Ghosh et al, 2008; Yan et al, 2000). In the dual AAV trans-splicing strategy, 
the transgene is divided into two parts, at either an endogenous intron or an engineered 
synthetic intron, and a splice donor (SD) signal is placed at the 3’ end of the 5’-half 
vector and a splice acceptor (SA) signal at the 5’ end of the 3’-half vector (Fig. 19). 
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Upon co-infection of the same cell by the dual AAV vectors and ITR-mediated tail-to-
head concatemerization of the halves, trans-splicing results in the production of a 
mature mRNA that encodes a full-size WT protein (Yan et al, 2000). Trans-splicing has 
been successfully used to express large genes in muscle and retina (Lai et al, 2005; 
Reich et al, 2003). However, the transduction efficiency of this system was found to be 
lower than that of a single intact AAV vector, as it is impacted by a number of factors: 
(i) gene splitting site, as the sequences surrounding exon/intron junction can influence 
the splicing efficiency; (ii) levels of co-infection reached in the cells; (iii) formation of 
the concatemers in the tail-to-head orientation; and (iv) transcription and splicing across 
the complex structure formed by the ITRs upon concatemerization. 
Alternatively, the halves of a large transgene expression cassette contained in dual AAV 
vectors may contain homologous overlapping sequences (at the 3’ end of the 5’-half 
vector and at the 5’ end of the 3’-half vector, termed dual AAV overlapping), which, in 
a cell co-infected by both vectors, could mediate the reconstitution of a single large 
genome by homologous recombination (Duan et al, 2001). The success of this strategy, 
however, largely depends on the recombinogenic properties of the transgene 
overlapping sequences. Thus, only if a gene contains a highly recombinogenic region it 
will be possible to achieve therapeutic levels of expression (Ghosh et al, 2006). To 
overcome this problem, a third dual AAV strategy (hybrid) was developed by the group 
of Ghosh. This strategy is based on the addition of a highly recombinogenic region from 
an exogenous gene (i.e. alkaline phosphatase, AP (Ghosh et al, 2011; Ghosh et al, 2008) 
to the trans-splicing vector to increase recombination between the dual AAVs. The 
exogenous region is placed downstream of the SD signal in the 5'-half vector and 
upstream of the SA signal in the 3'-half vector (Fig. 19).  Importantly, the efficiency of 
this strategy is transgene-independent as the reconstitution of the full-length cassette 
relies on the recombination mediated by the exogenous homology region.  
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Figure 19. Schematic representation of AAV-based strategies for large gene 
transduction 
CDS: coding sequence; pA: poly-adenylation signal; SD: splicing donor signal; SA: 
splicing acceptor signal; AP: alkaline phosphatase recombinogenic region (Ghosh et al, 
2011); AK: F1 phage recombinogenic region. Pointed lines show overlapping regions 
available for homologous recombination, dotted lines show the splicing between SD 
and SA. 
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AIMS 
My Ph.D. project was aimed at overcoming the major limitation to the use of AAV 
vectors, the limited packaging capacity, for the treatment of IRDs such as STGD that 
are due to mutations in large (>5 kb) genes. IRDs are mainly due to mutations in genes 
expressed in PRs and, among the available gene transfer vectors, those based on AAV 
are the most efficient at targeting PRs and have been demonstrated to be safe and 
effective in humans. However, AAV small cargo capacity limits the application of AAV 
gene therapy approaches for common IRDs that are caused by mutations in genes whose 
coding sequence (CDS) is larger than 5 kb. The identification of AAV-based strategies 
that allow the delivery of large genes to the retina would thus expand the applicability 
of AAVs to these otherwise untreatable diseases. 
 Accordingly to this, the specific aims of my project were to: 
- develop dual AAV vector-based strategies for large gene delivery to the retina; 
- compare the efficiency of oversize to that of dual AAV vectors strategies for the  
delivery of large genes both in vitro and in vivo, in the retina; 
- compare the transduction efficiency of dual AAV vectors to that of a single 
normal size AAV vector; 
- characterize the effect of the AAV-mediated large gene expression in animal 
models of STGD. 
To this end, I generated oversize and dual AAV vectors encoding for either the reporter 
EGFP or the therapeutic ABCA4 protein. The efficiency of the various systems was 
first evaluated in vitro, in HEK293 cells, by Western blot (WB) analysis on lysates from 
cells infected with the vectors from each approach. The strategies subsequently found to 
be the best performing were tested in vivo, by subretinal injection in C57BL/6 mice and 
in pigs. Analysis of retinal cryosections and WB analysis of retinal lysates from eyes 
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injected with vectors coding for EGFP or ABCA4, respectively, were used to evaluate 
the relative efficiency of the AAV vector strategies. The transduction efficiency of the 
best performing dual AAV vectors was also evaluated, both in vitro and in vivo, in 
comparison to that of a single normal size AAV vector, by either WB analysis on 
cellular lysates or ELISA on retinal lysates of C56BL/6 mice. Finally, to assess the 
efficacy of dual AAV vector-mediated large gene delivery to the retina, I injected 
subretinally the most effective in vivo performing AAV vector approaches in the mouse 
model of the STGD (the Abca4-/- mouse) and evaluated the rescue of the retinal 
phenotypes.  
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MATERIALS AND METHODS 
Generation of AAV vector plasmids 
The plasmids used for AAV vector production were derived from either the pZac2.1 
(Gao et al, 2000) or pAAV2.1 (Auricchio et al, 2001a) plasmids that contain the 
inverted terminal repeats (ITRs) of AAV serotype 2 (Table 3). Normal size and oversize 
AAV vector plasmids contained full-length expression cassettes including the promoter, 
the full-length transgene CDS and the poly-adenylation signal (pA) (Table 3). The two 
separate AAV vector plasmids (5’ and 3’) required to generate dual AAV vectors 
contained either the promoter followed by the N-terminal portion of the transgene CDS 
(5’ plasmid) or the C-terminal portion of the transgene CDS followed by the pA signal 
(3’ plasmid). Normal size EGFP plasmids were generated by cloning the EGFP CDS of 
pAAV2.1-CMV-EGFP plasmid (720 bp) (Auricchio et al, 2001a) in pZac2.1 (Gao et al, 
2000); oversize EGFP was generated from pAAV2.1-CMV-EGFP (Auricchio et al, 
2001a) by inserting a DNA stuffer sequence of 3632 bp from human ABCA4 
(NM_000350.2, bp 1960-5591) upstream of the CMV promoter and a second DNA 
stuffer sequence of 3621 bp, composed of: murine ABCA4  (NM_007378.1, 1066-1 and 
7124-6046 bp; 2145 total bp) and human Harmonin (NM_153676.3 131-1606 bp; 1476 
total bp), downstream of the pA signal. To generate dual AAV vector plasmids, the 
EGFP CDS (720 bp) was split into two constructs: one containing the N-terminal CDS 
(PMID: 9759496, bp 1-393) and the other containing the C-terminal CDS (PMID: 
9759496, bp 394-720). The stuffer sequences flanking the EGFP expression cassette in 
the EGFP OZ plasmid were used to generate dual AAV-TS-L and dual AAV-AK-L 
plasmids (Table 3) with a combined (5’+3’) genome length similar to the EGFP OZ 
construct size. 
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The oversize ABCA4 plasmids contained the full-length human ABCA4 CDS 
(NM_000350.2, bp 105-6926). To generate plasmids for dual AAV OV vectors the 
ABCA4 CDS was split into two constructs, one containing N-terminal CDS 
(NM_000350.2, bp 105-3588) and the other containing C-terminal CDS 
(NM_000350.2, bp 2819-6926). Therefore, the region of homology shared by 
overlapping vector plasmids was 770bp. To generate trans-splicing and hybrid vector 
plasmids the ABCA4 CDS was split between exons 19-20 (5’ half: NM_000350.2, 105-
3022 bp; 3’ half: NM_000350.2, bp 3023-6926). The ABCA4 protein was tagged at its 
C-terminus with either the 3xflag or hemagglutinin (HA) tag. In addition, the ABCA4 
protein was tagged at both N- (amino acidic position 590) and C-termini with the 3xflag 
tag for the experiments shown in Figures 34-35. The splice donor (SD) and splice 
acceptor (SA) signals contained in dual trans-splicing and hybrid AAV vector plasmids 
are as follows: 5-
’GTAAGTATCAAGGTTACAAGACAGGTTTAAGGAGACCAATAGAAACTGGG
CTTGTCGAGACAGAGAAGACTCTTGCGTTTCT-3’ (SD); 5’-
GATAGGCACCTATTGGTCTTACTGACATCCACTTTGCCTTTCTCTCCACAG-3’ 
(SA). The recombinogenic sequence contained in hybrid AP vector plasmids was 
derived from alkaline phosphatase (AP) gene (NM_001632, bp 823-1100), as 
previously described (Ghosh et al, 2011). The recombinogenic sequence contained in 
hybrid AK vector plasmids was derived from the F1 phage genome (Gene Bank 
accession number: J02448.1; bp 5850-5926). The AK sequence is: 5’-
GGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAA
AATTTAACGCGAATTTTAACAAAAT-3’. To generate the pZac2.1-CMV-RFP 
plasmid, the monomeric RFP CDS (Campbell et al, 2002) (675bp) was amplified and 
cloned in pZac2.1-CMV-EGFP plasmid using EcoRI and BamHI restriction sites.  
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The ubiquitous CMV promoter is that contained in pZac2.1 (Gao et al, 2000) or 
pAAV2.1-CMV-EGFP (Auricchio et al, 2001a); the PR-specific human RHO and 
RHOK promoters were derived from pAAV2.1-RHO-EGFP and pAAV2.1-RHOK-
EGFP, respectively (Allocca et al, 2007); the RPE-specific VMD2 promoter 
(NG_009033.1, 4870-5470 bp) corresponds to the previously described EcoRI-XcmI 
promoter fragment (Esumi et al, 2004) and was amplified from human genomic DNA.  
 
AAV vector production and characterization 
AAV vectors were produced by the TIGEM AAV Vector Core by triple transfection of 
HEK293 cells followed by two rounds of CsCl2 purification (Mueller et al, 2012). For 
each viral preparation, physical titers [genome copies (GC)/mL] were determined by 
averaging the titer achieved by dot-blot analysis (Drittanti et al, 2000) and by PCR 
quantification using TaqMan (Applied Biosystems, Carlsbad, CA, USA) (Mueller et al, 
2012). The probes used for dot-blot and PCR analyses were designed to anneal with 
either the ITRs or regions within 1Kb from the ITRs. No statistically significant 
differences were found in the titers (GC/mL) of NS AAV2/2 or AAV2/8 compared to 
those of dual AAV OV, TS and hybrid vectors (Table 4). The alkaline Southern blot 
analysis shown in Figure 20 was carried out as follows: 3x1010 GC of viral DNA were 
extracted from AAV particles. To digest unpackaged genomes, the vector solution was 
resuspended in 240 µL of PBS pH 7.4 1X (GIBCO, Invitrogen S.R.L., Milan, Italy) and 
then incubated with 1U/µL of DNase I (Roche, Milan, Italy) in a total volume of 300 µL 
containing 40mM TRIS-HCl, 10mM NaCl, 6mM MgCl2, 1mM CaCl2 pH 7.9 for 2 
hours at 37°C. The DNase I was then inactivated with 50 mM EDTA, followed by 
incubation with proteinase K and 2.5% N-lauroyl-sarcosil solution at 50°C for 45 
minutes to lyse the capsids. The DNA was extracted twice with phenol-chloroform and 
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precipitated with 2 volumes of ethanol 100% and 10% sodium acetate (3M, pH 7). 
Alkaline agarose gel electrophoresis and blotting were performed as previously 
described (Sambrook & Russell, 2001). Ten µL of the 1 kb DNA ladder (N3232L, New 
England Biolabs, Ipswich, MA, USA) were loaded as molecular weight marker. Three 
different double strand DNA fragments were radio-labeled with [α-32]-CTP using the 
Amersham Rediprime II DNA labeling System (GE Healthcare Europe, GmbH, Milan, 
Italy) and used as probes. The 5’ probe (875 bp) was generated by digestion of the 
pZac2.1-CMV-ABCA4_5’ plasmid with EagI; the 3’ probe (880 bp) was generated by 
double digestion of the pZac2.1-ABCA4_3’_3xflag_SV40 plasmid with StuI and NcoI; 
the EGFP probe (735 bp) was generated by digestion of the pAAV2.1-CMV-EGFP 
plasmid with NotI and BamHI. Prehybridization and hybridization were performed at 
65°C in Church buffer (Sambrook & Russell, 2001) for 1 hour and overnight, 
respectively. Then, the membrane (Whatman Nytran N, charged nylon membrane, 
Sigma-Aldrich, Milan, Italy) was washed for 30 minutes in SSC 2X-0.1% SDS and for 
30 minutes in SSC 0.5X-0.1% SDS at 65°C, and then for 30 minutes in SSC 0.1X-0.1% 
SDS at 37°C. The membrane was then analyzed by X-ray autoradiography using 
Amersham HyperfilmTM MP (GE Healthcare Europe, GmbH, Milan, Italy). 
 
AAV infection of HEK293 cells 
HEK293 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% fetal bovine serum and 2 mM L-glutamine (GIBCO, Invitrogen S.R.L., 
Milan, Italy). Cells were plated in six-well plates at a density of 2×106 cells/well and 
transfected 16 hours later with 1.3 µg of pDeltaF6 helper plasmid which contains the Ad 
helper genes (Zhang et al, 2000) using the calcium phosphate method. After 5 hours, 
cells were washed once with DMEM and incubated with AAV2/2 vectors (m.o.i: 5x104 
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GC/cell of each vector; 1:1 co-infection with dual AAV vectors resulted in of 1x105 
total GC/cell) in a final volume of 700 µL serum-free DMEM. Two hours later 2 mL of 
complete DMEM were added to the cells. Cells were harvested 72 hours following 
infection for Western blot analysis. To compare dual AAV to single AAV NS vectors 
(Figure 22) I used the same dose of each vector because I considered that one GC of the 
5’-vector plus one GC of the 3’-vector of dual AAVs are required to re-constitute one 
full-size functional genome as that contained in one particle of AAV NS. 
 
Animal models  
Mice were housed at the Institute of Genetics and Biophysics animal house (Naples, 
Italy) and maintained under a 12-hour light/dark cycle (10-50 lux exposure during the 
light phase). C57BL/6 and BALB/c mice were purchased from Harlan Italy SRL 
(Udine, Italy). Albino Abca4-/- mice were generated through successive crosses and 
backcrosses with BALB/c mice (homozygous for Rpe65 Leu450) (Radu et al, 2004) and 
maintained inbred. Breeding was performed crossing homozygous mice. The Large 
White Female pigs used in this study were registered as purebred in the LWHerd Book 
of the Italian National Pig Breeders’ Association (Azienda Agricola Pasotti, Imola, 
Italy). 
 
Subretinal injection of AAV vectors in mice and pigs 
This study was carried out in accordance with the Association for Research in Vision 
and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision 
Research and with the Italian Ministry of Health regulation for animal procedures. All 
procedures on mice were submitted to the Italian Ministry of Health; Department of 
Public Health, Animal Health, Nutrition and Food Safety on October 17th, 2011. The 
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Ministry of Health approved the procedures by silence/consent, as per article 7 of the 
116/92 Ministerial Decree. Surgery was performed under anesthesia and all efforts were 
made to minimize suffering. 
Mice (4-5 weeks-old) were anesthetized with an intraperitoneal injection of 2 mL/100 g 
body weight of avertin [1.25% w/v of 2,2,2-tribromoethanol and 2.5% v/v of 2-methyl-
2-butanol (Sigma-Aldrich, Milan, Italy)] (Papaioannou & Fox, 1993), then AAV2/8 
vectors were delivered subretinally via a trans-scleral trans-choroidal approach as 
described by Liang et al (Liang, 2000). All eyes were treated with 1 µL of vector 
solution. The AAV2/8 doses (GC/eye) delivered vary across the different mouse 
experiments as it is described in the “RESULTS” section. To compare dual AAV to 
single AAV NS vectors (Figure 29) I used the same dose of each vector because I 
considered that one GC of the 5’-vector plus one GC of the 3’-vector of dual AAVs are 
required to re-constitute one full-size functional genome as that contained in one 
particle of AAV NS. 
AAV2/1-VMD2-human Tyrosinase (Gargiulo et al, 2009) (dose: 2-5x108 GC/eye) was 
added to the AAV2/8 vector solution that was delivered subretinally to albino mice 
(Abca4-/- and BALB/c). This allowed to mark the RPE within the transduced part of the 
eyecup, which was subsequently dissected and analysed. Subretinal delivery of AAV 
vectors to the pig retina was performed as previously described (Mussolino et al, 2011). 
All eyes were treated with 100 µL of AAV2/8 vector solution. The AAV2/8 dose was 
1x1010 (Fig. 24) or 1x1011 GC of each vector/eye (Fig. 31 and Fig. 33) and co-injection 
of dual AAV vectors resulted in a total dose of 2x1010 GC/eye or 2x1011 GC/eye, 
respectively.  
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Western blot analysis & ELISA.  
Samples [(HEK293 cells, retinas or eyecups (cups+retinas)] for Western blot analysis 
were lysed in RIPA buffer (50 mM Tris-HCl pH 8.0, 150mM NaCl, 1% NP40, 0.5% 
Na-Deoxycholate, 1mM EDTA pH 8.0, 0.1% SDS) to extract EGFP protein, or in SIE 
buffer (250 mM sucrose, 3 mM imidazole pH 7.4, 1% ethanol, and 1% NP-40) to 
extract ABCA4 protein. Lysis buffers were supplemented with protease inhibitors 
(Complete Protease inhibitor cocktail tablets, Roche, Milan, Italy) and 1 mM 
phenylmethylsulfonyl. After lysis EGFP samples were denatured at 99°C for 5 minutes 
in 1X Laemli sample buffer; ABCA4 samples were denatured at 37°C for 15 minutes in 
1X Laemli sample buffer supplemented with 4M urea. Lysates were separated by 6% 
(ABCA4 samples) or 12% (EGFP samples) SDS-polyacrylamide gel electrophoresis. 
The antibodies used for immuno-blotting are as follows: anti-EGFP (sc-8334, Santa 
Cruz, Dallas, TX, USA, 1:500); anti-3xflag (A8592, Sigma-Aldrich, 1:1000); anti-β-
Tubulin (T5201,Sigma Aldrich, 1:10000); anti-Filamin A (catalog#4762, Cell Signaling 
Technology, Danvers, MA, USA, 1:1000); anti-Dysferlin (Dysferlin, clone Ham1/7B6, 
MONX10795, Tebu-bio, Le Perray-en-Yveline, France, 1:500). The quantification of 
EGFP and ABCA4 bands detected by Western blot was performed using ImageJ 
software (free download is available at http://rsbweb.nih.gov/ij/). EGFP expression was 
normalized to β-Tubulin; ABCA4 expression was normalized to Filamin A or Dysferlin 
for the in vitro and in vivo experiments, respectively, while Ponceau S (P7170, Sigma-
Aldrich, Sigma-Aldrich, Milan, Italy) staining was used as loading control of the 
Western Blot depicted in Figure 33. Different proteins were used for normalization 
based on the similarity of their molecular weight to those of the different transgene 
products. The TS (Fig. 21B), TS-L (Fig. 21D) and NS (Fig. 22B) histogram do not have 
standard error bars as only one TS, TS-L or NS sample has been loaded on each SDS-
PAGE and used as internal reference sample in each independent experiment. To show 
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the internal variability of TS, TS-L and NS samples I calculated the expression of 
proteins as percentage relative to the AK sample (set to 100%) which are the following: 
Fig. 21B: TS=106±16%; Fig. 21D: TS-L=39±6%; Fig. 22B: NS=906±281%. The 
ELISA was performed on retina or eyecup lysates using the Max Discovery Green 
Fluorescent Protein Kit ELISA (Bioo Scientific Corporation, Austin, TX, USA). 
 
Fundus photography 
The fundus live-imaging was performed by dilating the eye of C57BL/6 with a drop of 
tropicamide 1% (Visufarma, Rome, Italy) and subsequent eye stimulation with a 300W 
flash. Fundus photographs were taken using a Topcon TRC-50IX retinal camera, with a 
FITC filter, connected to a charge-coupled-device Nikon D1H digital camera (Topcon 
Medical System, Oakland, NJ, USA). 
 
Histology, light and fluorescence microscopy 
To evaluate EGFP expression in histological sections, eyes from C57BL/6 mice or 
Large White pigs (Mussolino et al, 2011) were enucleated one month after AAV2/8 
injection. Mouse eyes were fixed in 4% paraformaldehyde over-night and infiltrated 
with 30% sucrose over-night; the cornea and the lens were then dissected and the 
eyecups were embedded in optimal cutting temperature compound (O.C.T. matrix, 
Kaltek, Padua, Italy). Serial cryosections (10 µm thick) were cut along the horizontal 
meridian and progressively distributed on slides. PR co-transduction following 
subretinal combined delivery of AAV2/8-CMV-EGFP and -RFP vectors has been 
evaluated as follows: retinal cryosections from n=6 eyes were analysed under a 
fluorescent microscope using either the FITC (to visualize EGFP+ cells) or Rhodamine 
(to visualize RFP+ cells) filters. For each eye, RFP+ PRs contained in one field at 20X 
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magnification (at least 100) and the corresponding EGFP+ PRs (at least 200) were 
photographed and then counted. PRs expressing both EGFP and RFP were 
unequivocally identified based on their identical shape on picture micrographs of the 
same field taken under either the FITC or Rhodamine filter. To calculate the percentage 
of co-transduced PRs, the number of PRs expressing both EGFP and RFP was divided 
by the total number of transduced PRs, i.e. PRs expressing at least one of the two 
reporter genes. 
Pig eyes were fixed in 4% paraformaldehyde for 48 hours, infiltrated with 10% sucrose 
for 4 hours, 20% sucrose for 4 hours and finally 30% sucrose overnight. Then, the 
cornea, the lens, and the vitreous body were dissected and the EGFP-positive portions 
of the eyecups were embedded in optimal cutting temperature compound (O.C.T. 
matrix, Kaltek). Serial cryosections (12 µm thick) were cut along the horizontal 
meridian and progressively distributed on slides. Retinal histology pictures were 
captured using a Zeiss Axiocam (Carl Zeiss, Oberkochen, Germany). Subretinal 
delivery in pigs of AAV vectors encoding for EGFP under the control of the Rhodopsin 
promoter resulted in PRs transduction in: 100% of the retinas injected with: dual AAV 
TS (4/4); and dual AAV hybrid AK (3/3) (Fig. 31). 
 
Electron microscopy and immuno-gold labelling 
For electron microscopy analyses, eyes were harvested from Abca4-/- mice 3 months 
after AAV injection. Eyes were fixed in 0.2% glutaraldehyde-2% paraformaldehyde in 
0.1M PHEM buffer pH 6.9 (240 mM PIPES, 100 mM HEPES, 8mM MgCl2, 40 mM 
EGTA) for 2 hours and then rinsed in 0.1 M PHEM buffer. Eyes were then dissected 
under the light to select the Tyrosinase-positive portions of the eyecups of albino 
Abca4-/-and BALB/c mice. The transduced portion of the eyecups was subsequently 
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embedded in 12% gelatin, infused with 2.3M sucrose and frozen in liquid nitrogen. 
Cryosections (50 nm) were cut using a Leica Ultramicrotome EM FC7 (Leica 
Microsystems) and extreme care was taken to align PR connecting cilia longitudinally. 
To avoid bias in the attribution of morphological data to the various experimental 
groups, measurements of RPE thickness and counts of lipofuscin granules in Abca4-/- 
eyes were performed by a masked operator (Roman Polishchuk) using the iTEM 
software (Olympus SYS, Hamburg, Germany). Briefly, RPE thickness was measured in 
at least 30 different areas along the specimen length using the “Arbitrary Line” tool of 
iTEM software. The “Touch count” module of the iTEM software was utilized to count 
the number of lipofuscin granules in the 25μm2 areas distributed randomly across the 
RPE layer. The granule density was expressed as number of granules per 25μm2. The 
immuno-gold analysis aimed at testing the expression of ABCA4-HA in Abca4-/- 
samples after AAV vector delivery was performed by incubating cryosections 
successively with monoclonal anti-HA antibody (MMS-101P-50, Covance, 1:50), rabbit 
anti-mouse IgG, and 10-nm gold particle-conjugated protein A.  
 
Electrophysiological analyses 
Electroretinograms (ERGs) measure the electrical response of the retina to flashes of 
light and are recorded with an electrode in contact with the cornea (Ogden, 2001). A 
single-flash with light, if the retina is dark-adapted, elicits a combined rod-plus-cone 
response, characterized by an initial a-wave, showing a hyperpolarization of the PRs 
and a subsequent b-wave resulting from a depolarization of the cells in the inner nuclear 
layer. The ERG were performed as previously described (Allocca et al, 2011). Briefly, 
ERG were evoked by 10ms flashes of different light intensities ranging from 10e-4 to 
20 cd m-2 s-1 generated through a Ganzfield stimulator. To minimize the noise, three 
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different responses evoked by light were averaged for each luminance step (with a time 
interval between light stimuli of 15-30 sec). After completion of responses obtained in 
dark-adapted conditions (scotopic) the recording session continued with the aim to 
dissect the cone pathway mediating the light response (photopic). To this end, the 
electroretinogram in response to light of 20 cd m-2 s-1 was recorded in the presence of a 
continuous background light (background light set at 50 cd m-2). 
To assess the recovery from light desensitization, after 180 min of dark adaptation, eyes 
were stimulated with 3 light flashes of 1 cd s/m2 and then desensitized by exposure to 
constant light (300 cd/m2) for 3 minutes. Then, eyes were stimulated over time using the 
pre-desensitization flash (1 cd s/m2) at 0, 5, 15, 30, 45 and 60 minutes post-
desensitization. The recovery of rod activity was evaluated by performing the ratio 
between the b-wave generated post-desensitization (at the different time points) and that 
generated pre-desensitization.  
 
RNA extraction, cDNA production and reverse transcription analyses.  
RNA was extracted at 72 hours after HEK293 cells infection with dual AAV2/2 TS and 
hybrid AK vectors encoding for either ABCA4 (5’+3’halves) or, as negative controls, 
with either the 5’or 3’half of dual AAV2/2 vectors or with a single NS AAV2/2 EGFP 
vector. Total RNA was extracted using the RT-PCR RNeasy MiniKit (Qiagen, Milan, 
Italy). One µg of RNA was submitted to DNase I digestion (RNase Free DNase set, 
Qiagen) and cDNA was generated using the QuantiTect reverse transcription kit 
(Qiagen). To amplify the ABCA4 mRNA region corresponding to the exon-intron 
junction used in dual AAV TS and hybrid AK vectors, one µL of cDNA and the 
following primers were used: Abca4_RT_Fw 5’-GCTGGGAAAACCACCACC-3’ and 
Abca4_RT_Rev 5’-GTGGACACATGCCAAGGC-3’. A PCR product of the expected 
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size (130 bp) was then sequenced. Five µL of cDNA were insted used to amplify the 
full-length ABCA4 mRNA (6.9 Kb) with a long-range PCR using TaKaRa LA Taq 
DNA polymerase kit (TaKaRa, Kioto, Japan), and the following primers: ATGFw: 5’- 
GGTACCTCTAGAGTCGACCCGG-3’, which anneals upstream of the ATG start 
codon and SV40polyA-Rev 5’-ACTCATCAATGTATCTTATCATGTCTG-3’.  
 
Statistical analysis 
Statistical p values ≤0.05 were considered significant. One-way ANOVA with post-hoc 
Multiple Comparison Procedure was used to compare data depicted in: Figure 21 (p 
ANOVA= B. 0.012; D. 0.002); Figure 22B (p ANOVA=2.3x10-8); Figure 28 (p 
ANOVA= A: 0.13; B: 0.16); Figure 29 (p ANOVA=1.9x10-12); Figure 37 (p 
ANOVA=0.1639) Figure 40B (p ANOVA=0.00126); Figure 42 (p ANOVA=2.2x10-5); 
Table 4 (2/2 preps: p ANOVA=0.0698; 2/8 preps: p ANOVA=0.0767). As the counts of 
lipofuscin granules (Fig. 39) are expressed as discrete numbers, these were analyzed by 
deviance from a Negative Binomial generalized linear models (Venables VN & Ripley 
BD, 2002) (p value analysis of deviance: 1.7x10-7). The statistically significant 
differences between groups determined with the post-hoc Multiple Comparison 
Procedure are the following: Figure 21B: OV vs OZ p=0.03; OV vs AP p=0.016; Figure 
21D: AK-L vs OZ p=0.003; AK-L vs TS-L p=0.005; Figure 22B: NS-EGFP vs TS-
EGFP p=0; NS-EGFP vs AK-EGFP p=1x10-7; Figure 29: NS-EGFP vs TS-EGFP p=0; 
NS-EGFP vs AK-EGFP p=0; Figure 39: WT vs Abca4-/- neg p=0.016; WT vs Abca4-/- 
AK-ABCA4 p=0.03; Abca4-/- neg vs Abca4-/- TS-ABCA4 p=0.0005; Abca4-/- neg vs 
Abca4-/- AK-ABCA4 p=9x10-8; Figure 40: Abca4-/- neg vs Abca4-/- TS-ABCA4 
p=0.012; Abca4-/- neg vs Abca4-/- AK-ABCA4 p=0.002; Figure 42 (60 min): Abca4-/- 
neg vs Abca4-/- AK-ABCA4: 0.05; Abca4-/- neg vs Abca4-/- TS-ABCA4: 0.009; Abca4-
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/- AK-ABCA4 vs WT: 0.002; Abca4-/- TS-ABCA4 vs WT: 0.02 Abca4-/- neg vs WT 
1x10-5.  
The Student’s t-test was used to compare data depicted in Figures 30, 37 and 41. The 
data in the manuscript are depicted as mean ± s.e.m (standard error of the mean). The 
s.e.m has been calculated using the number of independent in vitro experiments or eyes 
(not replicate measurements of the same sample). 
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RESULTS 
1. Generation of normal size, oversize and dual AAV vectors. 
The first part of the project was focused on the design and generation of the plasmids, 
and the corresponding AAV vectors, for the previously described AAV vector 
strategies. In addition to the vectors expressing the therapeutic ABCA4 gene, to treat the 
STGD mouse model, I have decided to also use vectors expressing the reporter EGFP 
gene to compare the efficiency of the different approaches. The latter transgene allowed 
me the advantage of direct visualization of the layer of retinal cells expressing the 
reporter gene as well as the ability to compare the efficacy of dual AAVs to that of a 
single normal-size AAV vector. The constructs generated for AAV vector production 
used in this study are listed in Table 3. In particular, for the therapeutic ABCA4 gene, I 
generated AAV oversize (OZ), dual AAV overlapping (OV), dual AAV trans-splicing 
(TS) and hybrid vectors. The recombinogenic sequences included in the dual AAV 
hybrid vectors were based on either a previously reported region of the alkaline 
phosphatase transgene (AP, dual AAV hybrid AP) (Ghosh et al, 2011) or a 77 bp 
sequence from the F1 phage genome (AK, dual AAV hybrid AK) that we found to be 
recombinogenic in previous in vitro experiments (Colella and Auricchio, unpublished 
data). Additionally, I generated AAV OZ and dual AAV vectors including the reporter 
EGFP with the exception of the dual AAV OV approach since its efficiency relies on 
transgene-specific overlaps for reconstitution (Ghosh et al, 2006) and, therefore, can not 
be extrapolated from one gene to another. For EGFP I also generated single AAV 
vectors of normal size (NS) to compare levels of transgene expression from the various 
strategies. I used AAV2/2 vectors for the in vitro experiments, with the ubiquitous 
cytomegalovirus (CMV) promoter, which efficiently transduce HEK293 cells (Dong et 
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al, 2010b). In the experiments performed in vivo in the retina, I used AAV2/8 vectors, 
which efficiently transduce RPE and PRs (Allocca et al, 2007; Mussolino et al, 2011; 
Vandenberghe et al, 2011) but poorly infect HEK293 cells, and either the ubiquitous 
CMV promoter (Mussolino et al, 2011), the RPE-specific vitelliform macular dystrophy 
2 (VMD2) (Esumi et al, 2004), or the PR-specific Rhodopsin (RHO) and Rhodopsin 
kinase (RHOK) promoters (Allocca et al, 2007). 
 
Plasmid 
Size 
ITR- ITR (bp) 
AAV serotype 
2/2 2/8 
N
o
rm
a
l 
S
iz
e 
(N
S
) 
pZac2.1-CMV-EGFP-SV40 3006 X X 
pZac2.1-CMV-RFP-SV40 2653  X 
pZac2.1-RHO-EGFP-SV40 2900  X 
O
v
er
si
ze
 
(O
Z
) 
pAAV2.1-CMV-EGFP-9.9-SV40 9954 X X 
pZac2.1-CMV-ABCA4_3xflag-SV40 8619 X  
O
v
er
la
p
p
in
g
 (
O
V
) 
pZac2.1-CMV-ABCA4_5’ 4900 X X 
pZac2.1-RHO-ABCA4_5’ 4805  X 
pZac2.1-RHOK-ABCA4_5’ 4169  X 
pZac2.1-VMD2-ABCA4_5’ 4658  X 
pZac2.1-ABCA4_3’_3xflag_SV40 4740 X X 
T
ra
n
s-
sp
li
ci
n
g
 (
T
S
) 
pZac2.1-CMV-ABCA4 _5’TS 4431 X  
pZac2.1-CMV-3xflag-ABCA4 _5’TS 4497 X X 
pZac2.1-RHO-ABCA4_ 5’TS 4321  X 
pZac2.1-ABCA4 _3’TS_3xflag_SV40 4587 X X 
pZac2.1-CMV-EGFP_5’TS 1906 X X 
pZac2.1-CMV-EGFP_5’TS-L 4016 X X 
pZac2.1-RHO-EGFP_5’TS 1802  X 
pZac2.1-EGFP_3’TS_SV40 1510 X X 
pZac2.1-EGFP_3’TS_SV40-L 4551 X X 
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Plasmid 
Size 
ITR- ITR (bp) 
AAV serotype 
2/2 2/8 
H
y
b
ri
d
 
A
P
 (
A
P
) pZac2.1-CMV-ABCA4_5’AP 4708 X  
pZac2.1-ABCA4 _3’AP_3xflag_SV40 4871 X  
H
y
b
ri
d
 A
K
 (
A
K
) 
pZac2.1-CMV-ABCA4 _5’AK 4540 X  
pZac2.1-CMV-3xflag-ABCA4 _5’AK 4606 X X 
pZac2.1-RHO-ABCA4_ 5’AK 4436  X 
pZac2.1-ABCA4 _3’AK_3xflag_SV40 4702 X X 
pZac2.1-ABCA4_ 3’AK_HA_SV40 4663  X 
pZac2.1-CMV-EGFP_5’AK 2015 X X 
pZac2.1-CMV-EGFP_5’AK-L 4125 X X 
pZac2.1-RHO-EGFP_5’AK 1911  X 
pZac2.1-EGFP_3’AK_SV40 1614 X X 
pZac2.1-EGFP_3’AK_SV40-L 4660 X X 
 
Table 3. Plasmids for AAV vector production 
CMV: cytomegalovirus promoter; RHO: human Rhodopsin promoter; RHOK: human 
Rhodopsin kinase promoter; VMD2: vitelliform macular dystrophy 2 promoter; EGFP: 
enhanced green fluorescent protein; RFP: red fluorescent protein; ABCA4: human ATP-binding 
cassette, sub-family A, member 4; SV40: simian virus 40 poly-adenilation signal; 3xflag: 3xflag 
tag; HA: hemagglutinin tag; AP: alkaline phosphatase recombinogenic region; AK: F1 phage 
recombinogenic region; L: dual AAV vectors containing a combined (5'+3') large (>5 Kb in 
length) genome. 
 
 
As shown in Table 3, each half of the dual AAV approaches was designed to have a 
genome that is compatible with the packaging capacity of normal size AAV vectors. 
However, to better assess the genome content of these vectors and to confirm that the 
presence of recombinogenic region in some of these vectors did not influenced the 
production of the viruses, I performed Southern blot analysis of viral DNA extracted 
from several dual AAV OV, TS and hybrid AK viral preparations. This analysis 
confirmed that the genome contained in dual AAV vectors is homogeneous and has the 
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expected length, independent of the presence of recombinogenic elements in the dual 
AAV vectors (Fig. 20) 
 
Figure 20. The genome of dual AAV RHO-ABCA4 vectors is correctly packaged in 
AAV capsids. 
Alkaline Southern blot analysis of DNA extracted from 3x1010 genome copies of either 
single AAV of normal size (NS-EGFP) or dual AAV2/8-overlapping (OV-ABCA4), 
hybrid AK (AK-ABCA4) and trans-splicing (TS-ABCA4) vectors containing the RHO-
ABCA4-3xflag expression cassette. The expected size of each genome is depicted in 
brackets above each corresponding lane. The molecular weight marker (kb) is shown on 
the left. The probes used for the hybridization are described in the Materials and 
Methods section. 
 
 
In addition, the titers (GC/mL) of both AAV2/2 and AAV2/8 viral preparations were 
comparable to the titers of the regular NS AAV vectors (Table 4).  
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AAV2/2 AAV2/8 
NSa 
(GCb/mL) 
5'-half 
(GC/mL) 
3'-half 
(GC/mL) 
NS 
(GC/mL) 
5-half 
(GC/mL) 
3'-half 
(GC/mL) 
Average 3.8x1012 8.3x1012 4.2x1012 9.8x1012 1.1x1013 6.7x1012 
s.e.m.c 6.8x1011 1.6x1012 9.6x1011 2.3x1012 1.3x1012 1.4x1012 
nd preps 20 31 19 20 47 27 
 
Table 4. The titers of dual AAV vectors are similar to those of regular AAV 
vectors of normal size. 
N.B. aNS: normal size; bGC: genome copies; cs.e.m.: standard error of the mean; dn: 
number of AAV preparations. The 5’-half sample includes single 5’-halves of dual 
AAV overlapping, trans-splicing and hybrid vectors; the 3’-half sample includes single 
3’-halves of dual AAV overlapping, trans-splicing and hybrid vectors. No statistically 
significant differences using ANOVA were found in the titers of NS AAV2/2 or 
AAV2/8 compared to those of dual AAV vectors.  
 
 
  
 
2. Dual AAV vectors allow high levels of transduction in vitro. 
I initially compared the efficiency of the various OZ, dual AAV OV, TS and hybrid AP 
and AK strategies for AAV-mediated large gene transduction in vitro by infecting 
HEK293 cells with the AAV2/2 vectors [multiplicity of infection, m.o.i.: 105 genome 
copies (GC)/cell of each vector] under the control of the ubiquitous CMV promoter. 
Cell lysates were analyzed by Western blot with anti-3xflag (to detect ABCA4-3xflag, 
Fig. 21A) antibodies. All strategies resulted in the expression of proteins of the expected 
size. As predicted, no bands of the expected size were observed when only one of the 
dual AAV vectors was used for infection. Quantification of protein expression (Fig. 
21B) showed that the dual AAV hybrid AP approach resulted in the lowest levels of 
transgene expression, while the dual AAV OV, TS and hybrid AK approaches were 
more efficient than the AAV OZ approach. I then confirmed this using the EGFP 
transgene. For this purpose I selected the best performing dual AAV strategies (TS and 
hybrid AK; I did not use the transgene-specific OV strategy with EGFP, since, as 
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previously mentioned, its efficiency relies on transgene-specific overlaps for 
reconstitution and therefore can not be extrapolated from one gene to another) and 
further compared them to AAV OZ. I thus produced AAV2/2-CMV-OZ-EGFP vectors 
and for comparison -TS- and -AK-EGFP-L in which the combined dual AAV vector 
genome length is similar to that of AAV OZ (Table 3). 
 
Figure 21. Dual AAV overlapping, trans-splicing and hybrid AK vectors efficiently 
transduce large genes in vitro. 
Representative Western blot analysis of HEK293 cells infected with AAV2/2 vectors 
encoding for ABCA4 (A-B) and EGFP (C-D). (A, C) The arrows indicate full-length 
proteins, the micrograms of proteins loaded are depicted under each lane, the molecular 
weight ladder is depicted on the left. (B, D) Quantification of ABCA4 (B) and EGFP 
(D) protein bands. The intensity of the ABCA4 and EGFP bands was divided by the 
intensity of the Filamin A or Tubulin bands, respectively. The histograms show the 
expression of proteins as a percentage relative to dual AAV trans-splicing (TS) vectors, 
the mean value is depicted above the corresponding bar. Values are represented as mean 
± s.e.m. (standard error of the mean). (A-D) The Western blot images are representative 
of and the quantifications are from n=4 independent experiments. OZ: AAV oversize; 
OV: dual AAV overlapping; TS: dual AAV trans-splicing; AP: dual AAV hybrid AP; 
AK: dual AAV hybrid AK; TS-L: dual AAV trans-splicing EGFP with a combined 
genome size similar to OZ-EGFP; AK-L: dual AAV hybrid AK EGFP with a combined 
genome size similar to OZ-EGFP; 5’+3’: cells co-infected with 5’- and 3’-half vectors; 
5’: control cells infected with the 5’-half vector; 3’: control cells infected with the 3’-
half vector; α-3xflag: Western blot with anti-3xflag antibody; α-EGFP: Western blot 
with anti-EGFP antibody; α-β-Tubulin: Western blot with anti-β-Tubulin antibody, used 
as loading control; α-Filamin A: Western blot with anti-Filamin A antibody, used as 
loading control. *p ANOVA<0.05. More details on the statistical analysis including 
specific statistical values can be found in the Statistical analysis paragraph of the 
Materials and Methods section. 
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I infected HEK293 cells with AAV2/2-CMV-EGFP vectors [multiplicity of infection, 
m.o.i.: 105 genome copies (GC)/cell of each vector] and performed Western blot 
analysis of cell lysates with anti-EGFP antibodies (Fig. 21C). Similarly to what was 
observed with the ABCA4 transgene, quantification of EGFP expression (Fig. 21D) 
showed that dual AAV TS and hybrid AK approaches are more efficient than AAV OZ. 
Then, to assess which was the  in vitro efficiency of the dual AAV vectors relatively to 
a single AAV vector, I infected HEK293 cells with dual AAV TS and hybrid AK 
vectors encoding for EGFP [multiplicity of infection, m.o.i.: 105 genome copies 
(GC)/cell of each vector] and compared, by Western blot analysis, the levels of protein 
expression achieved with these vectors to those of a single AAV-NS-EGFP (Fig. 22).  
 
Figure 22. In vitro transduction efficiency of dual AAV trans-splicing and hybrid 
AK vectors compared to single normal size AAV vector. 
(A) Representative Western blot analysis of HEK293 cells infected with AAV2/2 
vectors encoding for EGFP under the control of the ubiquitous cytomegalovirus (CMV) 
promoter. The arrow indicates full-length protein, 50 micrograms of proteins were 
loaded in each lane, the molecular weight ladder is depicted on the left. (B) 
Quantification of EGFP protein bands. The intensity of the EGFP bands was divided by 
the intensity of the Tubulin bands. The histograms show the expression of proteins as 
percentage relative to single normal size AAV (NS) vector, the mean value is depicted 
above the corresponding bar. Values are represented as mean ± s.e.m. (standard error of 
the mean). The Western blot images are representative of and the quantifications are 
from n=3 independent experiments. NS: cells infected with normal size AAV vector; 
TS: cells infected with dual AAV trans-splicing vectors; AK: cells infected with dual 
AAV hybrid AK vectors; neg: cells infected with the 5’-half of either the dual AAV TS 
or hybrid AK vectors, as negative controls; α-EGFP: Western blot with anti-EGFP 
antibody; α-β-Tubulin: Western blot with anti-β-Tubulin antibody, used as loading 
control. **p ANOVA<0.001. More details on the statistical analysis including specific 
statistical values can be found in the Statistical analysis paragraph of the Materials and 
Methods section. 
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Quantification of EGFP expression showed that the levels achieved with dual AAV TS 
and hybrid AK vectors were about 13-25 folds lower (7-4%) than with AAV NS. 
 
 
3. Assessment of co-transduction efficiency in mice retinas. 
The enclosed and small subretinal space should favour co-infection and transduction of 
the same cell by two independent AAV vectors. To test this, specifically in PRs, I 
injected subretinally C57BL/6 mice with a mixture of AAV2/8-CMV-EGFP and -RFP 
vectors (dose of each vector/eye: 1.4x109 GC/eye) and analysed co-transduction on 
retinal cryosections, which allows for the unequivocal identification of PRs from RPE 
(Fig. 23). I found that 24±2% of transduced PRs expressed both EGFP and RFP.  
 
 
Figure 23. Photoreceptor co-transduction following subretinal combined delivery 
of single AAV-EGFP and -RFP vectors 
Fluorescence analysis of a representative retinal cryosection from C57BL/6 mice 3 
weeks following subretinal co-injection of single AAV2/8-CMV-EGFP and-RFP 
vectors (dose of each vector/eye: 1.4x109 GC, n=6 eyes) demonstrating RFP+ cells (left 
panel) and EGFP+ cells (central panel) is presented. The scale bar (50 μm) is depicted 
in the figure. Circles highlight PRs transduced by both vectors. PR: photoreceptors; 
RFP: native RFP fluorescence; EGFP: native EGFP fluorescence; DAPI: 4',6'-
diamidino-2-phénylindole staining.  
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However, since the number of RFP-single-positive cells was lower than the number of 
EGFP-single-postive cells, likely due to a weaker RFP fluorescence compared to EGFP, 
co-transduction efficiency may have been under-estimated. Indeed, considering the 
number of RFP+ cells that are also EGFP+, the percentage of co-transduction reaches 
53±4%. This co-transduction efficiency is similar to that previously reported by Palfi 
and colleagues (Palfi et al, 2012). 
 
 
4. Dual AAV trans-splicing and hybrid AK, but not overlapping, 
vectors transduce mouse and pig photoreceptors. 
 
I evaluated the best in vitro performing AAV-based systems for large gene transduction 
in the mouse retina. To test the dual AAV OV, which is transgene-specific, I used the 
therapeutic ABCA4 gene (Fig. 24), while the EGFP reporter was used to evaluate the 
AAV OZ and the dual AAV TS and hybrid AK approaches (Fig. 26).  
Western blot analysis on retinal lysates, one month post-subretinal injection of the dual 
AAV OV vectors (dose of each vector/eye: 1.3x109 GC) in C57BL/6 mice, expressing 
ABCA4-3xflag from the ubiquitous CMV promoter, revealed robust protein expression 
(Fig. 24A). However, as ABCA4 is specifically expressed in PRs, I attempted to 
determine which cell type in the retina expressed ABCA4, taking advantage of the use of 
various promoters that restrict transgene expression to specific cell layers.  I, therefore, 
injected subretinally C57BL/6 mice with dual AAV OV vectors (dose of each 
vector/eye: 1x109 GC) that contained either the PR-specific RHO and RHOK, or the 
RPE-specific VMD2 promoters. I detected ABCA4 protein expression in retinas 
injected with the VMD2 but not in those containing the RHO and RHOK promoters 
(Fig. 24A). These results were also confirmed in the Large White pig retina. The pig 
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retina is an excellent model to evaluate vector efficiency because of its size, which is 
similar to the human retina, and because it is enriched with cones that are concentrated 
in a streak-like region with a cone density that is comparable to that of the primate 
macula (Mussolino et al, 2011). I injected Large White pig subretinally with dual AAV 
OV vectors encoding ABCA4-3xflag (dose of each vector/eye: 1x1010 GC), and 
observed ABCA4 protein expression with the CMV but not the RHO promoter (Fig. 
24B). 
   
 
Figure 24. Dual AAV overlapping vectors transduce RPE but not photoreceptors 
in the mouse and pig retina. 
Representative Western blot analysis of C57BL/6 (A) and Large White pig (B) retinal 
lysates one month following injection of dual AAV2/8 overlapping vectors encoding for 
ABCA4-3xflag (OV) or AAV2/8 vectors expressing EGFP (neg), under the control of 
the ubiquitous cytomegalovirus (CMV) promoter, the PR-specific Rhodopsin (RHO) 
and Rhodopsin kinase (RHOK) promoters, or the RPE-specific vitelliform macular 
dystrophy 2 (VMD2) promoter. The arrows indicate full-length proteins, the molecular 
weight ladder is depicted on the left, 150 micrograms of proteins were loaded in each 
lane. The number (n) and percentage of ABCA4-positive retinas out of total retinas 
analysed is depicted; α-3xflag: Western blot with anti-3xflag antibody; α-Dysferlin: 
Western blot with anti-Dysferlin antibody, used as loading control. 
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To rule out that this was due to a lower transcriptional activity from either the RHO or 
RHOK promoters compared to CMV, I injected subretinally C57BL/6 mice with 
1.5x109 GC/eye of AAV2/8 vectors expressing EGFP from each of the promoters and 
found that CMV and RHO drive similarly robust PR transgene expression (Fig. 25).  
 
Figure 25. CMV, RHO and RHOK promoters drive transgene expression in 
murine photoreceptors. 
Fluorescence analysis of representative retinal cryosections from C57BL/6 mice one 
month following subretinal injection of single AAV2/8 vectors encoding for EGFP 
under the control of the ubiquitous cytomegalovirus (CMV) promoter or the PR-specific 
Rhodopsin (RHO) and Rhodopsin kinase (RHOK) promoters. Arrow points at 
transduced RPE. The scale bar (50 μm) is depicted in the figure. RPE: retinal pigmented 
epithelium; PR: photoreceptors; DAPI: 4',6'-diamidino-2-phenylindole staining; EGFP: 
native EGFP fluorescence. 
 
 
Overall, these data suggest that the dual AAV OV approach is more efficient for large 
gene transfer to RPE than to PRs, thus it is not a strategy applicable to ABCA4 delivery.  
To find an AAV-based strategy that efficiently transduces large genes in PRs, I 
compared the retinal transduction properties of the other best performing approaches in 
vitro in addition to dual AAV OV: AAV OZ and dual AAV TS and hybrid AK 
approaches.  I used EGFP, which allowed me to easily localize transgene expression in 
the various retinal cell types, including PRs. C57BL/6 mice were injected subretinally 
with AAV OZ and dual AAV TS-L and hybrid AK-L vectors (dose of each vector/eye: 
1.7x109 GC), all encoding EGFP under the transcriptional control of the CMV 
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promoter. One month later, fundus photographs showed that the highest levels of 
fluorescence were obtained with the dual AAV TS and hybrid AK approaches (Fig. 26). 
Fluorescence microscope analysis of retinal cryosections showed that detectable levels 
of RPE and PR transduction could be achieved with all approaches.  
 
Figure 26. Dual AAV trans-splicing and hybrid AK vectors provide the most 
robust transduction of RPE and photoreceptors cell layers following subretinal 
delivery in mice. 
Live-imaging fundus fluorescence (A) and fluorescence analysis of retinal cryosections 
(B) from C57BL/6 mice one month following subretinal injection of AAV2/8 vectors 
encoding for EGFP under the control of the ubiquitous cytomegalovirus (CMV) 
promoter. (B) Arrows point at transduced RPE. The scale bar (200 μm) is depicted in 
the figure. OZ: AAV oversize (n=4); TS-L: dual AAV trans-splicing EGFP with a 
combined genome size similar to OZ-EGFP (n=4); AK-L: dual AAV hybrid AK EGFP 
with a combined genome size similar to OZ-EGFP (n=4); RPE: retinal pigmented 
epithelium; PR: photoreceptors.  
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However, the levels of expression were higher, although variable, in the eyes injected 
with dual AAV TS-L and hybrid AK-L than in the eyes injected with AAV OZ vectors. 
I also confirmed that no protein expression is observed when injecting only one of the 
dual AAV vectors, as seen in the in vitro experiments (Fig. 27). 
 
Figure 27. No detectable EGFP fluorescence in retinas injected with either the 5’- 
or 3’-half of dual AAV vectors.  
Fluorescence analysis of representative retinal cryosections from C57BL/6 mice one 
month following subretinal injection of either the combination of dual AAV vectors 
(5’+3’) encoding for EGFP or each of the single 5’- and 3’-half vectors. The eyes 
injected with the 5’-half include: 9 injected with CMV 5’AK, 6 injected with CMV 
5’TS, 8 injected with RHO 5’AK, 7 injected with RHO 5’TS (n=30). The eyes injected 
with the 3’-half include: 13 injected with 3’AK and 7 injected with 3’TS (n=20). The 
arrow points at transduced RPE. The scale bar (20 μm) is depicted in the figure. 5’+3’: 
retinas co-injected with 5’- and 3’-half vectors; 5’: retinas injected with the 5’-half 
vector; 3’: retinas injected with the 3’-half vector; RPE: retinal pigmented epithelium; 
PR: photoreceptors 
 
 
To test whether the levels and consistency of dual AAV-mediated transduction obtained 
can be improved by varying the ratio between the 5’- and 3’-half vectors, I injected 
subretinally C57BL/6 mice with dual AAV TS and hybrid AK vectors with different 
doses of 5'- and 3'-half vectors (Fig. 28). I set as 1:1 the dose of 2.5x108 GC/eye which 
is submaximal considering that the titers of our AAV preparations range around 109 
GC/L (Table 4) and that 1 L is the maximum volume tolerated by the mouse 
subretinal space. Thus, 2.5x109 GC/eye which is the high 1:1 dose (10:10) is the 
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maximum dose which is possible to administer to the murine eye. I found that none of 
the various ratios tested outperforms the 1:1 ratio of the high dose of vectors (10:10) 
used so far (Fig. 28). Therefore, I used the optimal 10:10 dose and ratio in the following 
experiments. 
 
Figure 28. Murine retinal transduction with various doses and ratios of dual AAV 
vectors. 
EGFP protein quantification by ELISA of eyecups from C57BL/6 mice one month 
following subretinal injection of dual AAV2/8 trans-splicing (A) and hybrid AK (B) 
vectors encoding for EGFP under the control of the ubiquitous cytomegalovirus (CMV) 
promoter. The various ratios of 5’- and 3’-half vectors used for the injections are 
depicted below each bar. The doses of 5’-and 3’-half vectors are the following: 1:1 
[2.5x108:2.5x108 genome copies (GC)/eye]; 10:10 (2.5x109:2.5x109 GC/eye); 5:1 
(1.25x109:2.5x108 GC/eye); 1:5 (2.5x108:1.25x109 GC/eye); 10:1 (2.5x109:2.5x108 
GC/eye); 1:10 (2.5x108:2.5x109 GC/eye). The number (n) of eyes analysed is depicted 
below each bar. The histograms show EGFP expression as percentage relative to the 1:1 
ratio. Values are represented as mean ± s.e.m. (standard error of the mean). TS: dual 
AAV trans-splicing; AK: dual AAV hybrid AK. No statistically significant differences 
were found using ANOVA. More details on the statistical analysis including specific 
statistical values can be found in the Statistical analysis paragraph of the Materials and 
Methods section. 
 
 
Then, I sought both to better assess PR-specific transduction levels achieved with dual 
AAV TS and hybrid AK vectors, which appears the most promising for large gene 
reconstitution in PRs, and to compare them to those of a single AAV NS vector. To this 
aim, I injected subretinally C57BL/6 mice with dual AAV and single NS vectors (dose 
of each vector/eye: 2.4x109 GC). All vectors encoded EGFP under the transcriptional 
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control of the PR-specific RHO promoter. One month after vector administration whole 
retina lysates were analyzed by ELISA to quantify EGFP protein levels (Fig. 29). Dual 
AAV TS and hybrid AK vectors reconstituted consistent EGFP expression in PRs at 
levels on average about 16-33 folds lower (6-3%) than with AAV NS. However, these 
levels were variable, similarly to what observed in retinal histological sections (Fig. 26), 
and some of the eyes treated with dual AAV vectors had EGFP levels in the range of 
those achieved with AAV NS (Fig. 29).  
 
Figure 29. Dual AAV trans-splicing and hybrid AK vectors efficiently transduce 
mouse  photoreceptors.  
EGFP protein quantification by ELISA of retinas from C57BL/6 mice one month 
following subretinal injection of AAV2/8 vectors encoding for EGFP under the control 
of the PR-specific Rhodopsin (RHO) promoter. The scatter plot depicts EGFP protein 
levels from each retina; the mean value for each group is depicted and indicated with a 
solid line. The number (n) of eyes analysed is depicted under the x axis. ** p 
ANOVA<0.001. NS: AAV normal size; TS: dual AAV trans-splicing; AK: dual AAV 
hybrid AK. More details on the statistical analysis including specific statistical values 
can be found in the Statistical analysis paragraph of the Materials and Methods section. 
 
 
As expected, no detectable EGFP expression was measured by ELISA in injected 
retinas when only one of the dual AAV vectors encoding for EGFP was used (n=9: 5 
eyes injected with 5’-half and 4 eyes with 3’-half). 
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To exclude competition between dual AAV capsids at the entry step which may lead to 
over-estimate the efficiency of AAV NS, I evaluated EGFP expression after subretinal 
delivery of either 1.7x109 GC of AAV2/8 NS-EGFP or 1.7x109 GC of AAV2/8-NS-
EGFP + 1.7x109 GC of an AAV2/8 vector carrying an unrelated genome. Notably, I 
found no significant differences in the levels of EGFP expression whether the unrelated 
AAV was added or not (Fig. 30), proving that the double dose of dual AAV capsids 
administered when compared to AAV-NS does not affect dual AAV-mediated 
transduction. 
 
Figure 30. Similar EGFP levels following subretinal delivery of single AAV2/8-
EGFP alone or in combination with the same dose of an unrelated AAV2/8 vector. 
ELISA quantification of EGFP protein in eyecups from C57BL/6 mice one month 
following subretinal injection of single AAV2/8-CMV-EGFP vector of normal size 
(NS-EGFP) in combination or not with the same dose of a single AAV2/8 vector of 
normal size carrying an unrelated transgene expression cassette (unrelated AAV2/8). 
The number (n) of eyes analyzed is depicted below each bar. Values are represented as: 
mean ± s.e.m. (standard error of the mean). No statistically significant differences were 
found using the Student’s t-test (p=0.8). 
 
 
Finally, to confirm that dual AAV TS and hybrid AK approaches transduce PRs also in 
pig, I injected subretinally Large White pigs with dual AAV TS and hybrid AK vectors 
expressing EGFP under the transcriptional control of the PR-specific RHO promoter 
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(dose of each vector/eye: 1x1011 GC) and I found efficient transduction of the PR cell 
layer (Fig. 31). 
 
Figure 31. Dual AAV trans-splicing and hybrid AK vecotrs efficiently transduce 
pig photoreceptors.  
Fluorescence analysis of retinal cryosections from Large White pigs one month 
following subretinal injection of AAV2/8 vectors encoding for EGFP under the control 
of the PR-specific RHO promoter. The pictures are representative of n=4 or n=3 eyes 
injected with dual AAV TS or hybrid AK, respectively. The scale bar (100 m) is 
depicted in the figure. NS: AAV normal size; TS: dual AAV trans-splicing; AK: dual 
AAV hybrid AK; DAPI: 4',6'-diamidino-2-phenylindole staining; EGFP: native EGFP 
fluorescence; Merge: overlay of DAPI and EGFP pictures; RPE: retinal pigmented 
epithelium; PR: photoreceptors. 
 
 
Taken together, these results show that dual AAV TS and hybrid AK strategies allow 
efficient PR transduction, both in mouse and in pig, although at levels which are lower 
than those obtained with an AAV NS.   
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5. Dual AAV trans-splicing and hybrid AK vectors are safe and 
efficient tools to deliver the large ABCA4 gene to the mouse and pig 
retina. 
 
To confirm that dual AAV TS and hybrid AK vectors can be efficiently used to deliver 
the large ABCA4 gene to the retina, I generated dual AAV TS and hybrid AK vectors 
encoding ABCA4-3xflag under the transcriptional control of the RHO promoter and 
evaluated their transduction abilities in mouse and pig PRs. To this aim, I first injected 
them subretinally in wild-type C57BL/6 mice (dose of each vector/eye: 3-5x109 GC) 
and one month later I analysed retinas by Western blot with anti-3xflag antibodies. Both 
approaches resulted in robust yet variable levels of ABCA4-3xflag expression, that 
were more consistent in retinas treated with the dual AAV hybrid AK vectors (Fig. 32).  
 
Figure 32. Subretinal administration of dual AAV vectors results in ABCA4 
expression in mouse photoreceptors. 
Representative Western blot analysis of C57BL/6 retinal lysates one month following 
the injection of dual AAV trans-splicing (TS) and hybrid AK (AK) vectors encoding for 
ABCA4 under the control of the PR-specific Rhodopsin promoter (RHO PROMOTER). 
The arrow points at full-length proteins, the molecular weight ladder is depicted on the 
left, 150 micrograms of protein were loaded in each lane. The number (n) and 
percentage of ABCA4-positive retinas out of total retinas analysed is depicted. AK: 
retinas injected with dual AAV hybrid AK vectors; TS: retinas injected with dual AAV 
TS vectors; neg: retinas injected with AAV vectors expressing EGFP, as negative 
controls; α-3xflag: Western blot with anti-3xflag antibody; α-Dysferlin: Western blot 
with anti-Dysferlin antibody, used as loading control 
 
 
Interestingly, this result was confirmed in pig retinas (Fig. 33). Indeed, Western blot 
analysis of pig retinas, one month post subretinal injection of dual AAV TS and hybrid 
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AK vectors, showed that both dual AAV approaches induce the expression of the full-
length ABCA4-3xflag protein in PRs, although at variable levels. In addition, similarly 
to what observed in mice, dual AAV hybrid AK vectors resulted in more consistent 
ABCA4 expression compared to dual AAV TS vectors. 
 
Figure 33. Subretinal administration of dual AAV vectors results in ABCA4 
expression in pig photoreceptors. 
Representative Western blot analysis of Large White pig retinal lysates one month 
following the injection of dual AAV trans-splicing (TS; n=2) and hybrid AK (AK; n=3) 
vectors encoding for ABCA4 or for normal size EGFP (neg), as negative control, under 
the control of the PR-specific Rhodopsin promoter (RHO PROMOTER). The arrows 
indicate full-length proteins, the molecular weight ladder is depicted on the left, 180 
micrograms of proteins were loaded in each lane. α-3xflag: Western blot with anti-
3xflag antibody. Ponceau staining was used as loading control. 
 
 
Then, I decided to evaluate the possibility that the delivery of dual AAV vectors results 
in the production of aberrant proteins from both the 5’-half vectors, that contain the 
promoter sequence, and the 3’-half vectors, due to the low promoter activity of the ITRs 
(Flotte et al, 1993). To address this point, I generated 5’-halves of dual AAV vectors 
tagged with the 3xflag tag at the N-terminus of the ABCA4 protein and used these 
constructs, in combination with the 3’-halves tagged with the 3xflag tag at the C-
terminus, to transduce both HEK293 cells and the C57BL/6 mouse retina. Importantly, 
no truncated and/or aberrant ABCA4 proteins were detected by Western blot analysis of 
C57BL/6 eyecups treated with dual AAV TS and hybrid AK vectors using anti-3xflag 
antibodies although two proteins (>100 KDa) smaller than the full length are produced 
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in vitro following infection with either the single 5’- or 3’-half of both dual AAV 
approaches (Fig. 34-35).  
 
Figure 34. ABCA4 proteins smaller than expected are produced in vitro by dual 
AAV trans-splicing and hybrid AK vectors as well as by their corresponding single 
5’- and 3’-half vectors. 
Representative Western blot analysis of HEK293 cells infected with dual AAV2/2 
trans-splicing (TS) and hybrid AK (AK) vectors encoding for ABCA4 under the control 
of the cytomegalovirus (CMV) promoter. Anti-3xflag antibodies recognize the 3xflag 
tag located at both the N- and C-termini of the ABCA4 protein. The upper arrow 
indicates the full-length ABCA4 protein; the lower arrows indicate the shorter products 
(>100 KDa) which derive from either single 5’- or 3’-half vectors. Thirty micrograms of 
proteins from transfected and infected cells were loaded; the molecular weight ladder is 
depicted on the left. The Western blot images are representative of n=3 independent 
experiments. p3xflag-ABCA4-3xflag: cells transfected with a plasmid encoding for full-
length ABCA4 tagged with 3xflag at both N- and C-termini, as positive control; TS: 
cells infected with both 5'- and 3'-halves of dual AAV trans-splicing vectors; AK: cells 
infected with both 5'- and 3'-halves of dual AAV hybrid AK vectors; 5’: cells infected 
with the 5’-half vector of either dual AAV TS (5'TS) or hybrid AK (5'AK) approaches; 
3’: cells infected with the 3’-half vector of either dual AAV TS (3'TS) or hybrid AK 
(3'AK) approaches; EGFP: cells infected with AAV vectors expressing EGFP, as 
negative control; α-3xflag: Western blot with anti-3xflag antibody; α-Filamin A: 
Western blot with anti-Filamin A antibody, used as loading control. 
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Figure 35. ABCA4 products of the expected size are detected in the eyes of 
C57BL/6 mice following subretinal delivery of dual AAV trans-splicing and hybrid 
AK vectors. 
Representative Western blot analysis of C57BL/6 eyecups one month after subretinal 
delivery of dual AAV2/8 trans-splicing (TS; A) and hybrid AK (AK; B) vectors 
encoding for ABCA4 under the control of the ubiquitous cytomegalovirus (CMV) 
promoter. Anti-3xflag antibodies recognize the tag located at both the N- and C-termini 
of the ABCA4 protein. The lysates from HEK293 cells infected with single 5’- and 3’-
half vectors of dual AAV2/2 TS and hybrid AK vectors were loaded as positive controls 
of the smaller than expected ABCA4 proteins observed in vitro (see Fig. 34). The upper 
arrow indicates the full-length ABCA4-3xflag; the lower arrows indicate the smaller 
products (>100KDa) which derive from either single 5’- or 3’-half vectors. Thirty or 
150 micrograms of proteins from infected cells and injected eyecups were loaded, 
respectively; the molecular weight ladder is depicted on the left. The picture is 
representative of the following number of eyecups: n=10 treated with TS; n=10 treated 
with AK; n=5 treated with 5’TS, n=5 treated with 5’AK, n=5 treated with 3’TS, n=5 
treated with 3’AK, n=7 treated with EGFP. TS: eyes injected with both 5'- and 3'-halves 
of dual AAV TS vectors; AK: eyes injected with both 5'- and 3'-halves of dual AAV 
hybrid AK vectors; 5’: eyes injected or cells infected with the 5’-half of either dual 
AAV TS (5'TS) or hybrid AK (5'AK) vectors; 3’: eyes injected or cells infected with the 
3’-half of either dual AAV TS (3'TS) or hybrid AK (3'AK) vectors; EGFP: eyes injected 
with AAV vectors expressing EGFP, as negative control; HEK293: lysates from 
HEK293 cells infected with AAV; α-3xflag: Western blot with anti-3xflag antibody; α-
Dysferlin: Western blot with anti-Dysferlin antibody, used as loading control. 
 
 
I then tested the production of a properly spliced full-length ABCA4 mRNA by ABCA4 
retrotranscription and amplification following infection of HEK293 cells with dual 
AAV vectors (Fig. 36). The successful amplification of the full size ABCA4 mRNA 
confirmed that intermolecular AAV joining and splicing occurred correctly, as expected 
by the size of the full-length protein detected by Western blot.  
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Figure 36. ABCA4 mRNA of the expected size is detected in HEK293 cells infected 
with dual AAV trans-splicing and hybrid AK vectors. 
Amplification products of long-range PCR on cDNA of HEK293 cells infected with 
dual AAV trans-splicing (TS) and hybrid AK (AK) vectors or infected with vectors 
expressing EGFP (neg), as negative control. The arrow points at the full-length 
retrotranscribed Abca4 mRNA (7 Kb). The molecular weight ladder is depicted on the 
left. RT+: sample from reverse transcription reaction made in the presence of the 
reverse transcriptase enzyme; RT-: sample from reverse transcription reaction made in 
the absence of the reverse transcriptase enzyme. 
 
 
This data was also confirmed by the sequencing of the ABCA4 transcript region 
corresponding to the joining point between tail-to-head dual AAV vectors.  
In addition no evident signs of retinal toxicity were observed in both C57BL/6 and 
Abca4-/- mice at 8 months after treatment with dual AAV TS and hybrid AK vectors by 
ERGs or conventional histological analysis, respectively (Fig. 37).  
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Figure 37. Normal retinal histology and function following subretinal delivery in 
mice of dual AAV trans-splicing and hybrid AK vectors  
(A) Representative paraffin-embedded sections of Abca4-/- retinas either uninjected 
(n=2) or treated at one month of age with dual AAV2/8-RHO-ABCA4 trans-splicing 
(TS-ABCA4, n=3), dual AAV hybrid AK (AK-ABCA4, n=4) or single 5’-half (neg) of 
either dual AAV TS (n=1) or hybrid AK (n=2; neg total n=3). Eyes were harvested 8 
months after treatment and retinal sections were stained with hematoxylin and eosin. 
The scale bar (50 m) is depicted. RPE: retinal pigmented epithelium; PR: 
photoreceptors; INL: inner nuclear layer; GCL: ganglion cell layer. (B) Mean b-wave 
amplitude (V) as a function of luminance in 9 months old C57BL/6 mice either 
uninjected or 8 months after subretinal injection of dual AAV hybrid AK vectors. The 
mean amplitude at 20 cd.s/m2 is depicted. C57BL/6 uninjected: eyes from WT mice not 
injected (n=6); C57BL/6 AK-ABCA4: eyes from WT mice injected with dual AAV 
hybrid AK vectors (n=12). Values are represented as mean ± s.e.m (standard error of the 
mean). No statistically significant differences were found neither using ANOVA nor 
using Student’s t-test on mean amplitudes at 20 cd.s/m2 (p=0.13). More details on the 
statistical analysis including specific statistical values can be found in the Statistical 
analysis paragraph of the Materials and Methods section. 
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6. Subretinal delivery of dual AAV vectors improves the retinal 
phenotype of a mouse model of STGD. 
 
To understand whether the levels of PR transduction obtained with the dual AAV TS 
and hybrid AK approaches may be therapeutically relevant, I investigated them in the 
retina of the mouse model of STGD.  
As previously mentioned (see section 2.3.2), although the Abca4-/- mouse model does 
not undergo severe PR degeneration (Wu et al, 2010a), the absence of the ABCA4-
encoded all-trans retinal transporter in PRs OS (Illing et al, 1997; Sun & Nathans, 1997) 
causes an accumulation of lipofuscin in PRs as well as in RPE, as result of PRs 
phagocytosis by RPE (Mata et al, 2001; Weng et al, 1999). As a consequence, both the 
number of lipofuscin granules in the RPE and the thickness of RPE cells are greater in 
Abca4-/- mice than in control mice (Allocca et al, 2008; Conley et al, 2012; Han et al, 
2012; Ma et al, 2011; Radu et al, 2008). In addition, Abca4-/- mice also show delayed 
recovery from light desensitization (Allocca et al, 2008; Han et al, 2012; Maiti et al, 
2006; Radu et al, 2008; Weng et al, 1999).  
To evaluate the biological and therapeutic activity of the recombinant ABCA4 protein 
produced by dual AAV vectors, one month-old albino Abca4-/- mice were injected 
subretinally with the dual AAV TS and hybrid AK RHO-ABCA4-HA vectors (dose of 
each vector/eye: 1-3x109GC). Three months later, eyes were harvested and immuno-
electron microscopy analysis with anti-hemagglutinin (HA) antibodies of retinal 
sections confirmed that immunogold particles were correctly localized in PRs OS only 
in animals that were injected with the combination of 5’ and 3’ dual AAV TS and 
hybrid AK vectors (Fig. 38).  
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Figure 38. Subretinal administration of dual AAV vectors results in ABCA4 
expression in Abca4-/- photoreceptors. 
Representative pictures of transmission electron microscopy analysis with anti-HA 
antibody of retinal sections from wild-type BALB/c (WT) and Abca4-/- mice injected 
with dual AAV trans-splicing (TS-ABCA4) and hybrid AK vectors (AK-ABCA4) or 
with either AAV vectors expressing EGFP or 5’-or 3’-half of the dual hybrid AK 
vectors (neg), as negative controls. The black dots represent the immuno-gold labelling 
of the ABCA4-HA protein. The scale bar (200 nm) is depicted in the figure. 
 
 
To assess the functionality of the ABCA4 protein expressed by the dual AAV vectors, I 
measured Abca4-/- retinal lipofuscin accumulation and recovery from light 
desensitization. To assess the former I performed transmission electron microscopy 
analysis to measure the number of RPE lipofuscin granules (Fig. 39) and RPE thickness 
(Fig. 40). Both were greater in the retina of Abca4 -/- mice injected with control vectors 
(independently of the size of the control constructs, Fig. 41) than in the retina of wild-
type, age-matched BALB/c controls, and were significantly reduced or normalized in 
the eyes injected either with the therapeutic dual AAV TS or hybrid AK vectors (Fig. 39 
and Fig. 40).  
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Figure 39. Subretinal administration of dual AAV vectors results in reduction of 
lipofuscin granule accumulation in Abca4-/- mice. 
(A) Representative pictures of transmission electron microscopy analysis showing 
lipofuscin granules content in the RPE of WT and Abca4-/- mice injected with either 
dual AAV or negative control vectors. The black arrows indicate lipofuscin granules. 
The scale bar (1.6 m) is depicted in the figure. (B) Quantification of the mean number 
of lipofuscin granules counted in at least 30 fields (25µm2) for each sample. The 
number (n) of eyes analysed is depicted below each bar. The mean value is depicted 
above the corresponding bar. Values are represented as mean ± s.e.m. (standard error of 
the mean). *p ANOVA<0.05; **p ANOVA<0.001. WT: BALB/c eyes; Abca4-/- neg: 
Abca4-/- eyes injected with either AAV vectors expressing EGFP (n=2) or the 5’- (n=3) 
or 3’- (n=4) half of the dual AAV hybrid AK vectors, as negative controls (neg total 
n=9); Abca4-/- TS-ABCA4: mice injected with dual AAV TS vectors; Abca4-/- AK-
ABCA4: mice injected with dual AAV hybrid AK vectors. More details on the statistical 
analysis including specific statistical values can be found in the Statistical analysis 
paragraph of the Materials and Methods section. 
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Figure 40. Subretinal injection of dual AAV vectors reduces the thickness of the 
RPE. 
(A) Representative pictures of transmission electron microscopy analysis of retinal 
sections from wild-type BALB/c (WT) and Abca4-/- mice injected with dual AAV 
trans-splicing (TS-ABCA4) and hybrid AK vectors (AK-ABCA4) or with either AAV 
vectors expressing EGFP or 5’-or 3’-half of the dual hybrid AK vectors (neg), as 
negative controls. The dotted lines indicate the edges of RPE cells. The scale bar (3.8 
m) is depicted in the figure. (B) Quantification of the mean RPE thickness counted in 
at least 30 fields for each sample. The number (n) of eyes analysed is depicted below 
each bar. The mean value is depicted above the corresponding bar. Values are 
represented as mean ± s.e.m (standard error of the mean). *p ANOVA<0.05. Abca4-/- 
neg includes Abca4-/- mice injected with either AAV vectors expressing EGFP (n=2) or 
5’- (n=3) or 3’- (n=4) half of the dual hybrid AK vectors (neg total n=9); Abca4-/- TS-
ABCA4: mice injected with dual AAV TS vectors; Abca4-/- AK-ABCA4: mice injected 
with dual AAV hybrid AK vectors. More details on the statistical analysis including 
specific statistical values can be found in the Statistical analysis paragraph of the 
Materials and Methods section. 
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Figure 41. Similar lipofuscin granules accumulation in the retina of Abca4-/- mice 
independently of the AAV control vector genome size. 
Quantification of lipofuscin granules in Abca4-/- mice injected subretinally with dual 
AAV trans-splicing and hybrid AK control vectors with a combined (5'-half+3'-half) 
large (8.9 Kb, dual AAV large) or small (2.7-2.9 Kb, dual AAV small) genome [dose of 
each vector/eye: 1.2x109 genome copies (GC)]. Eyes were harvested 2 months post-
injection and lipofuscin granules were counted in at least 30 fields (25 µm2) for each 
sample. The number (n) of eyes analysed is depicted below each bar. Dual AAV small 
includes Abca4-/- eyes injected with either trans-splicing small (n=2) or hybrid AK 
small (n=2; total n=4) vectors; dual AAV large includes Abca4-/- eyes injected with 
either trans-splicing large (n=2) or hybrid AK large (n=2; total n=4) vectors. Values are 
represented as mean ± s.e.m. (standard error of the mean). No statistically significant 
differences were found using the Student’s t-test (p=0.54). 
 
 
Importantly, the eyes treated with dual AAV TS and hybrid AK vectors showed also 
improved recovery from light desensitization when compared to eyes treated with 
control vectors (dose of each vector/eye: 1.2x109GC, Fig. 42), independently of the size 
of the control constructs [Student's t-test p value of dual AAV-EGFP-L (n=2 TS-L, n=4 
AK-L; total n=6) vs dual AAV-EGFP (n=5 TS, n=4 AK; total n=9): 0.23)]. 
88 
 
 
Figure 42. Subretinal injection of dual AAV vectors improves the recovery from 
light desensitization in Abca4-/- mice. 
Recovery from light desensitization in 3 month-old Abca4-/- and BALB/c mice at 6 
weeks post-injection. The relative b-wave is the ratio between the post- and the pre-
desensitization b-wave amplitudes (V) both evoked by 1 cd s/m2. The time (minutes) 
refers to the time post-desensitization. The mean recovery (%) at 60 minutes is depicted. 
WT: BALB/c eyes (n=4); Abca4-/- TS-ABCA4: eyes injected with dual AAV TS 
vectors (n=5); Abca4-/- AK-ABCA4: mice injected with dual AAV hybrid AK vectors 
(n=5); Abca4-/- neg: Abca4-/- mice either not injected (n=2) or injected with the 5’-half 
of the dual AAV TS (n=3) or hybrid AK (n=2) vectors (neg total n=7). Values are 
represented as mean ± s.e.m (standard error of the mean). *p ANOVA<0.05. More 
details on the statistical analysis including specific statistical values can be found in the 
Statistical analysis paragraph of the Materials and Methods section. 
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DISCUSSION 
While AAV-mediated gene therapy is effective in animal models and in patients with 
inherited blinding conditions (Bainbridge et al, 2008; Cideciyan et al, 2009a; Jacobson 
et al, 2006; Maguire et al, 2009; Maguire et al, 2008; Simonelli et al, 2010), its 
application to diseases affecting the retina and requiring a transfer of genes larger than 5 
kb (referred to as large genes, such as ABCA4 for STGD), is inhibited by AAV limited 
cargo capacity. To overcome this, I compared in vitro and in mouse and pig retina the 
efficiency of various AAV-based strategies which have been recently developed for 
large gene transduction, including: AAV oversize (OZ), dual AAV overlapping (OV), 
trans-splicing (TS), hybrid AP and AK approaches. 
The in vitro and in vivo results show that all the dual AAV strategies I tested (with the 
exception of the dual AAV hybrid AP) outperform AAV OZ vectors in terms of 
transduction levels. This may be explained by: i. the homogeneous size of the dual 
AAV genome population when compared to AAV OZ genomes, which may favour the 
generation of transcriptionally active large transgene expression cassettes; ii. the small 
volume of the subretinal space, which I show favours infection and transduction of the 
same cell by two independent AAV vectors. Although this has been suggested by 
previous work in the retina with either dual AAV TS vectors carrying the lacZ reporter 
gene (Reich et al, 2003) or with two single vectors encoding different fluorescent 
reporter proteins (Palfi et al, 2012), my study represents the first comprehensive 
comparison in the retina of the dual AAV strategies reported so far, as well as the first 
demonstration of their efficacy in animal models of common inherited blinding 
conditions.  
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Differently from what I have observed, Hirsch et al. have recently shown that AAV OZ 
vectors can reconstitute a large reporter gene (6.2 kb) in the retina of mice more 
efficiently than dual AAV TS vectors (Hirsch et al, 2013b). The following factors may 
account for this: i. the design of the dual AAV vectors, which may result in lower 
transduction levels in Hirsch et al. than in my case; ii. the purification of the AAV OZ 
vectors by Hirsch et al. that may promote the selection in the viral preparation of 
genomes with higher transduction properties; iii. the use of a shorter transgene by 
Hirsch et al. than by me that gives rise to genomes with longer overlaps which can 
positively influence AAV OZ transduction. My results also differ from those of another 
group that has reported that dual AAV hybrid AP outperforms TS (Ghosh et al, 2011). 
While I have generated the dual hybrid AP vectors based on the description provided in 
those publications, it is possible that minor differences in the AP sequences used may 
account for the different transduction levels I have observed. 
The dual AAV OV approach is particularly interesting when compared to the TS or 
hybrid AK approaches, which appear similarly efficient in vitro, as dual AAV OV 
vectors only contain sequences belonging to the therapeutic transgene expression 
cassette. However, when I administered dual AAV OV vectors to the subretinal space of 
adult mice and pigs, I could detect expression of the large ABCA4 protein only when 
the ubiquitous or the RPE-specific promoters, but not the PR-specific promoters, were 
used. This may suggest that the homologous recombination required for dual AAV OV 
reconstitution is more efficient in RPE than PRs. This is consistent with the low levels 
of homologous recombination reported in post-mitotic neurons (Fishel et al, 2007) and 
may partially explain the results recently reported by Lopes and co-workers (Lopes et 
al, 2013), who have found dual AAV OV vectors poorly efficient in the delivery to the 
retina of the large gene MYO7A (see Table 2). In conclusion, subretinal administration 
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of dual AAV OV vectors should not be used for large gene transfer to PRs, although it 
is not possible to exclude that sequences that are more recombinogenic than those 
included in dual AAV OV ABCA4 vectors I used may allow efficient homologous 
recombination in PRs.  
Dual AAV TS and hybrid AK approaches efficiently transduce mouse and pig PRs, 
differently from what I observed with dual AAV OV. This is consistent with the 
knowledge that the mechanism of large gene reconstitution mediated by dual AAV TS 
and hybrid AK approaches may be via ITR-mediated head-to-tail rejoining (Duan et al, 
1998; Ghosh et al, 2008; Yan et al, 2005) rather than homologous recombination. The 
transduction levels provided by the dual hybrid AK are more consistent than those of 
the TS approach in mouse and pig PRs. This was evident when using the large ABCA4 
but not the small EGFP transgene, suggesting an advantage of including the AK 
sequence for large transgene reconstitution in PRs. 
The levels of mouse PRs transduction I achieved with dual AAV TS and hybrid AK are 
lower than with single NS vectors. However, these levels may be effective for treating 
inherited blinding conditions that require relatively low levels of transgene expression, 
i.e. diseases inherited as autosomal recessive. Indeed, I show that subretinal delivery of 
dual AAV TS and hybrid AK improves and even normalizes the retinal defects of the 
animal models of STGD, which is due to mutations in the large ABCA4 gene and is an 
attractive target for gene therapy. Importantly, both levels and consistency of dual 
AAV-mediated large transgene expression could be improved by directing the 
productive head-to-tail genome concatemerization by either using heterologous ITRs 
(Yan et al, 2007) or by adding oligos to the injection solution (Hirsch et al, 2009). 
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Single normal size AAV vectors ensure multi-year retinal gene expression after a single 
vector administration (Testa et al, 2013). The data I have obtained so far from dual 
AAV vectors up to 4 months after retinal gene delivery, the last time point of my 
analysis, suggest that longevity of transgene expression may be similar between single 
normal size and dual AAV vectors. 
The genome size of dual AAV vectors is homogeneous, which means identity and 
safety issues related to their use should be less considerable than those related to AAV 
OZ vectors, which have heterogeneous genome sizes. However, the possibility that 
delivery of dual AAV vectors results in the production of aberrant proteins in the retina, 
i.e. truncated proteins from the 5’-half vector that contains the promoter sequence 
and/or from the 3’-half vector due to the low promoter activity of the ITRs (Flotte et al, 
1993) must be considered. The results I obtained show that proteins smaller than the 
full-length are produced from the 5’- and 3’-halves of dual AAV vectors in vitro but not 
in vivo in the retina where only full-length ABCA4 protein is detected. The production 
of properly spliced full length protein by dual AAV vectors is corroborated by the 
successful amplification of the full size ABCA4 mRNA retro transcribed from cells 
infected with dual AAV TS and hybrid AK vectors. Indeed the transcript sequences 
confirmed that intermolecular AAV joining and splicing occurred correctly, as expected 
by the size of the full length proteins detected by Western blot. In addition, I detected 
neither ERG nor retinal histological abnormalities in both C57/BL6 and Abca4-/- mice 
that I followed up to 8 months after dual AAV vector delivery. Future long-term safety 
studies as well as sensitive proteomic profiling will help to better define if any toxicity 
derives from intraocular administration of dual AAV vectors. 
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CONCLUSIONS 
During my Ph.D. thesis I focused my efforts on the identification of AAV-based 
strategies for delivery of large genes to the retina and on providing proof of principle of 
their efficacy in animal models of IRDs. In my study, I demonstrated that dual AAV 
vectors are efficient tools for large gene delivery, both in vitro and to the mouse and pig 
retina. This doubles the size of the therapeutic transcription cassette that dual AAV 
vectors allow to transfer when compared to a single AAV of normal size. Dual AAV 
OV vectors, however, efficiently transduce RPE but not PRs, and this limits the 
applicability of this strategy to those inherited disease that are due to mutations in genes 
expressed in PRs. In contrast, dual AAV TS and hybrid AK approaches drive efficient 
large gene reconstitution in both RPE and PRs, in mouse and pig. Importantly, although 
the levels of transgene expression achieved with dual AAV vectors are lower than those 
achieved with a single normal size AAV, they result in significant improvement of the 
retinal phenotype of the mouse model of STGD. These results provide evidence of the 
efficacy of these strategies for gene therapy for STGD and other blinding conditions, 
which require large gene transfer to PRs as well as RPE. 
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Abstract
Retinal gene therapy with adeno-associated viral (AAV) vectors is
safe and effective in humans. However, AAV’s limited cargo capacity
prevents its application to therapies of inherited retinal diseases
due to mutations of genes over 5 kb, like Stargardt’s disease (STGD)
and Usher syndrome type IB (USH1B). Previous methods based on
‘forced’ packaging of large genes into AAV capsids may not be eas-
ily translated to the clinic due to the generation of genomes of
heterogeneous size which raise safety concerns. Taking advantage
of AAV’s ability to concatemerize, we generated dual AAV vectors
which reconstitute a large gene by either splicing (trans-splicing),
homologous recombination (overlapping), or a combination of the
two (hybrid). We found that dual trans-splicing and hybrid vectors
transduce efﬁciently mouse and pig photoreceptors to levels that,
albeit lower than those achieved with a single AAV, resulted in sig-
niﬁcant improvement of the retinal phenotype of mouse models of
STGD and USH1B. Thus, dual AAV trans-splicing or hybrid vectors
are an attractive strategy for gene therapy of retinal diseases that
require delivery of large genes.
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Introduction
Inherited retinal degenerations (IRDs), with an overall global preva-
lence of 1/2000 (Sohocki et al, 2001), are a major cause of blindness
worldwide. Among the most frequent and severe IRDs are retinitis
pigmentosa (RP), Leber congenital amaurosis (LCA), and Stargardt’s
disease (STGD), which are most often inherited as monogenic con-
ditions. The majority of mutations causing IRDs occur in genes
expressed in neuronal photoreceptors (PR), rods and/or cones in
the retina (Dryja, 2001). No therapy is currently available for these
blinding diseases.
Gene therapy holds great promise for the treatment of IRDs.
Among the available gene transfer vectors, those based on the small
adeno-associated virus (AAV) are most efficient at targeting both PR
and retinal pigment epithelium (RPE) for long-term treatment upon
a single subretinal administration (Colella et al, 2009; Vandenber-
ghe & Auricchio, 2012). Recently, we and others have demonstrated
that subretinal administration of AAV is well-tolerated and effective
for improving vision in patients affected with type 2 LCA, which is
caused by mutations in RPE65, a gene expressed in the RPE (Bain-
bridge et al, 2008; Maguire et al, 2008, 2009; Cideciyan et al, 2009;
Simonelli et al, 2010). These results bode well for the treatment of
other forms of LCA and IRDs in general. The availability of AAV
vector serotypes such as AAV2/8, which efficiently targets PR (All-
occa et al, 2007; Natkunarajah et al, 2008; Auricchio, 2011; Musso-
lino et al, 2011; Vandenberghe et al, 2011) and RPE, further
supports this approach. However, a major limitation of AAV is its
cargo capacity, which is thought to be limited to around 5 kb, the
size of the parental viral genome (Hermonat et al, 1997; Dong et al,
2010a; Lai et al, 2010; Wu et al, 2010b; Wang et al, 2012). This lim-
its the application of AAV gene therapy approaches for common
IRDs that are caused by mutations in genes whose coding sequence
(CDS) is larger than 5 kb (herein referred to as large genes). These
include: (i) STGD (MIM#248200), the most common form of inher-
ited macular degeneration caused by mutations in the ABCA4 gene
(CDS: 6822 bp; Allikmets, 1997), which encodes the all-trans retinal
transporter located in the PR outer segment (Allikmets, 1997; Mol-
day & Zhang, 2010); (ii) Usher syndrome type IB (USH1B;
MIM#276900), the most severe form of RP and deafness caused by
mutations in the MYO7A gene (CDS: 6648 bp; Millan et al, 2011)
encoding the unconventional MYO7A, an actin-based motor
expressed in both PR and RPE within the retina (Hasson et al, 1995;
Liu et al, 1997; Gibbs et al, 2010).
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Various strategies have been investigated to overcome the limi-
tation of AAV cargo capacity. Several groups, including our own,
have attempted to ‘force’ large genes into one of the many AAV
capsids available by developing the so-called oversize vectors
(Grieger & Samulski, 2005; Wu et al, 2007; Allocca et al, 2008).
Although administration of oversize AAV vectors achieves thera-
peutically-relevant levels of transgene expression in rodent and
canine models of human inherited diseases (Allocca et al, 2008;
Monahan et al, 2010; Grose et al, 2012; Lopes et al, 2013),
including the retina of the Abca4/ and shaker 1 (sh1) mouse
models of STGD and USH1B (Allocca et al, 2008; Lopes et al,
2013), the mechanism underlying oversize AAV-mediated trans-
duction remains elusive. In contrast to what we and others origi-
nally proposed (Grieger & Samulski, 2005; Wu et al, 2007;
Allocca et al, 2008), oversize AAV vectors do not contain a pure
population of intact large size genomes but rather a heteroge-
neous mixture of mostly truncated genomes ≤5 kb in length
(Dong et al, 2010a; Lai et al, 2010; Wu et al, 2010b; Wang et al,
2012). Following infection, re-assembly of these truncated ge-
nomes in the target cell nucleus has been proposed as a mecha-
nism for oversize AAV vector transduction (Dong et al, 2010a;
Hirsch et al, 2010, 2013; Lai et al, 2010; Wu et al, 2010b). Inde-
pendent of transduction mechanism and in vivo efficacy, the het-
erogeneity in oversize AAV genome sizes is a major limitation for
their application in human gene therapy.
Alternatively, the inherent ability of AAV genomes to undergo
intermolecular concatemerization (Duan et al, 1998) is exploited
to transfer large genes in vivo by splitting a large gene expression
cassette into halves (<5 kb in size), each contained in one of two
separate (dual) AAV vectors (Yan et al, 2000; Duan et al, 2001;
Ghosh et al, 2008). In the dual AAV trans-splicing strategy, a
splice donor (SD) signal is placed at the 3′ end of the 5′-half vector
and a splice acceptor (SA) signal is placed at the 5′ end of the
3′-half vector (Fig 1). Upon co-infection of the same cell by the
dual AAV vectors and inverted terminal repeat (ITR)-mediated
head-to-tail concatemerization of the two halves, trans-splicing
results in the production of a mature mRNA and full-size protein
(Yan et al, 2000). Trans-splicing has been successfully used to
express large genes in muscle and retina (Reich et al, 2003; Lai
et al, 2005). Alternatively, the two halves of a large transgene
expression cassette contained in dual AAV vectors may contain
homologous overlapping sequences (at the 3′ end of the 5′-half
vector and at the 5′ end of the 3′-half vector, dual AAV overlap-
ping), which will mediate reconstitution of a single large genome
by homologous recombination (Duan et al, 2001). This strategy
depends on the recombinogenic properties of the transgene over-
lapping sequences (Ghosh et al, 2006). A third dual AAV strategy
(hybrid) is based on adding a highly recombinogenic region from
an exogenous gene [i.e. alkaline phosphatase, AP (Ghosh et al,
2008, 2011)] to the trans-splicing vectors. The added region is
placed downstream of the SD signal in the 5′-half vector and
upstream of the SA signal in the 3′-half vector (Fig 1) in order to
increase recombination between the dual AAVs.
To determine which AAV-based strategy most efficiently transdu-
ces large genes in the retina, we compared them side-by-side in
HEK293 cells and in mouse and pig retina using EGFP, ABCA4 or
MYO7A. We then used the dual AAV trans-splicing and hybrid strat-
egies, which were the most efficient for transducing PR as well as
RPE, to rescue the retinal phenotype of the Abca4/ and sh1 mouse
models of STGD and USH1B.
Results
Generation of normal size, oversize and dual AAV vectors
We generated AAV oversize (OZ), dual AAV overlapping (OV),
trans-splicing (TS) and hybrid vectors that included the therapeutic
ABCA4-3xflag and MYO7A-HA coding sequences. The recombino-
genic sequences included in the dual AAV hybrid vectors were
based on either a previously reported region of the alkaline phos-
phatase transgene (AP, dual AAV hybrid AP; Ghosh et al, 2011) or a
77 bp sequence from the F1 phage genome (AK, dual AAV hybrid
AK) that we found to be recombinogenic in previous in vitro experi-
ments (Colella and Auricchio, unpublished data). We additionally
generated AAV OZ and dual AAV vectors including the reporter
EGFP sequence with the exception of the dual AAV OV approach
since its efficiency relies on transgene-specific overlaps for reconsti-
tution (Ghosh et al, 2006) and therefore can not be extrapolated
from one gene to another. For EGFP we additionally generated sin-
gle AAV vectors of normal size (NS) to compare levels of transgene
expression from the various strategies. The constructs generated for
production of all AAV vectors used in this study are listed in supple-
mentary Table S1 and a schematic representation of the various
approaches is depicted in Fig 1.
We used AAV2/2 vectors for the in vitro experiments, with the
ubiquitous cytomegalovirus (CMV) or chicken beta-actin (CBA) pro-
Figure 1. Schematic representation of AAV-based strategies for large
gene transduction. CDS, coding sequence; pA, poly-adenylation signal; SD,
splicing donor signal; SA, splicing acceptor signal; AP, alkaline phosphatase
recombinogenic region; AK, F1 phage recombinogenic region. Pointed lines
show overlapping regions available for homologous recombination, dotted
lines show the splicing occurring between SD and SA.
EMBO Molecular Medicine ª 2013 The Authors
EMBO Molecular Medicine Retinal large gene delivery by dual AAV vectors I. Trapani et al
2
moters, which efficiently transduce HEK293 cells (Dong et al,
2010b). In the experiments performed in vivo in the retina, we used
AAV2/8 vectors, which efficiently transduce RPE and PR (Allocca
et al, 2007; Mussolino et al, 2011; Vandenberghe et al, 2011) but
poorly infect HEK293 cells, and either the ubiquitous CBA and CMV
promoters (Mussolino et al, 2011), or the RPE-specific vitelliform
macular dystrophy 2 (VMD2; Esumi et al, 2004) or the PR-specific
Rhodopsin (RHO) and Rhodopsin kinase (RHOK) promoters (Alloc-
ca et al, 2007; supplementary Table S1).
Dual AAV vectors allow high levels of transduction in vitro
We initially compared the efficiency of the various OZ, dual AAV
OV, TS and hybrid AP and AK strategies for AAV-mediated large gene
transduction in vitro by infecting HEK293 cells with the AAV2/2 vec-
tors [multiplicity of infection, m.o.i.: 105 genome copies (GC)/cell of
each vector] with ubiquitous promoters (CMV for ABCA4-3xflag,
CBA for MYO7A-HA). Cell lysates were analyzed by Western blot
with anti-3xflag (to detect ABCA4-3xflag, Fig 2A) or anti-Myo7a
(Fig 2B) antibodies. All strategies resulted in the expression of
proteins of the expected size. As predicted, no bands of the expected
size were observed when only one of the dual AAV vectors was used
for infection (Fig 2A and B). Quantification of ABCA4 and MYO7A
expression (Fig 2D and E) showed that the dual AAV hybrid AP
approach resulted in the lowest levels of transgene expression, while
the dual AAV OV, TS and hybrid AK approaches were more efficient
than the AAV OZ approach. We then confirmed this using the EGFP
transgene. For this purpose we selected the best performing dual
AAV strategies (TS and hybrid AK; we did not use the transgene-spe-
cific OV strategy with EGFP, which is a reporter gene) and further
compared them to AAV OZ. We thus produced AAV2/2-CMV-OZ-
EGFP vectors and for comparison -TS- and -AK-EGFP-L in which the
combined dual AAV vector genome length is similar to that of AAV
Figure 2. Dual AAV overlapping, trans-splicing and hybrid AK vectors efﬁciently transduce large genes in vitro.
A–F Western blot analysis of HEK293 cells infected with AAV2/2 vectors encoding for ABCA4 (A, D), MYO7A (B, E) and EGFP (C, F). The Western blot images (A-C) are
representative of and the quantiﬁcations (D-F) are from n = 4 (A, C, D, F) or n = 3 (B, E) independent experiments. OZ, AAV oversize; OV, dual AAV overlapping;
TS, dual AAV trans-splicing; AP, dual AAV hybrid AP; AK, dual AAV hybrid AK; TS-L, dual AAV trans-splicing EGFP with a combined genome size similar to OZ-EGFP;
AK-L, dual AAV hybrid AK EGFP with a combined genome size similar to OZ-EGFP; 5′+3′: cells co-infected with 5′- and 3′-half vectors; 5′: control cells infected
with the 5′-half vector; 3′: control cells infected with the 3′-half vector; a-EGFP: Western blot with anti-EGFP antibody; a-3xﬂag: Western blot with anti-3xﬂag
antibody; a-Myo7a: Western blot with anti-Myo7a antibody; a-b-Tubulin: Western blot with anti-b-Tubulin antibody, used as loading control; a-Filamin A:
Western blot with anti-Filamin A antibody, used as loading control. *P ANOVA < 0.05; **P ANOVA < 0.001.
A–C The arrows indicate full-length proteins, the micrograms of proteins loaded are depicted under each lane, the molecular weight ladder is depicted on the left.
D–F Quantiﬁcation of ABCA4 (D), MYO7A (E) and EGFP (F) protein bands. The intensity of the ABCA4, MYO7A and EGFP bands was divided by the intensity of the
Filamin A (D, E) or Tubulin (F) bands. The histograms show the expression of proteins as a percentage relative to dual AAV trans-splicing (TS) vectors, the mean
value is depicted above the corresponding bar. Values are represented as mean  standard error of the mean (s.e.m.).
Data information: (E) The asterisks represent signiﬁcant differences with both OZ and AP. (D–F) More details on the TS and TS-L variability as well as on the statistical
analysis including speciﬁc statistical values can be found in the Western blot and Statistical analysis paragraphs of the Materials and methods section, respectively.
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OZ (supplementary Table S1). We infected HEK293 cells with
AAV2/2-CMV-EGFP vectors [multiplicity of infection, m.o.i.:
105 genome copies (GC)/cell of each vector] and performed Western
blot analysis of cell lysates with anti-EGFP antibodies (Fig 2C). Simi-
larly to what observed with the ABCA4 and MYO7A transgenes,
quantification of EGFP expression (Fig 2F) showed that dual AAV TS
and hybrid AK approaches are more efficient than AAV OZ.
Then, we compared the efficiency of single AAV NS-EGFP to that
of dual AAV TS and hybrid AK of similar size (supplementary
Fig S1) by Western blot analysis of infected HEK293 cells. Quantifi-
cation of EGFP expression showed that the levels achieved with
dual AAV TS and hybrid AK were about 13–25-fold lower (7–4%)
than with AAV NS (supplementary Fig S1).
Dual AAV TS and hybrid AK but not OV vectors transduce mouse
and pig photoreceptors
The enclosed and small subretinal space should favour co-infection
and transduction of the same cell by two independent AAV vectors.
To test this, we injected subretinally WT mice with AAV2/8-CMV-
EGFP, AAV2/8-CMV-DsRed or a mixture of both vectors (dose of
each vector/eye: 3 9 109 GC) and harvested the eyes transduced by
single or both vectors 3 weeks post-injection. Neural retinas, sepa-
rated from the RPE, were dissociated and analyzed by flow cytome-
try. We found that 36  6% of the labelled cells were positive for
both EGFP and DsRed. However, since the number of DsRed+ only
cells (8  5%) was lower than the number of EGFP+ only cells
(56  8%) by counting the number of EGFP+/DsRed+ cells over the
total number of transduced cells we may have under-estimated the
co-transduction efficiency of the two vectors. Indeed, if we analyze
the DsRed-positive cell populations, 82% of these were also EGFP-
positive. This co-transduction efficiency is similar to that which we
have reported previously (Palfi et al, 2012). To determine the co-
transduction efficiency specifically in PR, and to test another red
fluorescent reporter possibly more potent than DsRed, we repeated
the injection in mice with a mixture of AAV2/8-CMV-EGFP and
-RFP vectors (dose of each vector/eye: 1.4 9 109 GC/eye) and ana-
lyzed co-transduction on retinal cryosections which allow to unequi-
vocably identify PR from RPE (supplementary Fig S2). We found
that 24  2% of transduced PR expressed both EGFP and RFP.
However, the number of RFP+ cells was still lower than the number
of EGFP+ cells due to weaker RFP fluorescence compared to EGFP,
and the percentage of co-transduction reaches 53  4% when we
consider the number of RFP+ cells that are also EGFP+.
We then evaluated the best in vitro performing AAV-based sys-
tems for large gene transduction in the mouse retina. To test the
dual AAV OV, which is transgene-specific, we used the therapeutic
ABCA4 and MYO7A genes (Fig 3 and data not shown). We used
EGFP to evaluate the AAV OZ and the dual AAV TS and hybrid AK
approaches (supplementary Fig S4).
Western blot analysis on retinal lysates, 1 month after subretinal
delivery in C57BL/6 mice of the dual AAV OV vectors (dose of each
vector/eye: 1.3 9 109 GC), encoding ABCA4-3xflag from the ubiqui-
tous CMV promoter, revealed robust protein expression (Fig 3A).
To determine which cell type in the retina expressed ABCA4, we
used dual AAV OV vectors (dose of each vector/eye: 1 9 109 GC)
that contained either the PR-specific RHO and RHOK, or the RPE-
specific VMD2 promoters. We detected ABCA4 protein expression in
retinas injected with the VMD2 but not with the RHO and RHOK
promoters (Fig 3A). These results were also confirmed in the Large
White pig retina (Fig 3B). The pig retina is an excellent model to
evaluate vector efficiency because of its size, which is similar to the
human retina, and because it is enriched with cones that are con-
centrated in a streak-like region whose cone density is comparable
to that of the primate macula (Mussolino et al, 2011). We injected
Large White pig subretinally with dual AAV OV vectors encoding
ABCA4-3xflag (dose of each vector/eye: 1 9 1010 GC), and
observed ABCA4 protein expression with the CMV but not the RHO
promoter (Fig 3B). Similarly, subretinal administration of dual AAV
OV vectors encoding MYO7A-HA resulted in weak MYO7A protein
expression in the mouse retina with the ubiquitous CBA (dose of
each vector/eye: 2.5 9 109 GC) and no detectable expression with
the RHO (dose of each vector/eye: 3.2 9 109 GC) promoter (data
not shown). To rule out that this was due to a lower transcriptional
activity from either the RHO or RHOK promoters compared to CMV,
we injected subretinally C57BL/6 mice with 1.5 9 109 GC/eye of
AAV2/8 vectors expressing EGFP from each of the promoters and
found that CMV and RHO drive similarly robust PR transgene
expression (supplementary Fig S3). Overall, these data suggest that
the dual AAV OV approach is more efficient for large gene transfer
to RPE than to PR.
To find an AAV-based strategy that efficiently transduces large
genes in PR, which are a major target of gene therapy for IRDs
including STGD and USH1B, we compared the retinal transduction
properties of the AAV OZ with those of dual AAV TS and hybrid
AK approaches, which in addition to dual AAV OV were the best
Figure 3. Dual AAV overlapping vectors transduce RPE but not
photoreceptors in the mouse and pig retina.
A–B Representative Western blot analysis of C57BL/6 (A) and Large White pig
(B) retinal lysates 1 month following injection of dual AAV2/8
overlapping vectors encoding for ABCA4-3xﬂag (OV) or AAV2/8 vectors
expressing EGFP (neg), under the control of the ubiquitous
cytomegalovirus (CMV) promoter, the PR-speciﬁc Rhodopsin (RHO) and
Rhodopsin kinase (RHOK) promoters, or the RPE-speciﬁc vitelliform
macular dystrophy 2 (VMD2) promoter. The arrows indicate full-length
proteins, the molecular weight ladder is depicted on the left, 150 lg of
proteins were loaded in each lane. The number (n) and percentage of
ABCA4-positive retinas out of total retinas analyzed is depicted;
a-3xﬂag, Western blot with anti-3xﬂag antibody; a-Dysferlin, Western
blot with anti-Dysferlin antibody, used as loading control.
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performing dual AAV approaches in vitro. We used EGFP, which
allowed us to easily localize transgene expression in the various reti-
nal cell types, including PR, as well as to properly compare the lev-
els of AAV-based large transgene transduction to those of a single
AAV NS vector. C57BL/6 mice were initially injected subretinally
with AAV OZ and dual AAV TS-L and hybrid AK-L vectors (dose of
each vector/eye: 1.7 9 109 GC), all encoding EGFP under the tran-
scriptional control of the CMV promoter. One month later, fundus
photographs showed that the highest levels of fluorescence were
obtained with the dual AAV TS and hybrid AK approaches (supple-
mentary Fig S4A). Fluorescence microscope analysis of retinal cryo-
sections showed that detectable levels of RPE and PR transduction
could be achieved with all approaches when combining the two
half-vectors but not with each of them separately (supplementary
Figs S4B and S5). However the levels of expression were higher,
although variable, in the eyes injected with dual AAV TS-L and
hybrid AK-L than in the eyes injected with AAV OZ vectors (supple-
mentary Fig S4).
To test whether the levels and consistency of dual AAV-mediated
transduction obtained can be improved by varying the ratio between
the 5′- and 3′-half vectors, we injected subretinally C57BL/6 mice
with dual AAV TS and hybrid AK vectors with different doses of 5′-
and 3′-half vectors (supplementary Fig S6). We set as 1:1 the dose
of 2.5 9 108 GC/eye which is submaximal considering that the
titers of our AAV preps range around 109 GC/ll (supplementary
Table S2) and that 1 ll is the maximum volume tolerated by the
mouse subretinal space. Thus, 2.5 9 109 GC/eye which is the high
1:1 dose (10:10) is the maximum dose which we can administer to
the murine eye. We show that none of the various ratios tested out-
performs the 1:1 ratio of the high dose of vectors (10:10) used so far
(supplementary Fig S6). Therefore we used the optimal 10:10 dose
and ratio in our following experiments.
We then assessed PR-specific transduction levels in C57BL/6
mice following subretinal administration of dual AAV TS and hybrid
AK vectors, which appears the most promising for large gene recon-
stitution in PR, as well as AAV NS vectors for comparison (dose of
Figure 4. Dual AAV trans-splicing and hybrid AK vectors efﬁciently transduce mouse and pig photoreceptors.
A EGFP protein quantiﬁcation by ELISA of retinas from C57BL/6 mice 1 month following subretinal injection of AAV2/8 vectors encoding for EGFP under the control of
the PR-speciﬁc Rhodopsin (RHO) promoter. The scatter plot depicts EGFP protein levels from each retina; the mean value for each group is depicted and indicated
with a solid line. The number (n) of eyes analyzed is depicted under the x axis. **P ANOVA<0.001. More details on the statistical analysis including speciﬁc
statistical values can be found in the Statistical analysis paragraph of the Materials and methods section.
B Fluorescence analysis of retinal cryosections from Large White pigs 1 month following subretinal injection of AAV2/8 vectors encoding for EGFP under the control
of the PR-speciﬁc RHO promoter. The pictures are representative of: n = 4 or n = 3 eyes injected with dual AAV TS or hybrid AK, respectively. The scale bar
(100 lm) is depicted in the ﬁgure. NS, AAV normal size; TS, dual AAV trans-splicing; AK, dual AAV hybrid AK; DAPI, 4′,6′-diamidino-2-phenylindole staining; EGFP,
native EGFP ﬂuorescence; Merge, overlay of DAPI and EGFP pictures; RPE, retinal pigmented epithelium; PR, photoreceptors.
ª 2013 The Authors EMBO Molecular Medicine
I. Trapani et al Retinal large gene delivery by dual AAV vectors EMBO Molecular Medicine
5
each vector/eye: 2.4 9 109 GC). All vectors encoded EGFP under
the transcriptional control of the PR-specific RHO promoter. One
month after vector administration whole retina lysates were ana-
lyzed by ELISA to quantify EGFP protein levels (Fig 4A). Dual AAV
TS and hybrid AK vectors reconstituted consistent EGFP expression
in PR at levels on average about 16–33-fold lower (6–3%) than with
AAV NS. However, these levels were variable, similarly to what
observed in retinal histological sections (supplementary Fig S4B),
and some of the eyes treated with dual AAV vectors had EGFP levels
in the range of those achieved with AAV NS (Fig 4A). As expected,
no detectable EGFP expression was measured by ELISA in injected
retinas when only one of the dual AAV vectors encoding for EGFP
was used (n = 9: five eyes injected with 5′-half and four eyes with
3′-half; data not shown).
Thus, we conclude that dual AAV TS and hybrid AK strategies
allow efficient mouse PR transduction although at levels which are
lower than those obtained with an AAV NS. We then confirmed that
subretinal administration of dual AAV TS and hybrid AK vectors
transduced PR of Large White pigs (Fig 4B; dose of each vector/eye:
1 9 1011 GC).
Dual AAV vectors improve the retinal phenotype of STGD and
USH1B mouse models
To understand whether the levels of PR transduction obtained with
the dual AAV TS and hybrid AK approaches may be therapeutically
relevant, we investigated them in the retina of two mouse models of
IRDs, STGD and USH1B, caused by mutations in the large ABCA4
and MYO7A genes, respectively.
Although the Abca4/ mouse model does not undergo severe
PR degeneration (Wu et al, 2010a), the absence of the ABCA4-
encoded all-trans retinal transporter in PR outer segments (Illing
et al, 1997; Sun & Nathans, 1997) causes an accumulation of lipo-
fuscin in PR as well as in RPE, as result of PR phagocytosis by RPE
(Weng et al, 1999; Mata et al, 2001). As a consequence, both the
number of lipofuscin granules in the RPE and the thickness of RPE
cells are greater in Abca4/ mice than in control mice (Allocca
et al, 2008; Radu et al, 2008; Ma et al, 2011; Conley et al, 2012;
Han et al, 2012). In addition, Abca4/ mice also show delayed
recovery from light desensitization (Weng et al, 1999; Maiti et al,
2006; Allocca et al, 2008; Radu et al, 2008; Han et al, 2012). Since
ABCA4 is expressed specifically in PR, we generated dual AAV TS
and hybrid AK vectors encoding ABCA4-3xflag under the transcrip-
tional control of the RHO promoter. These vectors were subretinally
injected in wild-type C57BL/6 mice (dose of each vector/eye: 3–
5 9 109 GC) and 1 month later retinas were lysed and analyzed by
Western blot with anti-3xflag antibodies (Fig 5A). Both approaches
resulted in robust yet variable levels of ABCA4-3xflag expression.
ABCA4-3xflag expression levels were more consistent in retinas
treated with the dual AAV hybrid AK vectors (Fig 5A). No truncated
and/or aberrant ABCA4 proteins were detected by Western blot
analysis of C57BL/6 eyecups treated with dual AAV TS and hybrid
AK vectors using anti-3xflag antibodies although two proteins
(>100 KDa) smaller than the full length are produced in vitro follow-
ing infection with either the single 5′- or 3′-half of both dual AAV
approaches (supplementary Figs S7 and S8). In addition no evident
signs of retinal toxicity were observed in Abca4/ mice at
8 months after treatment with dual AAV TS and hybrid AK vectors
by conventional histological analysis (supplementary Fig S9A).
To evaluate the biological and therapeutic activity of the recom-
binant ABCA4 protein produced by dual AAV vectors, 1 month-old
albino Abca4/ mice were injected subretinally with the dual AAV
TS and hybrid AK RHO-ABCA4-HA vectors (dose of each vector/
eye: 1–3 9 109 GC). Three months later, eyes were harvested and
immuno-electron microscopy analysis with anti-hemagglutinin (HA)
antibodies of retinal sections confirmed that immunogold particles
were correctly localized in PR outer segments only in animals that
were injected with the combination of 5′ and 3′ dual AAV TS and
hybrid AK vectors (Fig 5B). To assess the functionality of the
ABCA4 protein expressed by the dual AAV vectors, we measured
Abca4/ retinal lipofuscin accumulation and recovery from light
desensitization. To assess the former we performed transmission
electron microscopy analysis to measure the number of RPE lipofus-
cin granules (Fig 5C and D) and RPE thickness (Fig 6A and B). Both
were greater in the retina of Abca4/ mice injected with control
vectors (independently of the size of the control constructs, supple-
mentary Fig S10) than in the retina of wild-type, age-matched
BALB/c controls, and were significantly reduced or normalized in
the eyes injected either with the therapeutic dual AAV TS or hybrid
AK vectors (Figs 5C and D and 6A and B). We additionally
attempted at measuring A2E, the major component of lipofuscin
granules, by HPLC (Parish et al, 1998; Ben-Shabat et al, 2002; Alloc-
ca et al, 2008), however these measurements were inconsistent,
even between affected and normal retinas (data not shown), thus
we were not able to use these techniques in our rescue experiments.
Importantly, the eyes treated with dual AAV TS and hybrid AK vec-
tors showed improved recovery from light desensitization when
compared to eyes treated with control vectors (dose of each vector/
eye: 1.2 9 109 GC, Fig 6C), independently of the size of the control
constructs [Student’s t-test P value of dual AAV-EGFP-L (n = 2 TS-
L, n = 4 AK-L; total n = 6) versus dual AAV-EGFP (n = 5 TS, n = 4
AK; total n = 9): 0.23].
We then tested the efficacy of dual AAV-mediated MYO7A
gene transfer in the retina of sh1 mice, the most commonly used
model of USH1B (Liu et al, 1997, 1998, 1999; Lillo et al, 2003;
Gibbs et al, 2010). In sh1 mice, a deficiency in the motor Myo7a
causes the mis-localization of RPE melanosomes (Liu et al, 1998),
which do not enter into the RPE apical microvilli, and the accu-
mulation of rhodopsin at the PR connecting cilium (Liu et al,
1999). MYO7A is highly expressed in the RPE and to a lesser
extent in PR (Hasson et al, 1995; Liu et al, 1997), therefore we
used dual AAV TS and hybrid AK vectors expressing MYO7A-HA
under the transcriptional control of the ubiquitous CBA promoter.
One month-old wild-type C57BL/6 mice were injected with the
dual AAV vectors (dose of each vector/eye: 1.7 9 109 GC) and
eyecup lysates were evaluated 1 month later using Western blot
analysis with anti-HA antibodies. Results showed similarly robust
and consistent levels of MYO7A expression in retinas treated with
both approaches (Fig 7A). Taking advantage of our anti-Myo7a
antibody able to recognize both murine and human MYO7A
(although with potentially different affinity for the two ortholo-
gous proteins), we compared the levels of MYO7A achieved fol-
lowing delivery of dual AAV vectors to the sh1/ eye to those
expressed endogenously in the sh1+/ eye (Fig 7B). The levels of
human MYO7A driven by the CBA promoter 1 month after treat-
ment (Fig 7B; dose of each vector/eye: 1.7 9 109 GC) were 19–
21% of endogenous Myo7a expressed in both RPE and PR
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(Fig 7B) and these remained similar at 9 months after vector
delivery (MYO7A retinal levels after subretinal delivery of dual
AAV-TS, quantified on Western blot of eyecup lysates as in
Fig 7B: 19  6% of endogenous Myo7a, n = 5). Notably, subreti-
nal delivery of dual AAV TS and hybrid AK resulted in efficient
expression of human MYO7A specifically in PR when using the
RHO promoter (supplementary Fig S11). No MYO7A proteins of
size different from the full-length were detected by Western blot
analysis of sh1/ eyecups treated with either dual AAV TS or
hybrid AK vectors. However, two proteins smaller than the full
length MYO7A (<130 KDa) are detected in vitro following infec-
tion with either the single 5′- or 3′-half of both dual AAV
approaches (supplementary Fig S12 and S13).
To test the ability of MYO7A expressed from dual AAV vectors to
rescue the defects of the sh1/ retina, we evaluated RPE
melanosome (Fig 8A and B) and rhodopsin localization (Fig 8C) fol-
lowing subretinal injection of dual AAV TS and hybrid AK
CBA-MYO7A vectors (dose of each vector/eye: 1.7 9 109 GC) in
1 month-old sh1/ mice. Unlike in unaffected mice, the sh1/
melanosomes do not enter the RPE apical microvilli (Fig 8A and B),
this was significantly improved after the delivery of either dual AAV
TS or hybrid AK vectors encoding MYO7A (Fig 8A and B).
We also found that the number of rhodopsin particles at the
connecting cilium is greater in sh1/ retinas treated with con-
trol vectors (independently of the size of the control constructs,
supplementary Fig S14) than in unaffected sh1 (Fig 8C and sup-
Figure 5. Subretinal administration of dual AAV vectors results in ABCA4 expression in mouse photoreceptors and reduction in the accumulation of
lipofuscin granules in Abca4/ mice.
A Representative Western blot analysis of C57BL/6 retinal lysates 1 month following the injection of dual AAV trans-splicing (TS) and hybrid AK (AK) vectors
encoding for ABCA4 under the control of the PR-speciﬁc Rhodopsin promoter (RHO PROMOTER). The arrow points at full-length proteins, the molecular weight
ladder is depicted on the left, 150 lg of protein were loaded in each lane. The number (n) and percentage of ABCA4-positive retinas out of total retinas analyzed
is depicted. AK, retinas injected with dual AAV hybrid AK vectors; TS, retinas injected with dual AAV TS vectors; neg: retinas injected with AAV vectors expressing
EGFP, as negative controls; a-3xﬂag: Western blot with anti-3xﬂag antibody; a-Dysferlin: Western blot with anti-Dysferlin antibody, used as loading control.
B Representative pictures of immuno-electron microscopy analysis with anti-HA antibody of retinal sections from wild-type BALB/c (WT) and Abca4/ mice
injected with either dual AAV or with negative control vectors. The black dots represent the immuno-gold labelling of the ABCA4-HA protein. The scale bar
(200 nm) is depicted in the ﬁgure.
C Representative pictures of transmission electron microscopy analysis showing lipofuscin granules content in the RPE of WT and Abca4/ mice injected with
either dual AAV or negative control vectors. The black arrows indicate lipofuscin granules. The scale bar (1.6 lm) is depicted in the ﬁgure.
D Quantiﬁcation of the mean number of lipofuscin granules counted in at least 30 ﬁelds (25 lm2) for each sample. The number (n) of eyes analyzed is depicted
below each bar. The mean value is depicted above the corresponding bar. Values are represented as mean  standard error of the mean (s.e.m.). *P
ANOVA < 0.05; **P ANOVA < 0.001. More details on the statistical analysis including speciﬁc statistical values can be found in the Statistical analysis paragraph
of the Materials and methods section.
Data information: (B-D) WT, BALB/c eyes; Abca4/ neg, Abca4/ eyes injected with either AAV vectors expressing EGFP (n = 2) or the 50- (n = 3) or 30- (n = 4)
half of the dual AAV hybrid AK vectors, as negative control (neg total n = 9); Abca4/ AK-ABCA4: mice injected with dual AAV hybrid AK vectors; Abca4/
TS-ABCA4: mice injected with dual AAV TS vectors.
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plementary Fig S14). This was reduced in sh1/ retinas treated
with dual AAV TS and hybrid AK vectors expressing MYO7A,
although the differences were not statistically significant (Fig 8C).
Notably, the improvement of the sh1/ retinal defects is
associated with a normal retinal architecture (supplementary
Fig S9B) which further suggests that subretinal delivery of dual
AAV TS and hybrid AK vectors does not induce evident retinal
toxicity.
Discussion
While AAV-mediated gene therapy is effective in animal models and
in patients with inherited blinding conditions (Jacobson et al, 2006;
Bainbridge et al, 2008; Maguire et al, 2008, 2009; Cideciyan et al,
2009; Simonelli et al, 2010), its application to diseases affecting the
retina and requiring a transfer of genes larger than 5 kb (referred to
as large genes) is inhibited by AAV limited cargo capacity. To over-
come this, we compared the efficiency of various AAV-based strate-
gies for large gene transduction including: AAV OZ and dual AAV
OV, TS, hybrid AP and AK approaches in vitro and in mouse and
pig retina. Our in vitro and in vivo results show that the dual AAV
strategies we tested (with the exception of the dual AAV hybrid AP)
outperform AAV OZ vectors in terms of transduction levels. This
may be explained by: (i) the homogeneous size of the dual AAV
genome population when compared to AAV OZ genomes, which
may favour the generation of transcriptionally active large transgene
expression cassettes; (ii) the small volume of the subretinal space,
Figure 6. Subretinal injection of dual AAV vectors reduces the thickness of the RPE and improves recovery from light desensitization in Abca4/ mice.
A Representative pictures of transmission electron microscopy analysis of retinal sections from wild-type BALB/c (WT) and Abca4/ mice injected with dual AAV
trans-splicing (TS-ABCA4) and hybrid AK vectors (AK-ABCA4) or with either AAV vectors expressing EGFP or 5′- or 3′-half of the dual hybrid AK vectors (neg), as
negative controls. The dotted lines indicate the edges of RPE cells. The scale bar (3.8 lm) is depicted in the ﬁgure.
B Quantiﬁcation of the mean RPE thickness counted in at least 30 ﬁelds for each sample. The number (n) of eyes analyzed is depicted below each bar. Abca4/ neg
includes Abca4/ mice injected with either AAV vectors expressing EGFP (n = 2) or 5′- (n = 3) or 3′- (n = 4) half of the dual hybrid AK vectors (neg total n = 9).
The mean value is depicted above the corresponding bar. Values are represented as mean  standard error of the mean (s.e.m.). *P ANOVA < 0.05.
C Recovery from light desensitization in 3 month-old Abca4/ and BALB/c mice at 6 weeks post-injection. The relative b-wave is the ratio between the post- and
the pre-desensitization b-wave amplitudes both evoked by 1 cd s/m2. The time refers to the minutes post-desensitization. The mean recovery (%) at 60 min is
depicted. WT, BALB/c eyes (n = 4); Abca4/ TS-ABCA4, eyes injected with dual AAV TS vectors (n = 5); Abca4/ AK-ABCA4: mice injected with dual AAV hybrid AK
vectors (n = 5); Abca4/ neg: Abca4/ mice either not injected (n = 2) or injected with the 5′-half of the dual AAV TS (n = 3) or hybrid AK (n = 2) vectors (neg
total n = 7). Values are represented as mean  standard error of the mean (s.e.m.). *P ANOVA < 0.05. More details on the statistical analysis including speciﬁc
statistical values can be found in the Statistical analysis paragraph of the Materials and methods section.
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which we show favours infection and transduction of the same cell
by two independent AAV vectors. Although this has been suggested
by previous work in the retina with either dual AAV TS vectors car-
rying the lacZ reporter gene (Reich et al, 2003) or with two single
vectors encoding different fluorescent reporter proteins (Palfi et al,
2012), our study represents the first comprehensive comparison in
the retina of the dual AAV strategies reported so far, as well as the
first demonstration of their efficacy in animal models of common
inherited blinding conditions.
The dual AAV OV approach is particularly interesting when
compared to the TS or hybrid AK approaches, which appear simi-
larly efficient in vitro, as dual AAV OV vectors only contain
sequences belonging to the therapeutic transgene expression cas-
sette. However, when we administered dual AAV OV vectors to the
subretinal space of adult mice and pigs, we were able to detect
expression of the large ABCA4 and MYO7A proteins only when the
ubiquitous or the RPE-specific promoters, but not the PR-specific
promoters, were used. This may suggest that the homologous
recombination required for dual AAV OV reconstitution is more effi-
cient in RPE than PR. This is consistent with the low levels of
homologous recombination reported in post-mitotic neurons (Fishel
et al, 2007) and may partially explain the low levels of dual AAV
OV-mediated MYO7A transduction recently reported by other
groups (Lopes et al, 2013). We conclude that subretinal administra-
tion of dual AAV OV vectors should not be used for large gene
transfer to PR, although we can not exclude that sequences that are
more recombinogenic than those included in our dual AAV OV
ABCA4 and MYO7A vectors may allow efficient homologous recom-
bination in PR.
Dual AAV TS and hybrid AK approaches efficiently transduce
mouse and pig PR, differently from what we observed with dual
AAV OV. This is consistent with the knowledge that the mechanism
of large gene reconstitution mediated by dual AAV TS and hybrid
AK approaches may be via ITR-mediated head-to-tail rejoining
(Duan et al, 1998; Yan et al, 2005; Ghosh et al, 2008) rather than
homologous recombination.
The transduction levels provided by the dual hybrid AK are
superior to those of the TS approach in mouse PR but not
RPE. This was evident when using the large ABCA4 and MYO7A
but not the small EGFP transgene, suggesting an advantage of
Figure 7. Subretinal administration of dual AAV trans-splicing and hybrid AK vectors results in robust MYO7A expression in mice.
A Representative Western blot analysis of C57BL/6 eyecups 1 month following the injection of dual AAV trans-splicing (TS) and hybrid AK (AK) vectors encoding for
MYO7A-HA under the control of the ubiquitous chicken beta-actin (CBA) promoter. The arrow indicates full-length proteins, the molecular weight ladder is
depicted on the left, 100 lg of proteins were loaded in each lane. The number (n) and percentage of MYO7A-positive eyecups out of total eyecups analyzed is
depicted. AK: eyes injected with dual AAV hybrid AK vectors; TS: eyes injected with dual AAV TS vectors; neg: eyes injected with either 5′- or 3′-half of the dual AAV
TS and hybrid AK vectors; a-HA: Western blot with anti-hemagglutinin (HA) antibody; a-Dysferlin: Western blot with anti-Dysferlin antibody, used as loading
control.
B Quantiﬁcation of MYO7A levels expressed from dual AAV vectors in sh1/ eyecups relative to endogenous Myo7a expressed in littermate sh1+/ eyecups. sh1/
eyes were injected with dual AAV TS and hybrid AK vectors encoding MYO7A under the control of the CBA promoter and analyzed 1.5 months later. sh1+/ eyes
were injected with AAV vectors expressing EGFP. The number (n) of eyes analyzed is depicted below each bar. The quantiﬁcation was performed by Western blot
analysis using the anti-Myo7a antibody and measurements of MYO7A and Myo7a band intensities normalized to Dysferlin. The histograms show the expression of
MYO7A protein as percentage relative to sh1+/ Myo7a; the mean value is depicted above the corresponding bars. Values are represented as mean  standard
error of the mean (s.e.m.).
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including the AK sequence for large transgene reconstitution in
cells like PR which are more difficult to target by AAV2/8 than
RPE.
Differently from what we have observed, Hirsch et al (2013)
have recently shown that AAV OZ vectors can reconstitute a large
reporter gene (6.2 kb) in the retina of mice more efficiently than
dual AAV TS vectors. The following factors may account for this:
(i) the design of the dual AAV vectors which may result in lower
transduction levels in Hirsch et al than in our case; (ii) the purifica-
tion of the AAV OZ vectors by Hirsch et al that may promote the
selection in the viral preparation of genomes with higher transduc-
tion properties than in our preparations; (iii) the use of a shorter
transgene by Hirsch et al than by us that gives rise to genomes with
longer overlaps which can positively influence AAV OZ transduc-
tion. Our results also differ from those of another group that has
reported that dual AAV hybrid AP outperforms TS (Ghosh et al,
2011). While we have generated our dual hybrid AP vectors based
on the description provided in that publication, it is possible that
minor differences in the AP sequences used may account for the dif-
ferent transduction levels we have observed.
The levels of mouse PR transduction we achieved with dual AAV
TS and hybrid AK are lower than with single NS vectors. However,
we show that in the case of MYO7A, retinal transgene expression
levels are about 20% of endogenous. These may be effective for
Figure 8. Subretinal administration of dual AAV vectors rescues melanosome and rhodopsin localization in sh1/ retinas.
A Semi-thin retinal sections representative of both sh1+/+ and sh1+/ eyes (sh1+/+) injected with AAV vectors expressing EGFP and of sh1/ eyes injected with dual
AAV trans-splicing (TS-MYO7A), hybrid AK (AK-MYO7A) or the 5′- or 3′-half vectors (neg), as negative controls. The arrows point at correctly localized melanosomes,
the scale bar (10 lm) is depicted in the ﬁgure.
B Quantiﬁcation of melanosome localization in the RPE villi of sh1 mice 2–3 months following subretinal delivery of dual AAV vectors. The n of eyes analyzed is
depicted below each bar. The quantiﬁcation is depicted as the mean number of apical melanosomes/100 lm, the mean value is depicted above the corresponding
bar. sh1/ neg includes sh1/ eyes injected with AAV vectors expressing either 5′- (n = 1) or 3′- (n = 2) half of the dual TS vectors, or 5′-half (n = 2) of the dual
hybrid AK vectors (neg total n = 5). Values are represented as mean  standard error of the mean (s.e.m.). *P ANOVA < 0.05, **P ANOVA < 0.001.
C Quantiﬁcation of the number of rhodopsin gold particles at the PR connecting cilium of sh1 mice 2–3 months following subretinal delivery of dual AAV vectors.
The n of eyes and connecting cilia analyzed is depicted below each bar. sh1/ neg includes sh1/ eyes injected with AAV vectors expressing either 5′-half of the
dual TS vectors (n = 3) or 5′-half (n = 2) of the dual hybrid AK vectors (neg total n = 5). The quantiﬁcation is depicted as the mean number of gold particles per
length of connecting cilium, the mean value is depicted above the corresponding bar. Values are represented as mean  standard error of the mean (s.e.m.). More
details on the statistical analysis including speciﬁc statistical values can be found in the Statistical analysis paragraph of the Materials and methods section.
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treating inherited blinding conditions that require relatively low lev-
els of transgene expression, i.e. diseases inherited as autosomal
recessive. Indeed, we show that subretinal delivery of dual AAV TS
and hybrid AK improves and even normalizes the retinal defects of
two animal models of IRDs, STGD and USH1B, which are due to
mutations in large genes and are attractive targets of gene therapy.
Importantly, both levels and consistency of dual AAV-mediated
large transgene expression could be improved by directing the pro-
ductive head-to-tail genome concatemerization by either using het-
erologous ITRs (Yan et al, 2007) or by adding oligos to the injection
solution (Hirsch et al, 2009).
Single normal size AAV vectors ensure multi-year retinal gene
expression after a single vector administration (Testa et al, 2013).
The data we have obtained so far from dual AAV vectors up to
9 months after retinal gene delivery, the last time point of our analy-
sis, suggest that longevity of transgene expression may be similar
between single normal size and dual AAV vectors.
The genome size of dual AAV vectors is homogeneous, which
means identity and safety issues related to their use should be less
considerable than those related to AAV OZ vectors, which have het-
erogeneous genome sizes. However, the possibility that delivery of
dual AAV vectors results in the production of aberrant proteins in
the retina, i.e. truncated proteins from the 5′-half vector that con-
tains the promoter sequence and/or from the 3′-half vector due to
the low promoter activity of the ITRs (Flotte et al, 1993) must be
considered. Our results show that proteins smaller than the full-
length are produced from the 5′- and 3′-halves of dual AAV vectors
in vitro but not in vivo in the retina where only full-length ABCA4
and MYO7A proteins are detected. The production of properly
spliced full length proteins by dual AAV vectors is corroborated by
the successful amplification of the full size ABCA4 and MYO7A
mRNA retro transcribed from cells infected with dual AAV TS and
hybrid AK vectors (data not shown). Indeed the transcript
sequences confirmed that intermolecular AAV joining and splicing
occurred correctly (data not shown), as expected by the size of the
full length proteins detected by Western blot. In addition, we
detected neither ERG (data not shown) nor retinal histological
abnormalities in both Abca4/ and sh1/ mice that we followed
up to 3–8 months after dual AAV vector delivery. Future long-term
safety studies as well as sensitive proteomic profiling will help to
better define if any toxicity derives from intraocular administration
of dual AAV vectors.
In conclusion, we found that dual AAV vectors are efficient both
in vitro and in the retina in vivo. While dual AAV OV vectors effi-
ciently transduce RPE, they do not transduce PR, whereas dual AAV
TS and hybrid AK approaches drive efficient large gene reconstitu-
tion in both cell types. Administration of dual AAV TS and hybrid
AK approaches improved the retinal phenotype of mouse models of
STGD and USH1B, providing evidence of the efficacy of these strate-
gies for gene therapy of these and other blinding conditions, which
require large gene transfer to PR as well as RPE.
Materials and Methods
Generation of AAV vector plasmids
The plasmids used for AAV vector production were derived from
either the pZac2.1 (Gao et al, 2000) or pAAV2.1 (Auricchio et al,
2001) plasmids that contain the inverted terminal repeats (ITRs) of
AAV serotype 2 (supplementary Table S1). Normal size and over-
size AAV vector plasmids contained full length expression cassettes
including the promoter, the full-length transgene CDS and the poly-
adenylation signal (pA; supplementary Table S1). The two separate
AAV vector plasmids (5′ and 3′) required to generate dual AAV vec-
tors contained either the promoter followed by the N-terminal por-
tion of the transgene CDS (5′ plasmid) or the C-terminal portion of
the transgene CDS followed by the pA signal (3′ plasmid, supple-
mentary Table S1). Normal size EGFP plasmids were generated by
cloning the EGFP CDS of pAAV2.1-CMV-EGFP plasmid (720 bp; Au-
ricchio et al, 2001) in pZac2.1 (Gao et al, 2000); oversize EGFP was
generated from pAAV2.1-CMV-EGFP (Auricchio et al, 2001) by
inserting a DNA stuffer sequence of 3632 bp from human ABCA4
(NM_000350.2, bp 1960-5591) upstream of the CMV promoter and a
second DNA stuffer sequence of 3621 bp, composed of: murine
ABCA4 (NM_007378.1, 1066-1 and 7124-6046 bp; 2145 total bp)
and human Harmonin (NM_153676.3 131-1606 bp; 1476 total bp),
downstream of the pA signal. To generate dual AAV vector plas-
mids, the EGFP CDS (720 bp) was split into two constructs: one
containing the N-terminal CDS (PMID: 9759496, bp 1-393) and the
other containing the C-terminal CDS (PMID: 9759496, bp 394-720).
The stuffer sequences flanking the EGFP expression cassette in the
EGFP OZ plasmid were used to generate dual AAV-TS-L and dual
AAV-AK-L plasmids (supplementary Table S1) with a combined
(5′+3′) genome length similar to the EGFP OZ construct size.
The oversize ABCA4 plasmids contained the full-length human
ABCA4 CDS (NM_000350.2, bp 105-6926), while the oversize
MYO7A plasmids contained the full-length human MYO7A CDS
from isoform 1 (NM_000260.3, bp 273-6920). To generate plasmids
for dual AAV OV vectors the ABCA4 and MYO7A CDS were split
into two constructs, one containing N-terminal CDS (ABCA4:
NM_000350.2, bp 105-3588; MYO7A: NM_000260.3, bp 273-3782)
and the other containing C-terminal CDS (ABCA4: NM_000350.2, bp
2819-6926; MYO7A: NM_000260.3, bp 2913-6920). Therefore, the
region of homology shared by overlapping vector plasmids was
770 bp for ABCA4 and 870 bp for MYO7A. To generate trans-splic-
ing and hybrid vector plasmids the ABCA4 and MYO7A CDS were
split at a natural exon-exon junction. ABCA4 was split between
exons 19-20 (5′ half: NM_000350.2, 105-3022 bp; 3′ half:
NM_000350.2, bp 3023-6926) and MYO7A was split between exons
24-25 (5′ half: NM_000260.3, bp 273-3380; 3′ half: NM_000260.3, bp
3381-6926). The ABCA4 and MYO7A proteins were both tagged at
their C-terminus: ABCA4 with either the 3xflag or hemagglutinin
(HA) tag; MYO7A with the HA tag only. In addition, the ABCA4 pro-
tein was tagged at both N- (amino acidic position 590) and C-termini
with the 3xflag tag for the experiments shown in supplementary
Figs S7 and S8. The splice donor (SD) and splice acceptor (SA) sig-
nals contained in dual trans-splicing and hybrid AAV vector plas-
mids are as follows: 5′-GTAAGTATCAAGGTTACAAGACAGGTTT
AAGGAGACCAATAGAAACTGGGCTTGTCGAGACAGAGAAGACTCTTG
CGTTTCT-3′ (SD); 5′-GATAGGCACCTATTGGTCTTACTG ACATCC
ACTTTGCCTTTCTCTCCACAG-3′ (SA). The recombinogenic sequence
contained in hybrid AP vector plasmids was derived from alkaline
phosphatase (AP) gene (NM_001632, bp 823-1100), as previously
described (Ghosh et al, 2011). The recombinogenic sequence
contained in hybrid AK vector plasmids was derived from the
phage F1 genome (Gene Bank accession number: J02448.1; bp
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5850-5926). The AK sequence is: 5′-GGGATTTTGCC GATTTCGGCC
TATTGGTTAAAAAATGAGCTGATTTAACAAAAATT TAACGCGAATT
TTAACAAAAT-3′. To generate the pZac2.1-CMV-RFP plasmid, the
monomeric RFP CDS (Campbell et al, 2002; 675 bp) was amplified
and cloned in pZac2.1-CMV-EGFP plasmid using EcoRI and BamHI
restriction sites. The pAAV2.1-CMV-DsRed plasmid (Palfi et al,
2012) was obtained by cloning the DsRed gene from the pDsRed-
Express2 plasmid (Clontech, Saint-Germain-en-Laye, France) in the
pAAV-MCS plasmid (Stratagene, La Jolla, CA, USA).
The ubiquitous CMV promoter is that contained in pZac2.1 (Gao
et al, 2000) or pAAV2.1-CMV-EGFP (Auricchio et al, 2001); the
ubiquitous CBA promoter was derived from pAAV2.1-CBA-EGFP
(Mussolino et al, 2011), the PR-specific human RHO and RHOK pro-
moters were derived from pAAV2.1-RHO-EGFP and pAAV2.1-
RHOK-EGFP, respectively (Allocca et al, 2007); the RPE-specific
VMD2 promoter (NG_009033.1, bp 4870-5470) corresponds to the
previously described EcoRI-XcmI promoter fragment (Esumi et al,
2004) and was amplified by human genomic DNA. The details of
cloning strategies as well as plasmid sequences are available upon
request.
AAV vector production and characterization
AAV vectors were produced by the TIGEM AAV Vector Core by triple
transfection of HEK293 cells followed by two rounds of CsCl2 purifi-
cation (Doria et al, 2013). For each viral preparation, physical titers
[genome copies (GC)/ml] were determined by averaging the titer
achieved by dot-blot analysis (Drittanti et al, 2000) and by PCR
quantification using TaqMan (Applied Biosystems, Carlsbad, CA,
USA; Doria et al, 2013). The probes used for dot-blot and PCR ana-
lyzes were designed to anneal with either the ITRs or regions within
1 kb from the ITRs. No statistically significant differences were
found in the titers (GC/ml) of NS AAV2/2 or AAV2/8 compared to
those of dual AAV OV, TS and hybrid vectors (supplementary
Table S2). In addition alkaline Southern blot analysis of viral DNA
extracted from several dual AAV OV, TS and hybrid AK preps
showed that the AAV genome is homogeneous and its size corre-
sponds to that expected independently of the presence of recombino-
genic elements in the dual AAV vectors (supplementary Fig S15).
However, since recombination is sequence-specific, the conclusions
from supplementary Fig S15 can not be directly extrapolated to other
vectors. The alkaline Southern blot analysis shown in supplemen-
tary Fig S15 was carried out as follows: 3 9 1010 GC of viral DNA
were extracted from AAV particles. To digest unpackaged genomes,
the vector solution was resuspended in 240 ll of PBS pH 7.4 19
(GIBCO; Invitrogen S.R.L., Milan, Italy) and then incubated with
1 U/ll of DNase I (Roche, Milan, Italy) in a total volume of 300 ll
containing 40 mM TRIS–HCl, 10 mM NaCl, 6 mM MgCl2, 1 mM
CaCl2 pH 7.9 for 2 h at 37°C. The DNase I was then inactivated with
50 mM EDTA, followed by incubation with proteinase K and 2.5%
N-lauroyl-sarcosil solution at 50°C for 45 min to lyse the capsids.
The DNA was extracted twice with phenol-chloroform and precipi-
tated with two volumes of ethanol 100 and 10% sodium acetate
(3 M, pH 7). Alkaline agarose gel electrophoresis and blotting were
performed as previously described (Sambrook & Russell, 2001). Ten
microlitres of the 1 kb DNA ladder (N3232L; New England Biolabs,
Ipswich, MA, USA) were loaded as molecular weight marker. Three
different double strand DNA fragments were radio-labelled with [a-
32]-CTP using the Amersham Rediprime II DNA labelling System
(GE Healthcare Europe, GmbH, Milan, Italy) and used as probes.
The 5′ probe (875 bp) was generated by digestion of the pZac2.1-
CMV-ABCA4_5′ plasmid with EagI; the 3′ probe (880 bp) was gener-
ated by double digestion of the pZac2.1-ABCA4_3′_3xflag_SV40 plas-
mid with StuI and NcoI; the EGFP probe (735 bp) was generated by
digestion of the pAAV2.1-CMV-EGFP plasmid with NotI and BamHI.
Prehybridization and hybridization were performed at 65°C in
Church buffer (Sambrook & Russell, 2001) for 1 h and overnight,
respectively. Then, the membrane (Whatman Nytran N, charged
nylon membrane; Sigma-Aldrich, Milan, Italy) was washed for
30 min in SSC 29-0.1% SDS and for 30 min in SSC 0.59-0.1% SDS
at 65°C, and then for 30 min in SSC 0.19-0.1% SDS at 37°C. The
membrane was then analyzed by X-ray autoradiography using
Amersham HyperfilmTM MP (GE Healthcare Europe, GmbH).
AAV infection of HEK293 cells
HEK293 cells were maintained in Dulbecco’s modified Eagle’s med-
ium (DMEM) containing 10% fetal bovine serum and 2 mM L-gluta-
mine (GIBCO; Invitrogen S.R.L.). Cells were plated in six-well plates
at a density of 2 9 106 cells/well and transfected 16 h later with
1.3 lg of pDeltaF6 helper plasmid which contains the Ad helper
genes (Zhang et al, 2000) using the calcium phosphate method.
After 5 h, cells were washed once with serum-free DMEM and incu-
bated with AAV2/2 vectors (m.o.i: 5 9 104 GC/cell of each vector;
1:1 co-infection with dual AAV vectors resulted in 1 9 105 total
GC/cell) in a final volume of 700 ll serum-free DMEM. Two hours
later 2 ml of complete DMEM were added to the cells. Cells were
harvested 72 h following infection for Western blot analysis.
Animal models
Mice were housed at the Institute of Genetics and Biophysics animal
house (Naples, Italy) and maintained under a 12-h light/dark cycle
(10–50 lux exposure during the light phase). C57BL/6 and BALB/c
mice were purchased from Harlan Italy SRL (Udine, Italy). Albino
Abca4/ mice were generated through successive crosses and
backcrosses with BALB/c mice (homozygous for Rpe65 Leu450;
Radu et al, 2004) and maintained inbred. Breeding was performed
crossing homozygous mice. Pigmented shaker1 4626SB/4626SB
(referred to as sh1/) mice were imported from the Wellcome
Trust Sanger Institute (Cambridge, UK, a kind gift of Dr Karen Steel)
and back-crossed twice with CBA/Ca mice purchased from Harlan
Italy SRL to obtain heterozygous shaker1+/4626SB (referred to as
sh1+/) mice to expand the colony. The mice were maintained in-
tercrossed; breeding was performed crossing heterozygous females
with heterozygous males. The pigmented sh1 mice used in this
study were either affected (sh1/) or unaffected (sh1+/ and sh1+/
+). Albino shaker1 4626SB/4626SB mice (referred as sh1/) were
imported from the Medical Research Council Institute of Hearing
Research (Nottingham, UK) and maintained inbred; breedings were
performed crossing heterozygous female with homozygous males.
The albino sh1 mice used in this study were either affected (sh1/)
or unaffected (sh1+/). Figure 7B and supplementary Figs S13 and
S14 show data from albino sh1/ mice. The genotype for the
MYO7A4626SB allele was performed by PCR analysis of genomic
DNA (extracted from the mouse tail tip) followed by DNA sequenc-
ing. The primers used for the PCR amplification are as follows: Fw1
(GTGGAGCTTGACATCTACTTGACC) and Rev3 (AGC
TGACCCTCATGACTCTGC), which generate a product of 712 bp
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that was sequenced with the Fw1 primer. The Large White Female
pigs used in this study were registered as purebred in the LWHerd
Book of the Italian National Pig Breeders’ Association (Azienda Ag-
ricola Pasotti, Imola, Italy).
Subretinal injection of AAV vectors in mice and pigs
This study was carried out in accordance with the Association for
Research in Vision and Ophthalmology Statement for the Use of Ani-
mals in Ophthalmic and Vision Research and with the Italian Minis-
try of Health regulation for animal procedures. All procedures on
mice were submitted to the Italian Ministry of Health; Department
of Public Health, Animal Health, Nutrition and Food Safety on Octo-
ber 17th, 2011. The Ministry of Health approved the procedures by
silence/consent, as per article 7 of the 116/92 Ministerial Decree.
Surgery was performed under anesthesia and all efforts were made
to minimize suffering.
Mice (4–5 week-old) were anesthetized with an intraperitoneal
injection of 2 ml/100 g body weight of avertin [1.25% w/v of 2,2,2-
tribromoethanol and 2.5% v/v of 2-methyl-2-butanol (Sigma-
Aldrich)] (Papaioannou & Fox, 1993), then AAV2/8 vectors were
delivered subretinally via a trans-scleral trans-choroidal approach as
described by Liang et al (2000). All eyes were treated with 1 ll of
vector solution. The AAV2/8 doses (GC/eye) delivered vary across
the different mouse experiments as it is described in the Results sec-
tion. To compare dual AAV to single AAV NS vectors (supplemen-
tary Fig S1 and Fig 4A) we used the same dose of each vector
because we considered that one GC of the 5′-vector plus one GC of
the 3′-vector of dual AAVs are required to re-constitute one full-size
functional genome as that contained in one particle of AAV NS. To
exclude competition between dual AAV capsids at the entry step
which may lead us to over-estimate the efficiency of AAV NS, we
evaluated EGFP expression after subretinal delivery of either
1.7 9 109 GC of AAV2/8 NS-EGFP or 1.7 9 109 GC of AAV2/8-NS-
EGFP + 1.7 9 109 GC of an AAV2/8 vector carrying an unrelated
genome (AAV-unrelated, supplementary Fig S16). Notably, we
found no significant differences in the levels of EGFP expression
whether the unrelated AAV was added or not (supplementary
Fig S16), proving that the double dose of dual AAV capsids adminis-
tered when compared to AAV-NS does not affect dual AAV-medi-
ated transduction.
AAV2/1-VMD2-human Tyrosinase (Gargiulo et al, 2009; dose: 2–
5 9 108 GC/eye) or AAV2/5-CMV-EGFP (encoding normal size
EGFP, dose: 4 9 108 GC/eye) were added to the AAV2/8 vector
solution that was subretinally delivered to albino mice (Abca4/,
BALB/c, and sh1; Figs 5B, C and D and 6A and B; supplementary
Figs S10 and S14) or pigmented sh1 mice (Fig 8), respectively. This
allowed us to mark the RPE within the transduced part of the eye-
cup, which was subsequently dissected and analyzed. Subretinal
delivery of AAV vectors to the pig retina was performed as previ-
ously described (Mussolino et al, 2011). All eyes were treated with
100 ll of AAV2/8 vector solution. The AAV2/8 dose was 1 9 1010
(Fig 3B) or 1 9 1011 GC of each vector/eye (Fig 4B) and co-injec-
tion of dual AAV vectors resulted in a total dose of 2 9 1010 GC/eye
or 2 9 1011 GC/eye, respectively.
Western blot analysis and ELISA
Samples [HEK293 cells, retinas or eyecups (cups + retinas)] for
Western blot analysis were lysed in RIPA buffer (50 mM Tris–HCl
pH 8.0, 150 mM NaCl, 1% NP40, 0.5% Na-Deoxycholate, 1 mM
EDTA pH 8.0, 0.1% SDS) to extract EGFP and MYO7A proteins
from HEK293 cells and eyecups, or in SIE buffer (250 mM sucrose,
3 mM imidazole pH 7.4, 1% ethanol, and 1% NP-40) to extract
MYO7A from retinas and ABCA4 protein. Lysis buffers were sup-
plemented with protease inhibitors (Complete Protease inhibitor
cocktail tablets; Roche) and 1 mM phenylmethylsulfonyl. After
lysis EGFP and MYO7A samples were denatured at 99°C for 5 min
in 1X Laemli sample buffer; ABCA4 samples were denatured at
37°C for 15 min in 1X Laemli sample buffer supplemented with
4 M urea. Lysates were separated by 7% (ABCA4 and MYO7A
samples) or 12% (EGFP samples) SDS–polyacrylamide gel electro-
phoresis. The antibodies used for immuno-blotting are as follows:
anti-EGFP (1:500, sc-8334; Santa Cruz, Dallas, TX, USA); anti-
3xflag (1:1000, A8592; Sigma-Aldrich); anti-Myo7a (1:500, poly-
clonal; Primm Srl, Milan, Italy) generated using a peptide corre-
sponding to aminoacids 941–1070 of the human MYO7A protein;
anti-HA antibody (1:2000, PRB-101P-200, HA.11; Covance, Prince-
ton, NJ, USA); anti-b Tubulin (1:10 000, T5201; Sigma Aldrich);
anti-Filamin A (1:1000, catalog#4762; Cell Signaling Technology,
Danvers, MA, USA); anti-Dysferlin (1:500, Dysferlin, clone Ham1/
7B6, MONX10795; Tebu-bio, Le Perray-en-Yveline, France). The
quantification of EGFP, ABCA4 and MYO7A bands detected by
Western blot was performed using ImageJ software (free download
is available at http://rsbweb.nih.gov/ij/). ABCA4 and MYO7A
expression was normalized to Filamin A or Dysferlin for the in vi-
tro and in vivo experiments, respectively. EGFP expression was
normalized to b-Tubulin. Different proteins were used for normali-
zation based on the similarity of their molecular weight to those of
the different transgene products. The TS (Fig 2D and E), TS-L
(Fig 2F) and NS (supplementary Fig S1) histogram do not have
standard error bars as only one TS, TS-L or NS sample has been
loaded on each SDS–PAGE and used as internal reference sample
in each independent experiment. To show the internal variability
of TS, TS-L and NS samples we calculated the expression of
proteins as percentage relative to the AK sample (set to 100%)
which are the following: Fig 2D: TS = 106  16%; Fig 2E:
TS = 78  4%; Fig 2F: TS-L = 39  6%; supplementary Fig S1:
NS = 906  281%. The ELISA was performed on retina or eyecup
lysates using the Max Discovery Green Fluorescent Protein Kit
ELISA (Bioo Scientific Corporation, Austin, TX, USA).
Fundus photography
The fundus live-imaging was performed by dilating the eye of
C57BL/6 with a drop of tropicamide 1% (Visufarma, Rome, Italy)
and subsequent eye stimulation with a 300W flash. Fundus photo-
graphs were taken using a Topcon TRC-50IX retinal camera, with a
FITC filter, connected to a charge-coupled-device Nikon D1H digital
camera (Topcon Medical System, Oakland, NJ, USA).
Histology, light and ﬂuorescence microscopy
To evaluate EGFP expression in histological sections, eyes from
C57BL/6 mice or Large White pigs (Mussolino et al, 2011) were
enucleated 1 month after AAV2/8 injection. Mouse eyes were fixed
in 4% paraformaldehyde over-night and infiltrated with 30%
sucrose over-night; the cornea and the lens were then dissected and
the eyecups were embedded in optimal cutting temperature com-
pound (O.C.T. matrix; Kaltek, Padua, Italy). PR co-transduction fol-
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lowing subretinal combined delivery of AAV2/8-CMV-EGFP and
-RFP vectors has been evaluated as follows: retinal cryosections
from n = 6 eyes were analyzed under a fluorescent microscope
using either the FITC (to visualize EGFP+ cells) or Rhodamine (to
visualize RFP+ cells) filters. For each eye RFP+ PR contained in one
field at 209 magnification (at least 100) and the corresponding
EGFP+ PR (at least 200) were photographed and then counted. PR
expressing both EGFP and RFP were unequivocally identified based
on their identical shape on picture micrographs of the same field
taken under either the FITC or Rhodamine filter. To calculate the
percentage of co-transduced PR, the number of PR expressing both
EGFP and RFP was divided by the total number of transduced PR,
i.e. PR expressing at least one of the two reporter genes.
Pig eyes were fixed in 4% paraformaldehyde for 48 h, infil-
trated with 10% sucrose for 4 h, 20% sucrose for 4 h and finally
30% sucrose overnight. Then, the cornea, the lens, and the vitre-
ous body were dissected and the EGFP-positive portions of the
eyecups were embedded in optimal cutting temperature com-
pound (O.C.T. matrix; Kaltek). Serial cryosections (12 lm thick)
were cut along the horizontal meridian and progressively distrib-
uted on slides. Retinal histology pictures were captured using a
Zeiss Axiocam (Carl Zeiss, Oberkochen, Germany). Subretinal
delivery in pigs of AAV vectors encoding for EGFP under the con-
trol of the Rhodopsin promoter resulted in PR transduction in:
100% of the retinas injected with: dual AAV TS (4/4), and dual
AAV hybrid AK (3/3, Fig 4B).
To analyze melanosome localization in the RPE of pigmented
sh1 mice, eyes were enucleated 2–3 months following the AAV
injection, fixed in 2% glutaraldehyde-2% paraformaldehyde in
0.1 M phosphate buffer over-night, rinsed in 0.1 M phosphate
buffer and dissected under a florescence microscope. The EGFP-
positive portions of the eyecups were embedded in Araldite 502/
EMbed 812 (catalog #13940, Araldite 502/EMbed 812 KIT; Elec-
tron Microscopy Sciences, Hatfield, PA, USA). Semi-thin (0.5 lm)
sections were transversally cut on a Leica Ultratome RM2235 (Le-
ica Microsystems, Bannockburn, IL, USA), mounted on slides and
stained with Epoxy tissue stain (catalog #14950; Electron Micro-
scopy Sciences). Melanosomes were counted by a masked opera-
tor in about 10 different fields/eye under a light microscope at
1009 magnification. Retinal pictures were captured using a Zeiss
Axiocam (Carl Zeiss).
Flow cytometry
Flow cytometry analysis was carried out as described (Palfi et al,
2012). Briefly, eyes in adult 129 mice were subretinally injected with
3 ll of a 1:1 mixture of 3 9 109 GC of AAV2/8-EGFP and 3 9 109
GC of AAV2/8-DsRed. Control retinas were injected with 3 ll of
either 3 9 109 GC of AAV2/8-EGFP or 3 ll of 3 9 109 GC of AAV2/
8-DsRed or were left un-injected. Three weeks post-injection, retinas
were dissociated in trypsin/HBSS, stained with DRAQ5 (Biostatus,
Shepshed, UK) and EGFP (488:530/40), DsRed (564:615/20) and
DRAQ5 (633: 665/20) fluorescence signals analyzed in the live cells
using a Beckman Coulter Cyan ADP flow cytometer (Beckman Coul-
ter Diagnostics Limited, Lismeehan, Ireland) modified by Propel
Labs (Fort Collins, CO, USA). The analysis was carried out using
Summit v4.3 (Beckman Coulter) software. Nucleated events were
selected by gating the brightest DRAQ5 events in a bivariate density
plot of the forward light scatter (FSC) versus DRAQ5. A second
selection was done in the bivariate histogram of forward versus side
scatter (FSC versus SSC), selecting the homogeneous and perfectly
well defined population of events. Between 10 000 and 25 000
events were analyzed per sample.
Electron microscopy and immuno-gold labelling
For electron microscopy analyzes eyes were harvested from
Abca4/ or sh1 mice at 3 and 2–3 months after AAV injection,
respectively. Eyes were fixed in 0.2% glutaraldehyde-2% parafor-
maldehyde in 0.1 M PHEM buffer pH 6.9 (240 mM PIPES, 100 mM
HEPES, 8 mM MgCl2, 40 mM EGTA) for 2 h and then rinsed in
0.1 M PHEM buffer. Eyes were then dissected under light or fluores-
cence microscope to select the Tyrosinase- or EGFP-positive por-
tions of the eyecups of albino (Abca4/, BALB/c and sh1/) and
pigmented sh1 mice, respectively. The transduced portion of the
eyecups were subsequently embedded in 12% gelatin, infused with
2.3 M sucrose and frozen in liquid nitrogen. Cryosections (50 nm)
were cut using a Leica Ultramicrotome EM FC7 (Leica Microsys-
tems) and extreme care was taken to align PR connecting cilia longi-
tudinally. To avoid bias in the attribution of morphological data to
the various experimental groups, measurements of RPE thickness
and counts of lipofuscin granules in Abca4/ eyes were performed
by a masked operator (Roman Polishchuk) using the iTEM software
(Olympus SYS, Hamburg, Germany). Briefly, RPE thickness was
measured in at least 30 different areas along the specimen length
using the ‘Arbitrary Line’ tool of iTEM software. The ‘Touch count’
module of the iTEM software was utilized to count the number of
lipofuscin granules in the 25 lm2 areas distributed randomly across
the RPE layer. The granule density was expressed as number of
granules per 25 lm2. The immuno-gold analysis aimed at testing
the expression of ABCA4-HA in Abca4/ samples after AAV vector
delivery was performed by incubating cryosections successively
with monoclonal anti-HA antibody (MMS-101P-50; Covance, 1:50),
rabbit anti-mouse IgG, and 10-nm gold particle-conjugated protein
A. To quantify rhodopsin localization to the connecting cilium of
sh1 PR, cryosections of sh1 mice were successively incubated with
anti-rhodopsin antibody (1D4, ab5417; Abcam, Cambridge, UK,
1:100), rabbit anti-mouse IgG, and 10-nm gold particle-conjugated
protein A. The quantification of gold density of rhodospin in the
connecting cilia was performed by a masked operator using iTEM
software (Olympus SYS). Briefly, the ‘Touch count’ module of the
iTEM software was used to count the number of gold particles per
cilium that were then normalized to the cilium perimeter (nm) mea-
sured using the ‘Closed polygon tool’. Gold density was expressed
as gold particles/lm. Immunogold labelled cryosections were ana-
lyzed under FEI Tecnai-12 (FEI, Eindhoven, The Netherlands) elec-
tron microscope equipped with a Veletta CCD camera (Soft Imaging
Systems, Munster, Germany) for digital image acquisition.
A2E measurement in Abca4/ mice
To further evaluate lipofuscin accumulation in Abca4/ mice, we
attempted at measuring by either HPLC in combination with mass
spectrometry (Gutierrez et al, 2010) or by HPLC alone (Parish et al,
1998; Ben-Shabat et al, 2002; Allocca et al, 2008) the A2E content
of Abca4/ eyecups which is reported to be increased compared to
wild-type controls (Weng et al, 1999; Radu et al, 2004; Allocca et al,
2008).
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Electrophysiological analyzes
To assess the recovery from light desensitization eyes were stimu-
lated with three light flashes of 1 cd s/m2 and then desensitized by
exposure to constant light (300 cd/m2) for 3 min. Then, eyes were
stimulated over time using the pre-desensitization flash (1 cd s/m2)
at 0, 5, 15, 30, 45 and 60 min post-desensitization. The recovery of
rod activity was evaluated by performing the ratio between the b-
wave generated post-desensitization (at the different time points)
and that generated pre-desensitization.
RNA extraction, cDNA production and reverse
transcription analyzes
RNA was extracted at 72 h after HEK293 cells infection with dual
AAV2/2 TS and hybrid AK vectors encoding for either ABCA4 or
MYO7A (5′+3′halves) and as negative controls with either the 5′or 3′
half of dual AAV2/2 vectors or with a single NS AAV2/2 EGFP
vector.
Total RNA was extracted using the RT–PCR RNeasy MiniKit (Qia-
gen, Milan, Italy). One microgram of RNA was submitted to DNase I
digestion (RNase Free DNase set; Qiagen) and cDNA was generated
using the QuantiTect reverse transcription kit (Qiagen). To amplify
the ABCA4 mRNA region corresponding to the exon-intron junction
used in dual AAV TS and hybrid AK vectors, 1 ll of cDNA and the
following primers were used: Abca4_RT_Fw 5′-GCTGGGAAAAC
CACCACC-3′ and Abca4_RT_Rev 5′-GTGGACACATGCCAAGGC-3′.
A PCR product of the expected size (130 bp) was then sequenced.
Five microlitres of cDNA were insted used to amplify the full-length
ABCA4 mRNA (6.9 kb) with a long-range PCR using TaKaRa LA
Taq DNA polymerase kit (TaKaRa, Kioto, Japan), and the following
primers: ATGFw 5′-GGTACCTCTAGAGTCGACCCGG-3′, which anneals
upstream of the ATG start codon and SV40polyA-Rev 5′-ACTCAT
CAATGTATCTTATCATGTC TG-3′. To amplify the MYO7A mRNA
region corresponding to the exon-intron junction used in dual AAV
TS and hybrid AK vectors, 1.5 ll of cDNA and the following prim-
ers were used: Fw 5′-AGG GGACAACTACGCACTC-3′ Rev 5′- GTC
TTCTTGCCCAGGGTCTC-3′. A PCR product of the expected size
(218 bp) was then sequenced. Two micrograms of total RNA were
instead retro-transcribed using SuperScript III First-Strand Synthe-
sis System (Invitrogen) and 1 ll of cDNA was used to amplify the
full-length MYO7A mRNA (6.7 kb) with a long-range PCR using
TaKaRa LA Taq DNA polymerase kit (TaKaRa) and the following
primers: ATGFw 5′-GCGGC CGCCATGGTGATTCTTCAGCAG-3′ and
BgHpolyA-Rev 5′-TGGGA GTGGCACCTTCCA-3′.
Statistical analysis
Statistical P values ≤ 0.05 were considered significant. One-way
ANOVA with post-hoc Multiple Comparison Procedure was used to
compare data depicted in: Fig 2 (P ANOVA = A. 0.012; B. 1 9 107;
C. 0.002); Fig 4A (P ANOVA = 1.9 9 1012); Fig 6B (P ANO-
VA = 0.00126); Fig 6C (P ANOVA = 2.2 9 105); Fig 8B (P ANO-
VA = 1.2 9 105); Fig 8C (P ANOVA = 0.11); supplementary Fig S1
(P ANOVA = 2.3 9 108); supplementary Fig S6 (P ANOVA = A:
0.13; B: 0.16); supplementary Table S2 (2/2 preps: P ANO-
VA = 0.0698; 2/8 preps: P ANOVA = 0.0767). As the counts of lipo-
fuscin granules (Fig 5D) are expressed as discrete numbers, these
were analyzed by deviance from a Negative Binomial generalized
linear models (Venables & Ripley, 2002) (P value analysis of devi-
ance: Fig 5D: 1.7 9 107). The statistically significant differences
between groups determined with the post-hoc Multiple Comparison
Procedure are the following: Fig 2D: OV versus OZ P = 0.03; OV ver-
sus AP P = 0.016. Fig 2E: OV versus OZ P = 0.0001; OV versus AP
P = 1.1 9 105; OV versus AK P = 0.0017; TS versus OZ
P = 1.8 9 105; TS versus AP P = 2.3 9 106; TS versus AK
P = 0.026; AK versus OZ P = 9 9 107; AK versus AP P = 2 9 107.
Fig 2F: AK-L versus OZ P = 0.003; AK-L versus TS-L P = 0.005.
Fig 4A: NS-EGFP versus TS-EGFP P = 0; NS-EGFP versus AK-EGFP
P = 0. Fig 5D: WT versus Abca4/ neg P = 0.016; WT versus
Abca4/ AK-ABCA4 P = 0.03; Abca4/ neg versus Abca4/ TS-
ABCA4 P = 0.0005; Abca4/ neg versus Abca4/ AK-ABCA4
P = 9 9 108. Fig 6B: Abca4/ neg versus Abca4/ TS-ABCA4
P = 0.012; Abca4/ neg versus Abca4/ AK-ABCA4 P = 0.002.
Fig 6C (60 min): Abca4/ neg versus Abca4/ AK-ABCA4: 0.05;
Abca4/ neg versus Abca4/ TS-ABCA4: 0.009; Abca4/ AK-
ABCA4 versus WT: 0.002; Abca4/ TS-ABCA4 versus WT: 0.02
Abca4/ neg versus WT 1 9 105. Fig 8B: sh1+/+ and sh1+/ ver-
sus sh1/ neg P = 7.7 9 106; sh1+/+ and sh1+/ versus sh1/
TS-MYO7A P = 0.025; sh1/ neg versus sh1/ TS-MYO7A
P = 0.0028; sh1/ neg versus sh1/ AK-MYO7A P = 0.0002. Sup-
plementary Fig S1: NS-EGFP versus TS-EGFP P = 0; NS-EGFP versus
AK-EGFP P = 1 9 107.
The Student’s t-test was used to compare data depicted in sup-
plementary Fig S10, S14 and S16. The data in the manuscript are
depicted as mean  standard error of the mean (s.e.m.). The s.e.m
has been calculated using the number of independent in vitro exper-
iments or eyes (not replicate measurements of the same sample).
Supplementary information for this article is available online:
www.embomolmed.org
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Results
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by either splicing (trans-splicing, TS), homologous recombination
(overlapping, OV) or a combination of the two (hybrid). We show that
the delivery of dual AAV TS and hybrid vectors to the retina results in
efﬁcient reconstitution of large transgenes in mouse and pig photore-
ceptors, the major cell target of IRDs. Although the levels of transgene
expression achieved with dual AAV vectors are lower than those
achieved with a single normal size AAV, they result in signiﬁcant
improvement of the retinal disease of two mouse models of common
IRDs due to mutations in large genes, Stargardt’s disease (STGD) and
Usher syndrome type IB (USH1B).
Impact
Our results provide proof-of-concept of gene therapy for STGD and
USH1B using dual AAV vectors. Importantly, dual AAV vectors expand
AAV cargo capacity for gene therapy of IRDs requiring transfer of large
genes.
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